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The thesis entitled "Investigation of Inclusion Compounds of Pharmaceuticals 
with Cyclodextrin" is comprised of an introduction, a general discussion and NMR 
spectroscopic study of inclusion complexes of five pharmaceutical compounds with 
P-cyciodextrin (p-CD). 
The introduction describes a brief historical background, structural features of 
CDs and its derivatives, examples of various industrial applications of CDs inclusion 
complexes with the main emphasis in the area of pharmaceuticals, chiral recognition 
by CDs and the forces involved in the host-guest complexes. The general discussion 
deals with the use of 'H NMR and 2D NMR (COSY, ROESY) spectroscopy in the 
study of CD-inclusion complexes. The methods for the determination of 
stoichiometry and binding/association constant of the complex are also described. The 
objective of the study was to investigate the structure of the complex of 
pharmaceutical compounds with P-CD, formed in aqueous solution, because the use 
of these complexes for pharmaceutical purposes requires the establishment of their 
structure. 
CDs are cyclic oligosaccharides composed of 6(a), 7(P) or 8(7), a-(l—>4)-
linked glucose residue and characterized by a truncated cone shape. The primary 
hydroxyl groups (n) are located at the narrow rim while wider rim is lined with 
secondary hydroxyl groups (2n). The outer surface of the CDs is highly hydrophilic 
due to the presence of large number of hydroxyl groups while the CD cavity is 
relatively hydrophobic. Considering the presence of 18(a-CD), 21 (p-CD) and 24(Y-
CD) substitutable hydroxyl groups and involving cleavage of either 0-H, C-0 or C-
C bonds, the number of possible derivatives of CDs are unlimited. Functionalization 
of CDs can concern complete or partial functionalization of hydroxyls. 
By virtue of their sliape and hydrophobic nature of cavity, CDs can 
encapsulate a variety of hydrophobic molecule, or part of it, inside their cavity 
through non-covalent interactions to form inclusion complexes. Inclusion of the guest 
into the CD cavity results in altered physicochemical properties of the guest, like 
solubility, stability and volatility etc., which have found numerous applications in the 
field of pharmaceuticals. 
HO 
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H-r 
Model showing shape of P-cyclodextrin 
and its different protons 
Biological systems are largely constructed from chiral molecules such as 
L-amino acids and D-sugars. In such a highly chiral environment it is not surprising 
that drugs which possess asymmetric center/s exhibit a high degree of 
stereoselectivity in their interactions with biological macromolecules. It may be 
highly desirable to have all the activity in one enantiomer of the drug so as to avoid 
the unwanted activity and/or toxicity that may residue in the antipode but examples 
where this has been proven to be true are uncommon. The separation of enantiomer 
and their characterization are, therefore, of great importance for the pharmaceutical 
industry. CDs are chiral molecules and exhibit chiral recognition, i.e., they 
differentiate between enantiomeric species, forming diastereomeric complexes. 
Enantioselectivity of recognition is a thermodynamic quantity correlating in some 
way with the separation factor of enantiomers in separation techniques. It must be 
noted that among presently applied chiral selectors only CDs are effectively used in 
all enantioseperation techniques. A better understanding of the inclusion complex 
formation and the chiral recognition mechanism of CDs is, therefore, a subject of 
great importance. 
Multiple forces involved in guest-CD interaction make understanding of guest 
binding and chiral recognition mechanism by CDs extremely difficult. The 
understanding of the driving forces in the inclusion complexation of CDs is 
fundamentally important not only for CD chemistry but also for supramolecular 
chemistry as a whole. A large number of studies have been carried out on the subject 
and have been reviewed earlier. Nevertheless, it is often claimed that the driving 
forces leading to CD complexation still remain controversial subject. 
NMR spectroscopy is the most powerful tool in the complexation studies of 
CDs and its chiral recognition. The NMR spectroscopy helps to determine not only 
the stoichiometry and binding constant but it also shows the special relationship 
between hydrogen atoms of the host CD and guest molecule and dynamics of the 
complex and its constituent part. NMR studies of cyclodextrin complex commonly 
show rapid exchange of guest molecule between the host resulting in averaged shifts 
and no distinct species on the NMR time scale. The formation of an inclusion 
complex between a guest and CD results in the chemical shift changes (A5) in both 
the host and guest protons. The highfield shift changes in the CD cavity protons 
(H-3' and H-5') confirm the penetration of the guest into the CD cavity. The guest 
protons generally show downfield shift changes upon complexation but all the protons 
and not only the part included in the cavity display chemical shift changes. Sometimes 
highfield shift changes in the guest proton signals are also observed. The 2D ROESY 
(Rotating-frame Overhauser Effect Spectroscopy) has been found very helpful for the 
investigation of the interaction between CD and guest molecule since the Nuclear 
Overhausser Effect (NOE) cross peaks are observed between the protons that are 
closer than 0.4 nm in spaces in the ROESY spectrum. It gives information about the 
part of the guest included inside the CD cavity, the mode of penetration, i.e. either 
from narrower or wider rim side, the depth of penetration and orientation of the guest. 
NMR spectroscopic studies of complexation of fluvastatin sodium, 
desloratadine, cetirizine dihydrochloride, flunarizine dihydrochloride and midazolam 
hydrochloride with P-CD were carried out. In all the cases, the chemical shift changes 
in the proton resonances of studied compounds and P-CDs were observed in the 
spectra of mixtures of pharmaceutical compounds and P-CD compared to pure 
components. The cavity protons of P-CD, namely H-3' and H-5', showed significant 
highfield shift changes in the presence of drug while other protons (!', 2', 4', 6') 
generally showed insignificant chemical shift changes. Stoichiometry and overall 
association/binding constant of the inclusion complexes were determined by 'H NMR 
titration methods. The mode of penetration and orientation of the guest molecule into 
the P-CD cavity were established by ROESY spectral data in all the studied cases. 
Fluvastatin sodium (FLU) helps in preventing heart disease, angina, stroke and 
heart attacks by reducing the cholesterol and certain other fatty substances in the 
blood. FLU is a mixture of two isomers and has two aromatic rings. It forms one 1:1 
p-CD-FLU inclusion complex in aqueous solution by the penetration of the only 
F-substituted aromatic ring, from narrower rim side, into the P-CD cavity. The 
structure for the 1:1 P-CD-FLU inclusion complex has been shown in Fig. 1. The 
chemical shift changes (A5) for the F-containing ring protons of the two isomers were 
not identical which suggest the chirai differentiation by the P-CD between the two 
isomers. 
ONa 
Fluvastatin sodium p-Cyclodextrin P-CD-FLU inclusion complex 
Fig.l 
Desloratadine (DES), a new non-sedating selective HI-antihistamine, is 
efficacious and safe in the treatment of perennial allergic rhinitis and chronic 
idiopathic urticaria. DES contains a Cl-substituted aromatic ring and a pyridine ring. 
It forms a 1:1 P-CD-DES inclusion complex, in aqueous solution, involving only 
Cl-substituted aromatic ring. The mode of penetration of Cl-substituted aromatic ring 
into P-CD cavity was established from wider rim side. Two probable modes of 
penetration (Fig. 2) were considered and the Mode 11 was ruled out on the basis of 
ROESY spectral data. In the presence of p-CD, all the aromatic signals of DES 
exhibited induced shift changes as well as splitting indicating the chirai differentiation 
ofDESbyp-CD. 
Desloratadine p-Cyclodextrin 
Mode II 
p-CD-DES inclusion complexes 
Fig. 2 
Cetirizine dihydrochloride (CTZ), is an antihistamine drug with the amine 
piperazine in its molecule and is used to treat the symptoms of allergies, chronic 
urticaria, hay fever, angioedema, hives, and as a treatment adjunct in asthma. CTZ has 
two aromatic rings and both of these rings were confirmed to be involved in the 
inclusion complexes formation with P-CD. Two 1:1 P-CD-CTZ complexes were 
characterized, formed by the entry of the phenyl as well as Cl-substituted aromatic 
rings from wider rim side of the P-CD cavity. The structures of two 1:1 P-CD-CTZ 
complexes, present in solution, have been shown in Fig 3. In the presence of p-CD, 
the signals for both the aromatic ring protons of CTZ exhibited splitting, suggesting 
some chiral differentiation by P-CD. 
%Ui2»^ •iS 
Cetirizine dihydrochloride P-Cyclodextrin 
P-CD-CTZ inclusion complexes 
Fig. 3 
Flunarizine dihydrochloride (FLN) is a sedative and antihistaminic, effective 
in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of 
central and peripheral origin, and as an adjuvant in the therapy of epilepsy. FLN has 
two F-substituted aromatic and one phenyl ring. Complexes involving F-substituted 
aromatic ring and phenyl ring were confirmed to be present in solution. The modes of 
penetration of the F-substituted aromatic ring and phenyl ring, into P-CD cavity, were 
identical and from narrower rim side. The proposed structures of the complexes have 
been depicted in Fig. 4. The splitting of most of the signals of the FLN, in the 
presence of P-CD, suggests the chiral differentiation of the guest FLN by P-CD. 
Flunarizine dihydrochloride 
p-Cyclodextrin 
P-CD-FLN inclusion complexes 
Fig. 4 
Midazolam hydrochloride (MDL) is a pre-operative anaesthetic, belonging to 
the class of imidazobenzodiazepine compounds which are useful as antivonvulsants, 
anxiolytic, amnestic, hypnotic, skeletal muscle relaxant and sedative properties. MDL 
contains a F-substituted and a Cl-substituted aromatic rings. It was established that 
MDL forms one 1:1 P-CD-MDL inclusion complex in aqueous solution. It was 
confirmed on the basis of 2D ROESY spectral data that only F-substituted aromatic 
ring acted as a guest in the complexation. Two probable structures (Fig. 5) were 
considered, one formed by the penetration of the aromatic ring from wider rim side 
while the other from the narrower rim side. The penetration of the ring from the wider 
rim side was ruled out because the cross peaks between H-4 and H-6 of MDL with 
H-5' of p-CD were stronger compared to those with H-3' of P-CD, indicating close 
proximities of H-4 and H-6 with H-5' compared to H-3'. The structure shown as 
Mode I was assigned to the p-CD-MDL inclusion complex. Most of the aromatic 
signals of MDL exhibited induced shift changes as well as splitting, in the presence of 
P-CD, also indicating the chiral differentiation of MDL by p-CD. 
Midazolam hydrochloride 
P-Cyclodextrin 
HCl 
HCl 
Mode II 
p-CD-MDL inclusion complexes 
Fig. 5 
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AIM AND OBJECTIVE 
The objective of the work embodied in this thesis was to study the 
complexation of various pharmaceutical compounds with p-cyclodextrin in 
aqueous solution. Complexation of pharmaceutical compounds with 
cyclodextrins, to form a host-guest complex, results in altered various 
physicochemical properties of the guest, like solubility, stability, volatility and 
masking of undesirable properties etc., which are desirable for their use as 
pharmaceuticals. Moreover, these host-guest complexes are considered as new 
entities and are required to be characterized for their approval as a drug. 
Cyclodextrins are chiral molecules and differentiate between enantiomeric 
species. Enantioselectivity of recognition is related in some way to the 
separation factor of enantiomers in separation techniques. The separation of 
enantiomers of a racemic drug is of great importance to the pharmaceutical 
industry because in a racemic drug one enantiomer is usually unwanted. NMR 
spectroscopy is a very useful tool to understand the mechanism of chiral 
recognition and a better understanding of the subject will help in the use of 
cyclodextrins as chiral selectors in various separation techniques. 
CHAPTER! 
Introduction 
1.1 HISTORICAL BACKGROUND 
The area of chemistry that is concerned with the study of recognition phenomena is 
called supramolecular chemistry. The area covers studies of all kinds of interactions 
where covalent bonds are not formed between the interacting species. The majority of 
these interactions are of the host-guest type. The cyclodextrins (CDs) are often used in 
supramolecular chemistry for their unique capability to complex with a variety of 
small organic guests in aqueous environment. 
CDs have been described as "seductive molecule", appealing to investigators 
in both pure research and applied technologies. CDs were discovered in 1891 by 
Villiers by digesting starch with Bacillus amylobactor. He obtained about 3 g of a 
crystalline substance from 1000 g of starch, and determined its composition to be 
(C6Hio05)2-3H20, named "cellulosine", because it resembled cellulose. Schardinger 
in 1903 was first investigated the preparation and isolation of CDs from starch which 
was treated with a group of amylases called glucosyltransferases or cyclodextrinases, 
and therefore, CDs are also known as Schardinger's dextrins. In the early literature, 
CDs were also referred as cycloamylose, cycloglucoamylose etc. The correct 
chemical structure of the CDs was not published until 1938. It was Freudenberg, who 
characterized them as cyclic structures composed of a-1, 4-linked glucose units.^ In 
1948, y-cyclodextrin was discovered and the X-ray structure was elucidated. In the 
1950s, the chemical process for the production of CDs was thoroughly investigated by 
French and coworkers^ and the existence of larger CDs was confirmed. Also, during 
this time Cramer et al.^ first began to uncover the CDs potential as complex forming 
agent. They firstly investigated the application of CDs in drug formulations, and 
noted the stabilization, volatility reduction, and solubility changes that occurred as a 
result of complex formation of drugs with CDs. Only in 1953 the first patent on CDs 
and their inclusion complexes was registered.^ The numbers of patents and papers on 
CDs have increased exponentially since then. The first International Symposium on 
CD was organized in 1981.^ Since then, symposia have been held every second year 
and presentations have increased both in quantity and quality. Moreover, while in 
1970 the price of I Kg of p-CD was around US$ 2000, and it was available only as a 
lare fine chemical, it is a relatively inexpensive material and an important industrial 
commodity now in many ways. Today, the cost of CDs is reduced dramatically and as 
a result the group of scientists interested in CDs is continually growing. Also, a-, (3-
and 7-CDs, as well as several of their derivatives are produced industrially and used in 
various chromatographic methods, or are studied as potential drug carriers, stabilizers, 
catalysts etc. During the years 1980-2000, encouraging results of adequate 
toxicological studies became available which induced many scientists for developing 
CD-containing products for human use. 
1.2 STRUCTURAL FEATURES AND PROPERTIES 
The CDs belongs to the family of cyclic oligosaccharides, and have been studied 
extensively as a host in supramolecular chemistry.^ The three major types of CDs are 
crystalline, homogeneous, nonhygroscopic substances, consisting of six (a-), seven 
(P-), and eight (y-) D-glucose units, respectively, attached by a-(l-*4) glycosidic 
linkages (Fig. 1)."^ CDs consisting of more D-glucose units are also known, but they 
are too expensive. The internal diameter of the three CDs increases with the number 
of glucose units, while the height remains constant at 7.9 A. 
Each of the chiral glucose units is in the rigid "^Ci-chair conformation, giving 
the macrocycle shape of a hollow truncated cone with all the secondary hydroxyl 
group, 0(2)-H and 0(3)-H (2n), located on the wider rim, while all the primary 
hydroxyl groups, 0(6)-H (n), on the narrower rim (Fig. 2). The primary hydroxyls on 
the narrow side of the cavity can rotate, thus partially blocking the cavity, in contrast 
to the secondary hydroxyls, which are attached by relatively rigid chains and thus 
cannot rotate. 
The primary and secondary hydroxyls on the outside of the CDs make it 
water-soluble. CDs are insoluble in most organic solvents. The interior of the cavity is 
lined with (from the secondary hydroxyl rim inwards) a row of CH groups (the C-3 
carbons), then a row of glycosidic oxygen, and then a row of C-5 CH groups. 
Intramolecular hydrogen bonds 0(3)-H 0(2)-H or 0(3) H-0(2) exist between the 
secondary hydroxyl groups of adjacent glucose units, forming a complete secondary 
belt in p-CD. This hydrogen bond belt is incomplete in a-CD molecule due to the 
presence of one glucose unit in distorted position. Consequently, instead of the six 
possible H-bonds, only four can be established simultaneously. The y-CD has a non-
coplanar, more flexible structure; therefore, it is more water soluble of the three CDs. 
The non-bonding electron pairs of the glycosidic oxygen bridges are directed toward 
the inside of the cavity, producing a high electron density and lending it some Lewis 
base character. These features suggest that the CD cavity is relatively hydrophobic 
compared to the exterior faces which are hydrophilic.'^"''* Some important properties 
and the molecular dimensions of the three most common CDs are listed in Table 1. 
M ^ 3 i o ^ r i ) h 
o 
/OH 
HO 
^ " ' ^ . 
a-Cyclodextrin P-Cyclodextrin y-Cyclodextrin 
14.6 A 15.4 A 
7.9 A 
17.5 A 
7.9 A 
» ^ ' 
» 1 
Fig. 1. Structures and sizes of a-, P-, and y-CD. 
Secondary hydroxyls 
Molecular cavity 
Primary hydroxyls 
HOs^ 
Primary alcohol 
0 H 0 - -
Secondary alcohol 
Fig. 2. Schematic side view of CD and its three types of hydroxyl groups (one 
primary at C-6 and two secondary at C-2 and C-3). 
Table 1. Physical properties and molecular dimension of a-, p-, and y-CDs 9,14 
Property 
No. of glucose units 
Molecular weight 
Solubility in water. 
(g 100 mL"' at room temp.) 
Cavity diameter, A 
Height of torus, A 
Diameter of outer periphery, A 
Cavity volume, A'^  
Crystal forms (from water) 
Crystal water, wt % 
Diffusion constant at 40 ''C 
N D 25 °C 
F max value, min'' 
a-CD 
6 
972 
14.5 
4.7-5.3 
7.9 
14.6 
174 
Hexagonal plates 
10.2 
3.443 
150 ±0.5 
5.8 
p-CD 
7 
1135 
1.85 
6.0-6.5 
7.9 
15.4 
262 
Monoclinic 
parallelograms 
13.2-14.5 
3.224 
162.5 ±0.5 
166 
Y-CD 
8 
1297 
23.2 
7.5-8.3 
7.9 
17.5 
427 
Quadratic prisms 
8.13-17.7 
3.000 
177.4 ±0.5 
2300 
1.3 CYCLODEXTRIN DERIVATIVES 
Today, a number of derivatives of CDs are formed and being used in various ways. 
Various functional groups can covalently be attached to tiie hydroxyl groups. ' The 
complexation behaviour of CDs is altered when the hydroxyl groups are modified. 
Considering the presence of 18(a-CD), 21(p-CD) and 24(y-CD) substitutable 
hydroxyl groups and involving cleavage of either 0-H, C-0 or C-C bonds, the 
number of possible derivatives of CDs are unlimited. All the known CD derivatives 
can be classified as carriers (solubilizers, stabilizer) for biologically active substances, 
enzyme models, separating agents (for chromatography) and catalysts and additives 
(as detergents, viscosity modifiers etc.).'^' '" Actually, methylated CDs (randomly 
methylated-P-CD), hydroxyalkylated-CDs (hydroxypropyl-P-CD and hydroxypropyl-
y-CD) and branched CDs (glucosyl- and maltosyl-P-CD) are produced due to 
cost/benefit ratio. Complexation with such functionalized CDs can also take place in 
organic solvents since many of the functionalized CDs are soluble in organic solvents. 
Functionalization of CDs can concern complete sets of hydroxyls or partial 
functionalization. Commercial derivatives of CDs are shown in Table 2, while Table 3 
contains the pharmaceutically useful P-CD derivatives, classified into hydrophilic, 
hydrophobic, and ionic derivatives. 
Table 2. Chemical structures of cyclodextrin derivatives. 
R,0 
N^ 
Compound Ri 
Hydrophilic Derivatives 
Methylated cyclodextrins 
3 -Mono-O-methylcyclodextrins 
2, 6-Di-O-methylcyclodextrins 
2, 3, 6-Tri-O-methylcyclodextrins 
Randomly methylated cyclodextrins 
Hydroxyalkylated cycldoextrins 
2-Hydroxyethylcyclodextrins 
2-Hydroxypropylcyclodextrin 
3-HydroxypropylcycIodextrin 
2, 3-Dihydroxypropylcyclodextrin 
Branched cyclodextrins 
6-0-Glucosylcyclodextrins 
6-0-Maltosylcyclodextrins 
2, 6-0-Dimaltosylcyclodextrins 
H 
CH3 
CH3 
Ri, 
Ri, R2, R3 = 
Ri, R2, R3 -
Ri, R2, R3 = 
Ri, R2, R3 = 
H 
H 
maltose 
Hydrophobic Derivatives 
Alkylated cyclodextrins 
2, 6-Di-O-ethylcyclodextrins 
2, 3, 6-Tri-O-ethylcyclodextrins 
Acylated cyclodextrins 
2, 3-Di-O-hexanoylcyclodextrins 
2, 3, 6-Tri-O-acetylcyclodextrins 
2, 3, 6-Tri-O-propanoylcyclodextrins 
2, 3, 6-Tri-O-butanoylcyclodextrins 
2, 3, 6-Tri-O-valerylcyclodextrins 
2, 3, 6-Tri-O-hexanoylcyclodextrins 
2, 3, 6-Tri-O-octanoylcyclodextrins 
C2H5 
C2H5 
COCsHii 
COCH3 
COC2H5 
COC3H7 
COC4H9 
COC5H1, 
COC7H15 
lonizable Derivatives 
Anionic cyclodextrins 
6-0-(Carboxymethyl)cyclodextrins 
6-0-(Carboxymethyl)-
2,3-di-O-ethylcyclodextrins 
Cyclodextrin sulfates 
Sulfobutylcyclodextrins 
H 
C2H5 
Ri, R2, R 3 ' 
Ri, R2, R3 -
R2 
CH3 
H 
CH3 
R3 
H 
CH3 
CH3 
R2, R3 = H or CH3 
= H or CH2CH2OH 
-- H or CH2CH(OH)CH3 
= H or CH2CH2CH2OH 
= H or CH2CH(OH)CH20H 
H 
H 
H 
H 
C2H5 
COC5H,, 
COCH3 
COC2H5 
COC3H7 
COC4H9 
COCsHii 
COCyHis 
H 
C2H5 
= H or S03Na 
glucose 
maltose 
maltose 
C2H5 
C2H5 
H 
COCH3 
COC2H5 
COC3H7 
COC4H9 
COC5H11 
COC7H,5 
CH2C02Na 
CH2C02Na 
= H or (CH2)4S03Na 
"N = 6, a-CDs; N = 7, p-CDs; N - 8, y-CDs; N = 9, 5-CDs. 
Table 3. Pharmaceutically useful p-CD derivatives.'^ 
Derivative Characteristic Possible use (dosage form) 
Hydrophilic derivatives 
Methylated P-CD 
Me-p-CD 
DM-p-CD 
TM-p-CD 
DMA-p-CD 
Hydroxyalkylated p-CD 
2-HE-P-CD 
2-HP-P-CD 
3-HP-p-CD 
2, 3-DHP-p-CD 
Branched p-CD 
Gi-p-CD 
G2-P-CD 
GUG-P-CD 
Hydrophobic derivatives 
Alkylated P-CD 
DE-P-CD 
TE-p-CD 
Acylated p-CD 
TA-p-CD 
TB-p-CD 
TV-p-CD 
TO-p-CD 
lonizable derivatives 
Anionic p-CD 
CME-P-CD 
p-CDsulphate 
SBE4-P-CD 
SBE7-P-CD 
Al-p-CD-sulphate 
Soluble in cold water and in Oral, dermal, mucosal^ 
organic solvents, surface active, 
Hemolytic 
Soluble in water, Low hemolytic Parenteral, oral, mucosal 
Amorphous mixture with 
different degree of substitution. 
Highly water-soluble (> 50%), 
Low toxicity 
Highly water-soluble (> 50%), 
Low toxicity 
Water-insoluble, soluble in 
organic solvents, surface-active 
Water-insoluble, soluble in 
organic solvents 
Mucoadhesive 
Film formation 
pKa - 3 to 4, Soluble atpH > 4 
X>Ka> 1, Water-soluble 
Water-soluble 
Water-soluble 
Water-insoluble 
Parenteral, oral, mucosal 
Parenteral, oral, mucosal 
Parenteral, oral, mucosal 
Parenteral, oral, mucosal 
Parenteral, oral, mucosal 
Parenteral, oral, mucosal 
Parenteral, oral, mucosal 
Oral, subcutaneous 
(slow-release) 
Oral, parenteral 
(slow-release) 
(slow-release) 
(slow-release) 
Oral, dermal, mucosal 
(delayed-release, enteric^) 
Oral, mucosal 
Parenteral, oral 
Parenteral, oral 
Parenteral (slow-release) 
Abbreviations: Me: randomly-methylated; DM: 2, 6-di-O-methyl; TM: 2, 3, 6-tri-O-methyl; 
DMA: acetylated DM-p-CD; 2-HE: 2-hydroxyethyl; 2-HP: 2-hydroxypropyl; 3-HP: 
3-hydroxypropyl; 2, 3-DHP: 2, 3-dihydroxypropyl; G\: glycosyl; G2: maltosyl; GUG: 
Glucuronyl-glucosyl; DE: 2, 6-di-O-ethyl; TB: 2, 3, 6-tri-O-ethyl; CME: 0-carboxymethyl-O-
ethyl; TA: 2, 3, 6-tri-O-acyl (C2-C18); TB: 2, 3, 6-tri-O-butanoyl; TV: 2, 3 ,6-tri-O-valeryl; TO: 
2, 3, 6-tri-O-octyl; SBE4: degree of substitution 4 of sulfobutyl ether group; SBE7: degree of 
substitution 7 of sulfobutyl ether group. 
^Mucosal: nasal, sublingual, ophthalmic, pulmonary, rectal, vaginal, etc. 
Enteric: soluble in intestinal fluid (pH 6-7). THESIS 
1.4 INDUSTRIAL APPLICATIONS OF CYCLODEXTRINS 
Szejtii (1933-2004) divided the chemical and industrial developments of CDs into 
three stages, the discovery period (1891 to the mid 1930s), the exploratory period 
(mid 1930s to 1970), and the utilization period (1970 to present).^' '^  These three 
developmental phases closely follow the technological advances that took place 
during the last century, first in analytical instnmientation and then in biotechnology. 
Today in industry, CDs and their derivatives are incorporated into a variety of 
products. CDs ability to form inclusion complexes with a variety of compounds has 
found usefulness in a multitude of areas. CDs are commonly use in chewing gum, 
detergents, shampoo, toothpaste, deodorants, lotions, perfumes and most importantly 
formulation of pharmaceutical drugs. They are used to control solubility, mask agents 
and provide stabilization. CDs are also applied as general processing aids and are used 
to direct chemical reactions, compatibilize materials and control volatility. Due to 
their non-toxic and non-hazardous nature, CDs have found applications in usually all 
kinds of everyday products. At present CDs have general approval for use as food 
additives in Japan and Hungary and for specific applications in France and Denmark. 
This section will include a broad but brief introduction into the different ways CDs 
and their derivatives are being used today in industry due to their ability to 
accommodate guest molecules in their cavity. The industrial applications of the CDs 
have been divided into two parts: general applications and pharmaceutical 
applications. Fig. 3 shows the structures of some compounds that have been utilized 
recently for the formation of complexes involving P-CD derivatives. 
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HO,S HN 
^ 
Acridine Red 
NO, 
RhodamineB ^ 8-Anilino-l-naphthalenesulfonic acid 
L / HOiS 
OH 
4-Nitrophenol 2, 5 Norbornadiene 2-(/7-Toluidino)naphthalene-6-sulfonic acid 
F 
.N 
N' 
H2N-S=0 
II 
O 
4-(Aminosulfonyl)-7-fluoro-2, 1,3-benzoxadiazole Homocysteine Ibuprofen 
OH 
2, 6-Naphthalenedicarboxylic acid Carbamazepine 
CI 
Griseofulvin 
Fig. 3. Names and structures of some typical compounds utilized recently in the 
formation of host-guest complexes with P-CD and its derivatives. 
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1.4.1 GENERAL APPLICATIONS OF CYCLODEXTRINS 
Solubility 
The solubility of a compound can be altered by complexation with a CDs. The guest 
molecule in the cavity of the CD does not come in contact with the solvent. The outer 
surface of the CD interacts with the solvent, which contributes to the solubility of the 
complex and not the portion of the guest included in the CD cavity. Modification of 
the hydroxyl group of the outer surface of the CD markedly affects the solubility 
properties. Substitution of the hydroxyl groups with hydroxypropyl, carboxymethyl, 
tertiary amine or quaternary amine increases water solubility upto 60% or more. On 
the other hand, substitution of -OH groups with aliphatic groups such as hexyl or 
acetyl results in increased solubility in organic solvents. 
The cloudiness and bitter taste in the orange juice was discovered due to the 
presence of hespiridine. Addition of P-CD resulted in clearing the syrup and masking 
the bitter flavour of hespiridine.'^ *' Triterpenes which are water insoluble, such as 
oleanoic acid, ursolic acid and gederogenin, could be solubilized upto 400 |i.g/mL or 
more using CDs.^' Phenylalanine, tyrosine and tryptophan units of the peptides 
complex well with CDs resulting in the formation of CD-peptide complex. Ovine 
growth hormone is water insoluble, except at high pH such as 11.5, which is not 
useful for pharmacological purposes. It can be solubilized at pH 7.5 to 8.5 when 
complexed with hydroxypropyl P-CD.^ ^ Some plant oils cause a rash and irritation 
when they come in contact with skin. Washing can result in spreading of the oils and 
increased irritation. These oils can be removed from the skin by complexation with 
CDs especially y-CD and hydroxypropyl-P-CD.^^ Large lipids such as ear wax can 
also be solubilized by complexation with y-CD.^ '* 
Glycolic acid is used for superficial peeling of the skin but is irritating to the 
skin. When applied complexed with CDs, it was found to be non-irritating and due to 
prolonged release of glycolic acid there was increase in efficiency of exfoliating 
action and cellular removal.^^ 
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CDs have also been used for dyeing fabrics. Using CDs, more dye was 
absorbed on the fabric reducing the amount of dye left in the waste water. The 
solubility of the dye in water also increased and no auxiliaries were needed to 
solubilize the dye. A 3-fold increase in the binding of the florescent dye to polyester 
fiber was achieved using hydrophobic tosyl derivatives of P-CD.^ ^ In the presence of 
P-CD, disperse/reactive dye showed better fastness to washing properties on nylon-6 
and cotton fibers.^' 
Viscosity of water-based paints during their manufacture can be controlled 
using CDs.^ ^ Thickeners are added to paints to impart desired viscosity properties. By 
complexing CD with the thickener during the manufacture of the paints the viscosity 
is reduced and making mixing easier. Viscosity is restored upon addition of paint 
components which displace the thickener from the cavity of the CD to give the paints 
its desired viscosity properties. 
Modified P-CDs have been shown previously to enhance sterol conversion to 
4-androstene-3, 17-dione and 1, 4-androstadiene-3, 17-dione by growing 
Mycobacterium spp. The enhancement effect was mainly attributed to steroid 
solubilization by the formation of inclusion complexes with modified CDs.^ ^ 
Process Aids 
CDs have found invaluable roles as processing aids in industry. CD has been used in 
the removal of cholesterol from animal products.^^' ^ ' In one case, aqueous solution of 
CD was stirred with heated lard and tallow from which cholesterol was to be 
removed. The CD forms complex with cholesterol, which is insoluble in water or fat. 
The complex is removed by filtration or centrifugation. The CD-cholesterol complex 
is then suspended in water and heated which results in decomposition of complex 
causing CD to be solubilized in water and cholesterol to float on the surface. This way 
upto 80% of cholesterol has been removed from some treated material and CDs and 
cholesterol are obtained as pure products. CD complexation of cholesterol has also 
been found useftil in reducing dietary cholesterol intake.''^ 
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CDs have been successfully used as antibrowning agents in fruit juices. ' 
Fruit and vegetable juices were treated with a P-CD polymer to remove polyphenolics 
responsible for enzymatic browning.^^ Naringen and limonene, the bitter components 
of citrus fruits, have been removed using a polymer of P-CD. Organic compounds 
need to be solubilized in water for bioconversions and therefore, surfactants or 
solvents are used but these can be used in limited quantities because they affect the 
organism as well. By the use of methyted p-CD, a 6-fold increase in the bioconversion 
rate of podophyllotoxin was achieved compared to bioconversion in the absence of 
C D . " 
Stabilization 
Compounds capable of making complexes with CDs are stabilized as a result of 
complexation, because they cannot interact with other molecules. Moreover, there is 
steric hindrance, which prevents approach by a molecule to the exposed portion of the 
guest at the open cavities. Unsaturated fatty acids, for example in fish oil, are easily 
oxidized resulting in unpleasant taste and odour. These oils can be protected from 
oxidation by complexation with CD.^ ^ Peroxyacids are used as bleaching agents and 
their thermal stability and storage are a matter of concern. Complexation with CDs 
not only improves storage and thermal stability but odour is also reduced and complex 
is stable without using dilutants.^^ Explosives can also be stabilized by complexation 
with CDs."*" CDs play an important role in the stabilization of CD-oligonucleotide 
inclusion complex."" 
Masking of Effects of the Guest 
A guest molecule in the CD complex gets isolated, resulting in the masking of its 
various properties.''^ This technique has been used in masking the unwanted flavour in 
food and skin irritation effects. Lotions have been developed in which a fragrant but 
irritation causing component is complexed with CD in order to limit its direct physical 
contact with skin but still allowing evolution of the desired fragrance. Fixolide or 
tonalide, a synthetic fragrance, chemically known as 7-Acetyl-l, 1, 3, 4, 4, 6-
hexamethyl-1, 2, 3, 4-tetrahydronaphthalene (AHTN), is widely used to replace 
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natural musk odour which is more expensive. AHTN is semivolatile and is degraded 
under light exposure and high temperature. AHTN in the complexed forms with 
P-CD, methyl-CD and hydroxypropyUP-CD was more stable against high temperature 
and UV exposure than its free form."*^  The irritating or toxic effects of insecticides can 
also be reduced or eliminated by complexation with CDs. Azinophos-methyl forms an 
odourless complex with p-CD.'*'* No toxic effects were observed when the insecticide 
was administered dermally at a dose of 4000 mg/kg as CD-complex while free 
insecticide shows dermal toxicity at a does of 18 mg/kg. 
Reduction of Volatility 
Reduction of volatility and controlled release of chemicals are other important 
applications of CDs. Menthol, for example, forms an odourless complex with P-CD 
which can be dried at 100 °C while free menthol will be completely volatilized under 
these conditions. The release of fragrance from laundary dryer sheets can be 
controlled by complexing the fragrance with CDs.'* '^ '^^ 
Moreover, all the components of the fragrance have different volatility and 
some of the more highly volatile components are easily lost changing the composition 
of the fragrance. However, when these components are complexed with CDs, their 
volatility is reduced so that the character of the fragrance is not changed. CDs can also 
be used to prevent odour in the skin tanning and hair care preparations. A dry powder 
of CD can be used in products such as menstrual products, diapers, tissues, paper 
towels etc.''^ making them effective scavengers of unwanted odours. Perfumes can 
also be complexed to CDs to be released upon dissolution of the complex and 
displacement by odiferous compounds. 
CDs are effective in trapping pollutants and reducing their volatility, which 
help in pollution prevention. The organic pollutants are trapped in water by CDs via 
the formation of inclusion complexes and dechlorinated by a supported heterogeneous 
palladium catalyst. Catalytic investigations demonstrate that CDs act as efficient CCI4 
solubilizers and, much more interesting, as protective molecules against side 
reactions.'*^ 
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Directing of Chemical Reactions 
CDs are also used for the mediation of specific organic reactions. The formation of 
host/guest complex, not only alter the parameters such as solubility, but inclusion of 
the part of the guest molecule into the CD-cavity offers significant steric shielding. 
This concept has been utilized in many ways for highly selective syntheses. 
2, 6-Naphthalenedicarboxylic acid is an important monomer for liquid crystalline 
polymer synthesis. Synthesis of 2, 6-naphtba\enedicarboxylic acid is difficult d\ie to 
several reactive sites on the naphthalene ring leading to a range of products. It was 
found that when naphthalene was first complexed with CD then the yield of the 
desired 2, 6-product was greatly improved.^' The host CD sterically shielded the 
undesirable reaction sites on the naphthalene ring. In recent years CDs have been used 
as catalysts in organic reactions. The use of CDs in organic reactions as a 
supramolecular catalyst has also been investigated.^^ 
1.4.2 PHARMACEUTICAL APPLICATIONS OF CDs 
Of all the industrial applications of CDs, a large portion of their uses is devoted to 
their applications in the field of pharmaceuticals. The most important pharmaceutical 
applications of CDs are to enhance the solubility, stability and bioavailability of drug 
molecule. Each CD has its own ability to form inclusion complexes with specific 
guests, an ability which depends on a proper fit of the guest molecule within the 
hydrophobic CD cavity. At present, some 30-40 or so drug formulations are approved 
and marketed worldwide as CD complexes, generally natural CD complexes 
(Table 4). In pharmaceutical formulations, CDs are generally used as solubilizers but 
also sometimes as stabilizers or to reduce local drug irritation.^'' The structures of 
some of the pharmaceutical compounds marketed as CD complexes are shown in 
Fig. 4. 
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Table 4. Cyclodextrin-containing pharmaceutical products 18,54,55 
Drug/cyclodextrin 
a-CD 
Alprostadil (PGEi) 
OP-1206 
Cefotiam hexetil HCl 
P-CD 
Benexate HCi 
Cephalosporin 
(ME 1207) 
Chlordiazepoxide 
Dexamethasone 
Diphenhydramin HCl, 
Chlortheophyllin 
Iodine 
Nicotine 
Nimesulide 
Nitroglycerin 
Omeprazol 
PGE2 
Piroxicam 
Tiaprofenic acid 
2-Hydroxypropyl-P-CD 
Cisapride 
Itraconazole 
Mitomycin 
Methylated p-CD 
Chloramphenicol 
17p-Estradio! 
Sulfobutylether p-CD 
Voriconazole 
Ziprasidone mesylate 
2-HydroxypropyI-y-CD 
Diclofenac sodium 
Tc-99 Teoboroxime 
Trade name 
Prostavastin, 
Rigidur 
Opalmon 
Pansporin T 
Ulgut, Lonmiel 
Meiact 
Transillium 
Glymesason 
Stada-Travel 
Mena-Gargle 
Nicorette, Nicogum 
Nimedex 
Nitropen 
Omebeta 
Prostarmon E 
Brexin, Flogene, 
Cicladon 
Surgamyl 
Propulsid 
Sporanox 
Mitozytrex 
Clorocil 
Aerodiol 
Vfend 
Geodon, Zeldox 
Voltaren 
Cardiotec 
Formulation 
I. V. solution 
Tablet 
Tablet 
Capsule 
Tablet 
Tablet 
Ointment 
Chewing tablet 
Solution 
Sublingual tablet, 
chewing gum 
Tablet 
Sublingual tablet 
Tablet 
Sublingual tablet 
Tablet, 
Suppository, Liquid 
Tablet 
Suppository 
Oral and 
I. V. solutions 
I. V. infusion 
Eye drop solution 
Nasal spray 
I. V. solution 
IM solution 
Eye drop solution 
I. V. solution 
Country 
Japan, 
Europe, USA 
Japan 
Japan 
Japan 
Japan 
Argentina 
Japan 
Europe 
Japan 
Europe 
Europe 
Japan 
Europe 
Japan 
Europe, 
Brazil 
Europe 
Europe 
Europe, USA 
Europe, USA 
Europe 
Europe 
Europe, USA 
Europe, USA 
Europe 
USA 
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Alprostadil (PGE,) ^ Cefotiam Hexetil Hydrochloride 
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Cephalosporin-nucleus 
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Ziprasidone 
H / \ 
Itraconazole 
Fig. 4. Structures of some pharmaceutical compounds marketed as CD-complexes. 
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The principle advantage of nahiral CDs are their (1) well defined chemical 
structures yielding many potential sites for chemical modification (2) easy availability 
and low cost (3) low toxicity and pharmacological activity (4) some water solubility 
and (5) protection of included drug molecule from biodegradation. However, natural 
CDs have relativity low solubility, both in water and organic solvents, which limit 
their uses in pharmaceutical formulations. P-CD, the most common natural CD, has 
21 hydroxyl groups, i.e. 7 primary and 14 secondary, which are available as starting 
points for structural modifications and so a variety of CD derivatives have been 
prepared so as to extend the physicochemical properties and inclusion capacity of the 
parent host molecule. Typical examples of the pharmaceutically useful P-CD 
derivatives are listed in Table 2 and 3, classified into hydrophilic, hydrophobic and 
ionic derivatives. 
Solubilization of Drugs 
One of ihe niosc important appilv^ations of the CDs in the field of pharmaceutical 
sciences is to enhance aqueous solubility of drugs through complexation. While the 
solubility of many compounds is not sufficiently increased using unmodified CDs, 
derivatives can be used to increase the water solubility to higher concentrations than 
can be achieved with natural CDs. Itraconazole,^^ an antifimgal agent, is insoluble in 
water. Itraconazole can be solubilized using cosolvents but it precipitates in the 
stomach. Hydroxypropyl-P-CD prevents its precipitation in stomach thus allowing its 
use in an oral dosage formulation.^^ Similarly, a 16 fold increase in the water 
solubility of felodipine and 3-fold increase in the water solubility of amlodipine was 
reported on complexafion with methyl-P-CD. *^ 
CDs can also be used for reducing the water solubility of drugs. For example, 
flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) but the use of 
NSAIDs is limited because of their gastrointestinal side effects. Flufenamic acid is 
water soluble and a water insoluble CD derivative, triacyl P-CD, was used to complex 
the drug to slow the release of the drug.^ ^ The complexed drug did not have an 
immediate sharp increase in the plasma concentration as did the uncomplexed drug, 
but had a sustained plasma plateau lasting 6-8 h. Desirable plasma concentration were 
19 
achieved from the complexed drug without reaching high plasma levels which have 
adverse effects. 
Moreover, the solubility characteristics imparted by CD complexation are 
stable. The dissolution characteristics of glibomuride remained unchanged when it 
was stored for one year in the form of P-CD complex.^° A comparative study of the 
solubilizing effects of 2-hydroxyethyl-P-CD and 2-hydroxypropyl-P-CD, with 
different degrees of substitution was made on hydrocortisone, digitoxin, diazepam, 
and indomethacin.^' The solubilizing effect of 2-hydroxyethyl-P-CD with an average 
degree of substitution of 3.0 was similar to that of 2-hydroxypropyl-P-CD with an 
average of degree of substitution of 2.5. It was also observed that the degree of 
substitution markedly affected the solubilizing effect: the solubility of digitoxin in the 
presence of 2-hydroxyethyl-p-CD decreased with an increase in the average degree of 
substitution. 3-Hydroxyethyl-P-CD was found to have slightly higher solubilizing 
ability while 2, 3-dihydroxypropyl-P-CD had a lower solubilizing effect as compared 
to P-CD.^ ^ Several sulfated CD derivatives have also been studied for their 
complexation behaviour. Because both the CD rims are surrounded by negatively 
charged groups, CD sulfates interact with positively charged drug molecules such as 
chlorpromazine^^ and gentamicin.^ The inclusion ability of P-CD sulfate with 
chlorpromazine was weaker as compared to P-CD. The solubilizing ability of CD 
sulfates has not been studied in detail because of their weaker interaction with acidic 
and neutral drugs such as flufenamic acid, flurbiprofen, diazepam and steroids.^^ The 
weaker interaction between CD sulfate derivatives and guest may be due to the 
difficulty in approach of the guest to the CD cavity through highly hydrated entrance 
as well as the electrostatic repulsion between negative charges of the host and anionic 
guest. To overcome such a drawback with the CD sulfate derivatives, a series of 
sulfoalkyl ether derivatives have been used. It was found that sulfobutyUP-CD is a 
good solubilizer for various poorly water-soluble drugs such as kynostatin, steroids, 
cinnarizine, indomethacin, naproxen and miconazole etc.^ ^ 
When mono- or disaccharides are attached to one or two primary hydroxyl 
groups of CD through 2, 6-glycosidic linkage, their water solubility markedly 
increases: the solubility of 6-0-glucosyl-P-CD, 6-0-maltosyl-P-CD in water is over 
50% (w/v) at 25 C. The complexation ability of branched CDs against hydrophobic 
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guests is comparable to parent CDs and decreases only slightly with increase in the 
glucose number and the degree of substitution. However, the solubilizing ability of 
branched CDs is much greater than that of parent CDs. Branched CDs have higher 
affinity towards steroidal drugs such as progesterone, testosterone, dehydrocholic 
acid, digitoxin etc.^ '^ ^^  Due to their high solubilizing effect, branched CDs may be 
useful for parenteral preparations such as injections because of their weak hemolytic 
activity and high bioadaptability. 
The solubility of CDs can significantly be affected by water miscible cosolutes 
and cosolvents. For example, urea is known to increase solubility of a variety of polar 
and non-polar organic solutes in water. The solubilities of P- and y-CD were 
significantly enhanced in the presence of urea while that of a-CD decreased. Such 
solubility changes were observed for cosolvents such as alcohols, acetonitrile, 
dimethyl sulfoxide, dimethyl formamide, acetic acid and ethylene glycol etc.^ "^^ ° 
The cosolubilization method has been found useful for the preparation of solid 
2-hydroxypropylated CD complexes with unstable drugs such as steroids, peptides 
and antibiotics. The synergetic effect of CD derivatives (methylated, 
hydroxyalkylated, carboxymethylated and branched forms) and water soluble 
polymers (polyvinyl pirroridone, hydroxypropylmethyl cellulose and carboxymethyl 
cellulose) on the solubility of various poorly water soluble drugs were studied. It was 
found that the solubilizing effect of 2-hydroxypropyl-P-CD is enhanced on an average 
of 27% by carboxymethyl cellulose and 49% by polyvinyl pirroridone.^'' 
Carbamazepine, an anticonvulsant drug, is reported to form inclusion complex with 
P-CD, which could improve its biological performance^'' as well as solubility. '^* The 
lower solubility of poorly water-soluble drug, norfloxacin was enhanced by 
complexing it with the P-CD.^ ^ Ketoprofen, a non-steroidal anti-inflammatory drug 
with analgesic and antipyretic activity, has poor aqueous solubility. The initial 
dissolution rate of ketoprofen in the inclusion complex with P-CD showed 15-fold 
higher dissolution rate than that of plain drug powder.^^ Table 5 summarizes the 
solubility enhancement studies of variety of pharmaceutical compounds in the 
presence of CDs. 
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Table 5. Examples of CD enhanced solubility of pharmaceuticals. 
CD 
P-CD 
a-CD 
Y-CD 
Hydroxypropyl-P-CD 
Sulfobutylether-p-CD 
Randomly methylated P-CD 
Randomly acetylated 
amorphous-p-CD (Ac-p-CD) 
Dimethyl-p-CD 
Drug(s) 
Nimesulide, Sulfomethiazole, 
Lorazepam, Ketoprofen, 
Griseofulvin, Praziquantel, 
Chlorthalidone, Etodolac, 
Piroxicam, Itraconazole, Ibuprofen 
Praziquantel 
Praziquantel, Omeprazole, Digoxin 
Albendazole, DY-9760e, ETH-615, 
Levemopamil HCl, Sulfomethiazole, 
Ketoprofen, Griseofiilvin, 
Itraconazole, Carbamazepine, 
Zolpidem, Phenytoin, Rofecoxib 
DY-9760e, Danazol, Fluasterone, 
Spiranolactone 
ETH-615, Tacrolimus 
Naproxen 
Naproxen, Camptothesin 
Reference 
77-89 
83 
83, 89, 90 
91-94,78,80,82, 
87,95-100 
92, 101-103 
93, 104 
105 
106,107 
Stabilization 
The drugs must retain sufficient stability not only during storage but also in the 
gastrointestinal fluids, since reactions, which result in a product that is 
pharmacologically inactive or less active will reduce the therapeutic effectiveness. 
The main concern in the pharmaceutical field is, therefore, the rate of deceleration. 
CDs have been used to stabilize pharmaceutical compounds.'°^' "'^  
Thymopentin is a peptide, which blocks the stimulation of smooth muscle 
contractions induced by (+)-anatoxin-a, which is produced by blue green algae. 
Thymopentin is unstable in aqueous solution and cannot be stored in a ready to use 
form. The activity was retained over 14 months of storage at 25 ^C when the drug was 
complexed with 2-hydroxypropyl-P-CD in aqueous solution. In the absence of the 
CD, all the activity was lost within one week.'°^ 
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Erythropoeten is a glycoprotein hormone, which induces an increase in red 
cell mass. Complexed with 2-hydroxypropyl-p-CD, 100% of the activity was 
maintained for 10 days compared to only 50% of the activity in the absence of CD. 
The complexed erythropoeten retained 62% of the activity after 20 days compared to 
only 24% in the absence of CD.'°^ 
Nicardipine is light sensitive drug and decomposes if exposed to light. The 
rate of photodegradation was reduced by complexing the drug with CDs. CD 
complexes of nicardipine were irradiated by UV light. Photodegradation was slowed 
by a factor of 10 with methylated-P-CD, 8 mth 2-hydroxypropyl-p-CD, 6.5 with 
a-CDand 5 withy-CD.'"' 
Digoxin, one of the potent cardiac glycosides, is susceptible to hydrolysis in 
acidic media. The acid-catalyzed hydrolysis of the glycoside bonds in digoxin is 
decelerated by the addition of CDs. The hydrolysis of the glycosidic linkage 
connecting the A-ring of digoxin and the sugar was completely inhibited by P-CD. 
When the catalytic hydroxyl groups of the CD are blocked by substituents, their 
stabilizing effect is enhanced. The p-hydroxyketo-moiety of the E-type prostaglandins 
is extremely susceptible to dehydration under acidic or alkaline conditions. Parent 
CDs showed a positive catalytic effect but the use of methylated P-CD significantly 
decelerated the degradation reaction. Prostaglandin Ei has been stabilized by 
6-0-(carboxymethyl)-0-ethyl-P-CD in a fatty alcohol propylene glycol ointment, 
because prostaglandin Ei is most stable in acidic conditions."^ Carmofur is extremely 
susceptible to base and water catalyzed hydrolysis to 5-fluorouracil, which irritates 
the gastrointestinal tracts. The carmofur can be stabilized by complexing with 
6-0-(carboxymethyl)-0-P-CD."'' An antitumor drug, 0-6-benzylguanine, undergoes 
hydrolysis under acidic conditions to form guanine and benzyl alcohol. The 
hydrolysis atpH 4.8 was decelerated by a factor of 220 by complexing the drug with 
sulfobutyl-P-CD with an average degree of substitution of 4."'' The results of stability 
enhancement of pharmaceuticals in the presence of CDs are summarized in Table 6. 
Table 6. Effect of cyclodextrins on drug stability enhancement. 
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Effect 
Photostability 
Shelf life with unaffected 
dissolution rates for 4 years 
Thermal stability in solid 
state 
Stability against 
intramolecular cyclization 
in solid state 
Stability to acid hydrolysis 
and photodecomposition 
Stability against hydrolysis 
Deacetylation or 
degradation 
Photoreactivity 
Drug 
Promethazine 
DY-9760e 
2-Ethylhexyl-p-
dimethyl 
aminobenzoate 
Piroxicam 
Tenoxicam 
Nicardipine 
Glibenclamide 
Diclofenac sodium 
Quinaril 
Doxorubicin 
Acyl ester prodrugs of 
Ganciclovir 
Digoxin 
Rofecoxib 
Camptothesin 
Melphalan and 
Carmustine 
Paclitaxel 
Spiranolactone 
Flutamide 
CD 
Hydroxypropyl-P-CD, 
Dimethyl-p-CD 
Sulphobutylether-p-CD 
Hydroxypropyl- |3-CD 
Hydroxypropyl-p-CD 
p-CD 
P-CD, Hydroxypropyl-p-
CD, 
(2-hydroxyethyl)-p-CD 
P-CD 
P-CD 
P-CD, Hydroxypropyl-P-
CD 
Hydroxypropyl-P-CD, 
Hydroxypropyl-y-CD 
Hydroxypropyl-P-CD 
y-CD 
Hydroxypropyl-P-CD 
Randomly dimethylated 
P-CD 
Sulfobutyl-P-CD, 
Hydroxypropyl-p-CD 
y-CD, Hydroxypropyl-y-
CD, Hydroxypropyl-P-
CD 
Sulfobutylether-a-CD, 
Sulfobutylether-P-CD, 
Hydroxypropyl-P-CD, 
y-CD, p-CD 
P-CD 
Reference 
93 
92 
115 
116 
117 
118 
119 
120 
121 
122 
80 
90 
91 
100 
123 
124 
125 
126 
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Absorption Enhancement 
The enhanced water solubility of the drug upon complexation with CDs has been 
found to resuh in the enhanced bioavailability of the drug.''^' '^ "'''^ ^ The rate and extent 
of bioavailability of a poorly water-soluble drug from its CD complex is optimized by 
adjusting factors affecting the dissociation equilibria of the complex both in the 
formulation and in the biophase in which the complex is administered. Only a free 
form of the drug, which is in equilibrium with the complexed one in solution, is 
capable of penetrating the lipophilic barriers consisting of either mucosal epithelia or 
stratified cell layers and eventually entering the systemic circulation. Practical 
formulations usually contain a large quantity of pharmaceutical excipients, which may 
compete with the drug for the CD cavity. Moreover, the endogenous substances 
existing at the absorption site may also compete for the CD cavity. The displacement 
of the drug from the CD cavity by exogenous and endogenous substances is 
responsible for acceleration of the drug absorption. Some recent findings on the 
enhanced drug absorption by hydrophilic CDs administered via different routes are 
discussed here.'^ *^ 
Oral Delivery 
CD-drug complexes for oral preparations have two main advantages: one improved 
bioavailability and other reduced irritation. The commercial viability of the CD-based 
oral formulations has been established with the marketing of more than 
10 products.^ "*' '^'' '^ ^ Rapidly dissolving complexes of drugs with hydrophilic CDs are 
best suited for sublingual or buccal administration. This type of drug delivery not only 
gives a rapid rise in the systemic drug concentration but also avoids intestinal and 
hepatic first-pass metabolism of the drug. Water soluble complex of digoxin with 
y-CD can be formulated into a sublingual tablet to enhance bioavailability and to 
avoid acid hydrolysis of the drug by gastric juices.'^'' Other examples are sublingual 
administration of tablets containing complexes of steroids with CDs. 
2-Hydroxypropyl-p-CD and P-CD polymer supported the absorption of testosterone 
from the oral cavity and not from the gastrointestinal tracts.'"''*' ^^^ 
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Rectal Delivery 
The release of drugs from suppository bases is one of the important factors in the 
rectal absorption of the drug. In general, hydrophilic CDs enhance the release of 
poorly water-soluble drugs from oleaginous suppository bases. In comparison to 
parent CDs, the methylated CDs are found to significantly enhance the rectal 
absorption of hydrophobic drugs such as flurbiprofen,'^^ carmafur'^ ^ and 
biphenylylacetic acid'''^ from the oleaginous suppository. 2-Hydroxypropyl-p-CD was 
also found particularly useful for the enhancement of rectal absorption of the above 
drugs. The most striking effect of 2-Hydroxypropyl-p-CD was observed for the rectal 
absorption enhancement of the anti-inflammatory drug ethyl 4-biphenylylacetate, a 
lipophilic prodrug of biphenylylacetic acid.'^^ There is a great clinical need for the 
development of long-active types of rectal preparations for the potent opioid, 
morphine, in the treatment of intractable chronic pain in advanced cancer patients. 
Some hydrophilic CDs have been found to enhance the rectal absorption of morphine 
from the hollow-type oleaginous suppository in rabbits.''* 
Dermal Delivery 
CDs have a significant safety margin in dermal applications and can be used to 
optimizing the transdermal delivery of drugs intended either for local or systemic 
use.''" Some CD based formulations available for dermal and ocular applications are 
given in Table 7. A suitable vehicle must be selected so that CDs fully exert their 
fiinctions. For instance, the in vitro release rate of corticosteroids for water containing 
ointments (hydrophilic, absorptive or polyacrylic base) is markedly increased by 
hydrophilic CDs, whereas in other ointments (a fully alcohol propylene glycol or 
macrogol base) the CDs retard the drug release.''*^ When the hydrophilic ointment 
containing ethyl 4-biphenylylacetate or its CD complexes was applied to the skin of 
rats, the release of ethyl 4-biphenylylacetate from the ointment into the skin was 
enhanced by heptakis(2,6-di-0-methyl)-p-CD or 2-hydroxypropyl-P-CD, while P-CD 
had no appreciable effect. In addition, the p-CDs assisted the bioconversion of ethyl 
4-biphenylylacetate to biphenylylacetic acid in the skin and consequently facilitated 
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the delivery of active biphenylylacetic acid to subcutaneous tissues, where its action is 
most desired.''*^' ^'^ 
Table 7. CD-based formulations for dermal and ocular applications. 
Active 
L-Camitin 
Tocopherol 
Vitamin A 
Vitamin A 
Seaweed green 
tea 
Dexamethasone 
Chloramphenicol 
Diclofenac 
Product type 
OTC 
OTC 
Cosmetic 
Cosmetic 
Cosmetic 
Pharmaceutical 
Pharmaceutical 
Pharmaceutical 
Trade name 
Cellutex 
Luminys 
Mirakelle™ 
Sweden 
A.I.YU.U 
Cream 
Glyteer 
(Glymesason 
ointment) 
Clorocil 
Voltaren 
Ophthalmic 
Formulation 
Cream 
Cream 
Cream Base 
Spray 
Topical 
Ointment 
Eye drops 
Eye drops 
Indication 
Anti-Cellulitis 
Cosmetic 
Wrinkle 
treatment 
Wrinkle 
treatment 
Wrinkle 
treatment 
Analgesic, 
anti-
inflammatory 
Antibiotic 
Antibiotic 
Country 
Germany 
Italy 
Distributor-
USA 
Japan 
Germany 
Japan 
Portugal 
Switzerlan( 
Ocular Delivery 
One of the pre-requisite for a new vehicle to be used in ophthalmic preparations is 
that it is not irritating to the ocular surface, because irritation causes reflex tearing and 
blinking, which results in a fast washout of the instilled drug. The major problem with 
eye drops is its inability to sustain high local concentrations of drug. The ability of 
CDs to solubilize hydrophobic drugs and provide a hydrophilic exterior makes it 
useful for ocular applications. As seen in Table 7, a number of ocular formulations are 
available that utilize CDs as enabling excipients. 
The administration of ophthalmic drugs in gels and in polymer matrixes has 
been shown to increase the contact time of the drug with cornea, a situation which 
increases their bioavailability. However, the patient's acceptance of such delivery 
systems is unsatisfactory. The possible advantages in the use of CDs are increase in 
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solubility and/or stability and avoidance of incompatibilities of drugs, such as 
irritation and discomfort.'^^ 
Hydrophilic CDs, especially 2-hydroxypropyl-P-CD and sulfobutyl-P-CD 
have been shown to be nontoxic to the eye and are well tolerated in aqueous eye drop 
formulations. These hydrophilic CDs do not penetrate tight biological barriers such as 
the eye cornea but enhance the ocular bioavailability of lipophilic drugs by keeping 
the drugs in solution and increasing their bioavailability at the surface of the corneal 
barriers.''*^' '''^  For example, dexamethasone acetate-2-hydroxypropyl-P-CD complex 
can be made as an ophthalmic solution. Recent studies have demonstrated that water 
soluble polymers such as hydroxymethylcellulose and polypyrroridone stabilize the 
complex of dexamethasone with 2-hydroxypropyl-P-CD probably through the 
formation of a ternary complex, a situation which increases the aqueous solubility in 
eye drops and enhances the drug penetration into the aqueous humor in humans. 
A combination of 2-hydroxypropyl-P-CD with hydroxypropyl-methyl-cellulose has 
also been shown to improve the topical delivery of carbonic anhydrase inhibitors to 
theeyes.'^-'^" 
Alleviation of Local and Systemic Toxicity 
The molecular entrapment of a drug into the CD cavity prevents its direct contact with 
biological surface as well as the entry of the drug into the cells of non-targeted tissues 
and thus reducing the local irritation.'^' Pilocarpine was administered as a prodrug, 
0,0'-dipropionyl(l,4-xylene)bipilocarpine acid diester, with 2-hydroxypropyl-P-CD. 
The amount of irritation decreased as the amount of CD was increased. At the 
concentration of 15%, the irritation was reduced to the same level as that with the 
commercial formulation and the ocular delivery was substantially improved.'^^ 
A complex of diclofenac was compared to a commercial preparation. Voltaren. Lysis 
of red blood cells was used to evaluate cellular lysis. The amoimt of complex needed 
to lyse the red blood cells was four times higher than for diclofenac alone. The results 
indicated the suitability of the hydroxypropyl-p-CD to optimize the ophthalmic 
application of the drug for improved transcomeal permeability and in vivo tolerance 
based upon the haemolysis studies.'" CDs also alleviate muscular tissue damage 
following intramuscular injection of drugs. For example, the intramuscular 
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administration of chlorpromazine in the absence as well as in the presence of P-CD 
derivatives to rabbits showed reduced chlorpromazine-induced muscular damage.'^ '* 
CDs diminish the ulcerogenic potency of several acidic anti-inflammatory drugs and 
mask their disgusting smells and tastes when they are administered orally. A similar 
protection by hydrophilic CDs after rectal and ocular administration of drugs was also 
described. For example, 2-hydroxypropyl-P-CD significantly reduced the irritation of 
rectal mucosa in rats caused by biphenylylacetic acid both for single and multiple 
administrations of the complex of ethyl 4-biphenylylacetate with 2-hydroxypropyl-p-
CD in oleaginous suppositories.'^^ 
Systemic Detoxification 
A study has demonstrated that the addition of P-CD to dialysis fluids accelerated the 
removal of phenobarbital by peritoneal dialysis, thereby proving effective in the 
treatment of drug overdose.'^^ A retinal-dextran conjugate solubilized by P-CD was 
reported to be less cytotoxic and retained the ability to inhibit the growth of cancer 
cells.'" CDs can be used not only as an enabling excipients in pharmaceutical 
formulations, but also as artificial carriers, for either exogenous or endogenous 
lipophiles, in the body.'^^ Some natural lipophiles are changed into toxic agents when 
the organism lacks the ability to transport and redistribute them properly by carrier 
proteins and their receptor systems. Furthermore, various exogenous lipophiles enter 
the body and accumulate in fat tissues. Consequently, these exogenous lipophiles may 
exert toxic action for a very long period. In such cases CDs act as an artificial 
circulating carrier for the lipophiles in order to redistribute them in extracellular 
space. 
When heptakis(2,6-di-0-methyl)-P-CD was administered parenterally to mice 
under retinoid induced hypervitaminosis A, the survival rate of poisoned animals was 
significantly improved.'^^ This preliminary result was the impetus for the use of 
2-hydroxypropyl-p-CD to rescue a patient with familial hypervitaminosis A caused by 
overloading retinal esters in the liver.'^° 
Gentamicin, an aminoglycoside antibiotic, is widely used in the clinical 
treatment of gram-negative infections, but its use is sometimes complicated by the 
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development of drug-induced acute renal failure. CD sulfates, when given 
intraperitoneally, protected rats against renal impairment due to gentamicin. The 
protection probably occurs through interfering with the intracellular events leading 
from the drug accumulation to nephrotoxicity.'^' 
Cyclodextrin Based Delivery Systems 
CDs possess a special ability to complex with drugs enabling them to increase 
solubility, reduce bitterness, enhance stability, and decrease tissue irritation upon 
dosing. CDs have been used extensively in pharmaceutical research and development, 
and there are currently over 30 marketed CD-containing pharmaceutical products 
worldwide.'^^ Due to their multifunctional characteristics, CDs have also been found 
useful in oral drug delivery,'^^ peptide and protein delivery, and site-specific delivery. 
There are numerous excellent reviews on the use of CDs in oral dosage forms, and 
many which specifically address the effect of CDs on oral absorption and/or 
bioavailability. One recent review by Loftsson et al. examines over 80 publications on 
the effect of CDs on oral bioavailability of 50 different drugs using 17 different CDs 
in the context of the Biopharmaceutical Classification System.'^^ Drug release should 
be controlled in accordance with the therapeutic purpose and the pharmacological 
properties of active substances. There has been a growing interest in developing the 
rate- or time-controlled type oral prepai-ations, because an appropriate drug release 
from the dosage forms is of critical importance in realizing their therapeutic efficacy. 
Various CD derivatives have been used for controlled drug release in oral 
preparations. The hydrophilic and hydrophobic CDs are usefiil for the immediate 
release'^^ and prolonged release'^^' '^ '' type oral formulations, respectively. The 
delayed release type oral formulation can be obtained by the use of 
6-0-(carboxymethyl)-0-ethyl-p-CD.' ^ ^ 
Advances in biotechnology have accelerated the economical, large-scale 
production of therapeutically active peptide and protein-based drugs used to combat 
poorly controlled diseases, making them more readily available for therapeutic use. 
The progress in molecular biology, however, has not been matched by the progress in 
the formulation and development of delivery systems for peptide and protein drugs. 
There are considerable hurdles to be overcome before practical use can be made of 
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therapeutic peptides and proteins because of chemical and enzymatic instability, poor 
absorption through biological membranes, rapid plasma clearance and 
immunogenicity. Many attempts have been made to address these problems by 
chemical modifications or by coadministration of adjuvants to eliminate undesirable 
properties of peptides and proteins. CD complexation is an attractive alternative to the 
above approaches.'*^ 
Recently, intensive efforts have been made to design systems able to deliver 
drugs more efficiently to specific organs, tissues, and cells, etc. " The CD 
complexes are in equilibrium with guest and host molecule in water, the degree of the 
dissociation being dependent on the magnitude of the stability constant. This property 
of the complex is a desirable quality, because the complex dissociates to free CD and 
drug at the absorption site, and only the drug in free form enters into systemic 
circulation. A typical example is the application of 2-hydroxypropyl-P-CD to the 
chemical delivery system developed by Bodor'''" which was used to deliver the polar 
drugs targeted on the brain. 
Toxicological Considerations and Regulatory Status 
It has been established that oral feeding of a-, or P-CD to rats did not cause any toxic 
reactions and that the previously observed toxicity was most likely due to 
impurities.''*' '^' CDs are practically non-toxic due to lack of absorption from the 
gastrointestinal tract.'^^ However, the lipophilic methylated p-CD are surface active 
and they are to some extent (-10%) absorbed from the gastrointestinal tract and 
consequently only limited amounts of these lipophilic CD derivatives can be included 
in oral formulations, and they are unsuited for perenteral formulations.^^ Due to 
toxicological considerations, P-CD cannot be used in perenteral formulations and 
usage of a-CD in parenteral formulation is severely limited although it can be found 
in one marketed formulation (Table 4).'^^ In case of animals, y-CD has been foimd to 
be virtually non-toxic when given intravenously.'^^ 2-Hydroxypropyl-P-CD'''' and 
sulfobutylether P-CD'^^ are available for parenteral formulations at relatively high 
concentrations (Table 4). 
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The regulatory status of CDs is continuously evolving. The natural p-CD can 
be found in a number of pharmaceutical formulations in numerous countries 
throughout the world (Table 4). All three natural CDs (i.e. a-, p-, and y-CD) are listed 
in Japanese Pharmaceutical Codex (JPC) and in Japan all three have been approved as 
food additives. a-CD is listed in European Pharmacopoeia and 2-hydroxypropyl-P-CD 
is listed in both European Pharmacopoeia and US Pharmacopoeia (USP/NF). 
2-Hydroxypropyl-p-CD is cited in the FDA's list of Inactive Pharmaceutical 
Ingredients. Thus, CDs are excipients and not part of drug substances, which is logical 
based on their physicochemical properties as drug solubilizers and stablizers. 
1.5 CHIRAL RECOGNITION BY CYCLODEXTRINS 
Enantiomerism has always been treated as rather "special" type of isomerism, 
probably because the only difference between the enantiomers is the manner in which 
they interact with polarized light. One enantiomer is therefore rarely regarded as an 
impurity when present in a sample of the other enantiomer, in contrast to, say, a 
mixture of two aromatic positional isomers or a mixture of E- and Z-alkenes. In fact, 
this lack of any difference other than optical activity, only holds in a truly achiral 
situation and as soon as any chirality is introduced into the envirorunent of a chiral 
molecule the enantiomers are differentiated. This will clearly be the case when a 
chiral drug interacts with an enzyme or a receptor, as such biomolecules will typically 
represent a chiral environment. Furthermore, processes such as drug absorption, 
distribution, excretion and metabolism are all potentially subject to enantioselection. 
It is important to realize that the other enantiomer of a chiral drug, usually 
present as a 50% admixture, as the result of chemical synthesis, may be more than just 
an ineffective version of hs mirror image, and may have dramatically different (and 
potentially undesirable) pharmacological effects in its own right. 
L-Dopa (1), a-dextropropoxyphene (2) and S-(-) timolol (3) are commercially 
available drugs that are marketed as single enantiomer because the antipode produced 
unwanted side effects. For L-Dopa, it was noted during early development that many 
of the serious side effects, such as granulocytopenia, were due to the D-isomer: the 
racemate is no longer used in humans.'^^ In contrast to flecainide (4) where both 
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enantiomers have been reported to have very similar activity,'^^ the isomers of 
propoxyphene appear to have completely different activities. D-Propoxyphene has 
analgesic properties whereas its optical isomer L-propoxyphene has antitussive 
properties but is devoid of analgesic properties. 
Indacrinone (5) is an interesting drug that has both diuretic and uricosuric 
activity. Preclinical and clinical studies showed that R-(-)-5 and its active metabolite 
are responsible for the diuretic activity, whereas S-(-)-5 promotes uric acid 
excretion.'^^ Each enantiomer seems to possess very little of the antipode's activity. 
Similarly, S-(-) enantiomer of 3 was selected for development as a p-blocking agent 
because the R-(+)-3 was found for the treatment of glaucoma. S-(-)-3 has been 
reported to cause fatal P-blockade induced bronchoconstriction when applied topically 
to treat glaucoma. It becomes obvious from these examples that each enantiomer 
needs to be evaluated separately before being regulated for use as a drug. The 
separation of enantiomers and their characterization are, therefore, of great 
importance for the pharmaceutical industry. 
Chiral recognition phenomena are of primary importance in most living 
systems and in chemistry. Chiral recognition, also often termed as 
enantiorecognition, refers to the ability of one chiral molecule to recognize the 
chirality of another molecule. CDs are chiral molecules and exhibit chiral recognition, 
i.e. they differentiate between enantiomeric species, forming diastereomeric 
complexes. The magnitude of the enantiorecognition in guest-CD interactions can be 
characterized by enantioselectivity. Enantioselectivity of recognition is a 
thermodynamic quantity correlating in some way with the separation factor of 
enantiomers in separation techniques. 
It must be noted that among presently applied chiral selectors only CDs are 
effectively used in all enantioseparation techniques.'^^ In fact, widespread industrial 
applications of CDs are primarily due to their two properties: complex formation and 
their chiral recognition ability. A better understanding of the inclusion complex 
formation and the chiral recognition mechanism of CDs is, therefore, a subject of 
great importance. 
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The basic mechanism of the interactions between CDs and other molecules is 
known'*^ but there are still questions to be answered. The most critical questions in 
CD chemistry are: (a) is the inclusion complex formation a prerequisite for chiral 
recognition by CDs? (b) Does any correlation exists between the binding strength and 
enantiorecognition power by CDs? (c) What sites of the CDs are primarily responsible 
for binding and enantiorecognition? (d) What are the major forces responsible for 
binding, and what factors are responsible for chirail recognition. 
Calorimetric titrations, mass spectrometry, X-ray analysis, various 
spectroscopic methods (Raman, circular dichroism, and fluorescence), potentiometry, 
and molecular mechanics and molecular dynamics calculations have been applied to 
study chiral recognition by CDs. 181. 184 Of all the techniques used to study chiral 
recognition, electrophoresis, chromatography techniques and NMR spectroscopy are 
the most frequently used methods.'^'* In chromatography, the separation of 
enantiomers is usually studied while spectroscopic techniques are used to study 
differences in other physicochemical parameters of the diastereomeric complexes 
involving CDs. 
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NMR spectroscopic studies have provided some of the most detailed 
information concerning the nature of these interactions and the structure of the 
diastereomeric complexes involved. The most distinct advantage of the NMR 
spectroscopy is that it allows the application of racemic san-iples or non-racemic 
mixtures of enantiomers for the enantioselective determination of the stoichiometry 
and equilibrium binding constants of the diastereomeric CD-complexes. Besides, the 
easier availability of racemic mixtures compared to pure enantiomers offers the 
possibility of competitive binding studies. This means that the interaction of one of the 
enantiomer of a racemic mixture with a chiral selector may be studied in the presence 
of the other enantiomer, which mimics closely the real condition in chiral 
chromatographic separations. 
NMR spectra of enantiomers in an achiral medium are identical because 
enantiotopic groups display same chemical shifts.'^^ Enantiodifferentiation in the 
spectra require the use of a chiral medium that converts the mixture of enantiomers 
into a mixture of diastereoisomeric complexes. The simplest application of the chiral 
discrimination by CDs is an observation of the separation of signals of diastereomeric 
forms. Such experiments enable a simple estimation of optical purity of the guest 
molecules and rely on evaluation of relative signal intensities belonging to respective 
species. Most of the observations of splitting signals due to chiral recognition pertain 
to ' H spectra. There are very few examples describing the effect in '^ C spectra'*^"'*^ 
and other nuclei, ' 'N , '«^ ' ^F ' ' ° and ^'P.'^' 
Evidence of chiral recognition is usually the first step for further structural, 
thermodynamic or theoretical studies. Although the chemical shifts of such species 
are generally different, the magnitude of the expected effect is not always large 
enough to be observed. Moreover, it depends on the chemical shift differences 
between the free and complexed forms of the guest, the actual binding constant and 
finally on the kinetics of host/guest exchange. Hence, in order to increase the 
separation of the signals, an excess of CD is usually used and an analysis of the guest 
spectra is made. In practice, the observation of the separation of ' H signals due to 
chiral recognition is easiest and straightforward in the case of relatively strong and 
narrow signals but may be very difficult for complicated multiplets or broad signals. 
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The observation of other nuclei provides several advantages, which include a larger 
chemical shift scale and a lack of multiplet structure as in 'H-coupled spectra. 
The spectra of (±)-pinene (6) complexes'^ ^ with a-CD in D2O present a typical 
example of the differentiation in 'H and '^ C signals due to chiral recognition,'** The 
corresponding A5=6(+) - 5(-) values are given in Table 8. The 'H signal separations 
were observed for almost all protons except H-7 and H-9, whereas, due to their larger 
chemical shift scale, the A5 ('^ C) values were larger by atleast 1 order of magnitude. 
10 
/V 
a-(+)-6 
Table 8. Differences between H and C complexation induced shifts (CIS) (ppm) of 
enantiomeric guest signals for the complexes of enantiomeric a-pinene with a-CD in 
D2O and DMSO. 
Atom 
1 
3 
4a 
4b 
5 
7a 
7b 
8 
9 
10 
'H 
-0.04 
-0.05 
-0.02 
0.00 
0.04 
-0.02 
0.01 
-0.02 
0.00 
0.04 
A8 CIS (D2O) 
'^C 
-0.5 
-0.2 
1.2 
0.3 
-1.3 
-0.3 
-0.4 
0.2 
A8 CIS (DMSO) 
U ( . 
0.01 
-0.01 
0.01 
0.01 
-0.01 
0.00 
-0.02 
-0.02 
36 
The influence of the magnitude of binding constants on the apparent signal 
separation is exemplified by the spectra observed for the same system in DMSO 
solution. In this case, due to greater solubility of free pinene, the binding constant 
should substantially decrease, consequently the differentiation of the ' H signals was 
too small to be observed and the difference in th6 magnitude of the C chemical 
shifts were reduced.'^^ Thus, as a result the differentiation of the signals of the 
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enantiomeric guest was seen only in the C spectrum. ' 
Spin-spin couplings, another NMR parameter, can also exhibit 
enantiodifferentiation. Since spin-spin coupling cannot be directly read out from the 
spectra of tightly coupled spin systems, it has seldom been used in chiral recognition 
studies. Lipkowitz and coworkers'^'' determined complexation induced differences in 
apparent couplings in the range of 0.01-1 Hz for tryptophan (7) enantiomers 
complexed by a-CD. The observation of enantiodifferentiation of coupling constants 
is expected to be more reliable for couplings involving heteronuclei, owing to their 
usually larger magnitude. 
r . ^ ^ ^ 
H 
,coo-
N H / 
The relaxation rates of nuclei are even more difficult to determine than spin-
spin coupling. Special experimental techniques and appropriate data reduction have to 
be applied in order to obtain their values.''^ On the other hand, relaxation rates of 
many magnetically active isotopes can provide valuable information on the dynamics 
of the system under study.'^^' '^ ^ 
Few relaxation studies for the complexes of CDs with enantiomeric guests 
have been reported. Interestingly, not all these works exhibit the differentiation of 
relaxation rates due to chiral recognition. The observations of differences in the 
relaxation rates of CD diastereomeric complexes are scarce and all but one is devoted 
to the studies of longitudinal relaxation rates. The first systematic study of this effect 
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was carried out for 7-CD complexes in D20.'^^ Longitudinal relaxation rates for all 
protons of host and guest molecules were determined in free 7 (0.26-2.3 s'), free 
a-CD (1.4-5.0 s"') and both diastereomeric complexes at a host-to-guest ratio of 1:1. 
The relaxation rates of 7 increased on complexation but were smaller than those for a-
CD protons. These results were interpreted in terms of larger motional freedom of the 
guest molecules than that of the host. According to authors, larger differential changes 
in relaxation rates of protons of 7 in the complex with R-enantiomer, as compared to 
those with the S-enantiomer complex, indicated that the latter enantiomer binds less 
tightly to a-CD. The cooperative effects of Coulomb interaction and inclusion were 
assumed to be essential for chiral recognition of anionic phenylacetic acid derivatives 
I no 
by several aminated CDs (8, 9). 
O^ JN 
(8)N=6,R|=R2=H 
(9)N=7,R,=R2=H 
Likewise, the importance of electrostatic interactions for chiral discrimination 
was proved for complexes of charged, cationic and anionic p-CD with various 
a-aminoacids.'^' It was demonstrated that protonated heptakis(6-amino-6-deoxy)-p-
CD favoured the complexation with (S)-enantiomers of N-acetylated tryptophan (10), 
phenylalanine (11), leucine (12) and valine (13) in their anionic form while the native 
a- and p-CD did not. Enantiodifferentiation was also found for cations of methyl 
esters of a-aminoacids interacting with the anionic form of heptakis(6-(thioglycolic 
acid)-6-deoxy)-p-CD where the (R)-enantiomers were preferred guests. 
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Enantiodifferentiation of anionic tetrahelicene (14) by native CDs was studied 
using binding constants and thermodynamic parameters determined by variable 
temperature 'H N M R titration.'*^ Tlie binding constant for the (M)-14 was found to be 
much higher than that for the corresponding (P)-14. However, the 2D ROESY 
(Rotating-frame Overhauser Effect Spectroscopy) measurements indicated a 
somewhat deeper insertion of the (P)-form into the CD cavity. The results were 
attributed to a domination of enthalpy effects in the process of complexation. 
-ooc COO- -OOC coo-
The binding constants and enthalpy change (AH) and entropy change (AS) 
vakies were determined for both the enantiomers of binaphthyl derivatives (15, 16) 
with native and heptakis(2,3,6-tri-0-methyl)-p-CD.''^' The results revealed that the 
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complexation is entropically driven. They also showed that the entropically driven 
complexation by the permethylated derivative differentiated the enantiomers more 
effectively. 
P 
15 16 
Several studies'^' "^^  reported the stoichiometry of CD complexes of 
enantiomers in combination with chemical electrophoresis (CE) enantioseparations, 
but a distinct difference in the stoichiometry of the complexes was observed in only 
few cases. Thus for example, Kano and coworkers^°' observed different 
stoichiometrics for the complexes of S- and R-l,r-binaphthyl-2,2'diol (17) with 
heptakis(2,3,6-tri-0-methyl)-p-CD. The stoichiometry of S-guest complex was 
determined to be 2:1 while for R-guest a 1:1 stoichiometry was found. 
,0H 
17 
An article on the structure determination of CD complexes, using NMR 
spectroscopy in relation to CE, was published by Yamashoji et al. in 1992.^ 2^ 
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Subsequently, several studies were reported^" '^ ^ "^  in which the authors tried to explain 
the quantitative differences observed in the behaviour of chiral selectors based on the 
structure with guest molecules. All these studies contributed significantly to a better 
understanding of CD-guest interactions. However, at present it is difficult even with 
very sophisticated powerful NMR techniques to define the structure and dynamics of 
the complexes on a level providing the key for the explanation of sometimes very fine 
quantitative differences in the enantioselective recognition by different CDs. 
The ' H NMR titration and ROESY studies of inclusion of l-(4-quinolyl) 
ethanol (18) by per-0-methylated-a-CD evidenced the formafion of equatorial and 
axial complexes of (R)- and (S)-enantiomers, respecfively.^"^ In addifion to the 
determination of the binding constants for both the enantiomers, the free energy 
changes (AG) were also determined. 
)—<! w 
\ // 
Axial 
18-(per-0-methylated)-a-CD complexes 
The screening of the affinity patterns of a wide range of chiral guests towards 
CD-type chiral selectors using CE revealed that the affinity pattern may change 
depending on the type and position of the substituents on the CD rim and on the CD 
cavity size. These studies help in elucidation of possible structural mechanism of 
qualitatively different behaviour of the CD type chiral selectors in CE, in particular, 
for examples in which the affinity of the enantiomers is opposite towards given chiral 
selectors. 
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The enantiomers of the anaesthetic drug ketamine (19) possesses an opposite 
affinity pattern towards native a- and p-CD.^ "^ ROESY spectroscopy indicated that 
there are no dramatic differences in the structures of the corresponding intermolecular 
complexes. The enantiomers are just more deeply included in the cavity of P-CD 
compared to a-CD?°^ Similar to this, no clear differences besides the extent of 
intermolecular inclusion could be observed between the structures of complexes of 
dimethinden (20) and chlorpheniramine (21) with P-CD and heptakis(2,3,6-tri-0-
methyl)-p-CD although the enantiomer affinity patterns were opposite for all three 
analytes towards these two CDs.^° '^ ^^ 
CH3 
In other examples, however, significant differences in the structures of 
intermolecular complexes could be observed. The enantiomers of clenbuterol (22) 
showed opposite affinity toward native p-CD and heptakis(2,3-0-diacetyl)-p-CD in 
CE experiments. The splitting of the resonance signals due to complexation induced 
chemical shifts of the protons of the enantiomers was primarily observed for the 
aromatic protons in the case of p-CD and for the protons of the tert-butyl moiety of 22 
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in the case of heptakis(2,3-0-diacetyl)-p-CD. These data indicate that the aromatic 
part of 22 is mainly involved in the interaction with P-CD while tert-butyl moiety is 
involved in the interaction with heptakis(2,3-0-diacetyl)-P-CD. 
HoN 
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The chiral cholinergic drug aminoglutethimide (23) shows opposite affinities 
in CE towards P- and y-CD.^ '^  The detailed NMR spectroscopic study confirmed the 
deep inclusion of the p-aminophenyl moiety of 23 into the p-CD cavity entering fi-om 
the wider secondary side while the p-aminophenyl ring enters the y-CD cavity from 
the narrower primary side. The glutarimide ring is apparently less involved in the 
complex formation. However, the involvement of the methyl group in complex 
formation cannot be completely ruled out. 
NHo 
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The complexation of antihistamine drug brompheniramine (24) with P-CD and 
heptakis(2,3,6-tri-0-methyl)-p-CD was studied by ID-ROESY experiments in 
solution.^" For the complexes of (+)-24 with both CDs unambiguous confirmation 
was obtained indicating the inclusion of the 4-bromophenyl moiety of the drug into 
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the CD cavity. In addition, in the case of (+)-24 complex with p-CD, the inclusion of 
the maleate counter ion into the p-CD cavity was also indicated, but this contradicts 
simple geometric considerations and the assumption that the stoichiometry of the 
complex is 1:1. The contradiction was solved by the X-ray crystallographic study 
performed on the monocrystals obtained from a 1:1 aqueous solution of (+)-24 
maleate and p-CD. The stoichiometry of the complex was found to be not 1:1 but 1:2 
and the brompheniramine maleate is sandwiched between two molecules of p-CD. 
The 4-bromophenyl moiety of the drug enters the cavity of one of the p-CD molecules 
whereas the cavity of another P-CD molecule is occupied by the maleate counter 
anion. 
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In a recent study, 27 cationic chiral analytes were resolved by CE using native 
P-CD and heptakis(2-0-methyl-3,6-di-0-sulfato)-P-CD, having both primary and 
secondary CD rims with 14 bulky sulfate substituents. The bulky substituents on both 
sides of the cavity entrance may hinder inclusion complex formation between chiral 
analytes and heptakis(2-0-methyl-3,6-di-0-sulfato)-p-CD. For 12 of 16 chiral 
analytes resolved with both chiral selectors the enantiomer migration order was 
opposite. Analysis of the structures of analyte-CD complexes in solution indicated 
that, in contrast to mainly inclusion type complexation between chiral analytes and 
p-CD, external complexes were formed between the chiral analytes and heptakis(2-0-
methyl-3,6-di-0-sulfato)-p-CD.^°^ 
The enantiomers of 23 enantioselectively bind to heptakis(2-0-methyl-3,6-di-
0-sulfato)-p-CD and are resolved with this chiral selectors in CE. In addition, 
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significant complexation induced chemical shift differences were observed for the 
protons of 23 enantiomers in NMR spectrum of the complex. It was established by ID 
ROESY experiments that 23 most likely does not form an inclusion complex with 
heptakis(2-0-methyl-3,6-di-0-sulfato)-(3-CD. Thus, inclusion complex formation 
between CDs and their chiral guests does not seem to be a necessary prerequisite for 
chiral recognition. 
In conclusion, multiple forces involved in guest-CD interactions make 
understanding of guest binding and chiral recognition mechanism by CDs extremely 
difficult. Molecular modeling studies when used in combination with instrumental 
techniques, especially with ROESY experiments in NMR spectroscopy and X-ray 
crystallography may significantly contribute to the understanding of the nature of the 
intermolecular forces responsible for guest-CD interactions and chiral recognhion. 
1.6 FORCES INVOLVED IN CD COMPLEXATION 
The understanding of the driving forces in the inclusion complexation of CDs is 
fundamentally important not only for CD chemistry but also for supramolecular 
chemistry as a whole. A large number of studies have been carried out on the subject 
and have been reviewed earlier.'^ '^  Nevertheless, it is often claimed that the driving 
forces leading to CD complexation still remain a controversial subject. Here we will 
only discuss the interactions between the substrates and the cavity wall of the CD. 
Electrostatic Interactions 
Electrostatic interactions include all kinds of electrostatic forces between permanent 
charges, dipoles and higher dipoles, present in the system. Three type of electrostatic 
interactions are usually important namely ion-ion, ion-dipole and dipole-dipole 
interactions. As native CDs are neutral molecules, the ion-ion interaction does not 
occur in CD complexation, unless the CD is appropriately substituted.^'^ 
The ion-dipole interaction, on the other hand, is expected to take place in CD 
complexation since CDs are polar molecules though the occurrence of this interaction 
is difficult to establish. The ion-dipole interaction should increase with increasing 
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ionic charge of the guest. It can be expected that dianions such as SO4" and CO3' will 
bind more tightly with CDs than ions such as CIO4" and NO3". However, though the 
complexation of CD with CIO4' and NO3' has been observed experimentally, no 
complexation could be detected for S04'^ or CO3 ^ '^'* The ion-dipole interaction, in 
aqueous solution, is not necessarily favourable since interaction between substrate and 
water is also strong. Chujo et al.^'^ first calculated the dipole moments of CDs, from 
the published X-ray crystal structures, in the range of 10-20 D suggesting that CDs 
are highly polarized. Later studies showed that dipole moments of CDs are highly 
susceptible to the chemical environment.^'^ Smaller dipole moments in the range of 
2-4 D were obtained for the CDs optimized by various theoretical methods. Since 
CDs have modestly large dipole moments, this must play an important role in their 
complexation. 
Dipole-Dipole Interaction 
Model studies for the complexation of a-CD with several substituted benzenes such as 
benzoic acid,/>-hydroxybenzoic acid and/'-nitrophenol^'^'^'^ were carried out and it 
was found that dipoles of the guest are antiparallel to that of the host. Interestingly, as 
the magnitude of the guest dipole increases, so does the value of the CD dipole but in 
opposite direction. Thus it was concluded that dipole-dipole interaction plays an 
important role in stabilizing the complex as well as determining its orientation. 
The free energy relationship analyses also prove the importance of 
dipole-dipole interaction in CD complexation. The • correlation studies between the 
binding constants of a-CD with 4-substituted benzoic acids and the Hammett a 
constants of the substituents were carried out.^'^ The results showed that as the 
-COOH group always stays at the positive end of the dipole of the host, it is readily 
understandable that binding is enhanced by electron release from the para 
substituents. However, in the case of complexation of a-CD with benzoate anions, it 
is the electron withdrawing para substituent that favours the binding.^^" This is again 
caused by the dipole-dipole interaction, because in the anion complexes, the 
carboxylate group stays at the negative end of the dipole of the CD. Davies et al.^ ^° 
also pointed out the importance of the dipole-dipole interaction in CD complexation 
based on the correlation studies. The Hammett a values were used to reflect the 
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electronic effects of the substituents in the 1, 4-disubstituted benzenes. It was 
observed that for neutral 1, 4-disubstituted benzenes, the group with a larger a value 
is bound in the narrower end of the CD cavity because of the favourable dipole-dipole 
interaction energy. The conclusion has been successfully applied to a number of 
systems^^' and it was found that the exceptions to the rule such as complexation of 
a-CD with para substituted aromatic sulfides, sulfoxides, sulfones and ketones are 
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caused by steric hindrance. 
Hamai et al.^" studied the effect of CD complexation on the acidities of 
several phenol derivatives such as 4-nitrophenol, 4-cyanophenol, 4-bromophenol and 
4-methoxyphenol which also supported the about results. It was found that, except for 
4-methoxyphenol, the acidities of phenol were enhanced as a result of CD 
complexation. The behaviour was though to be due to the dipole moments of the 
phenols, which are usually directed from the hydroxyl group to the para substituent. 
Thus, the dipole-dipole interaction was concluded to be an important factor in CD 
complexation. 
Yasuda et al.'^ '^* recently performed scanning tunneling microscopy studies on 
self-assembled a-CD inclusion complexes with water, methanol and 4-nitrophenol. 
The observed structures of a-CD-water and a-CD-methanol complexes were different 
from that of a-CD-4-nitrophenol complex. It is believed that the difference reflects the 
important role of the dipole-dipole interaction in CD complexation. 
van der Waals Interactions 
The presence of van der Waals forces, which seems to mean either the induction and 
dispersion forces combined or the dispersion force alone, in CD complexation is 
reasonable. The involvement of van der Waals interaction in the CD complexation has 
been claimed by many workers. It is generally believed that the hydrophobic 
interaction between two non-polar molecules is with a positive enthalpy, the 
observation of a negative enthalpy change in CD complexation is often considered to 
indicate the dominance of van der Waals interaction instead of hydrophobic 
mteractions. However, as CD complexation is a complicated process, the above 
argument is not always correct. 
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The correlation analysis between the binding strength and structural feature of 
the substrate is a reasonable method to show the involvement of van der Waals 
interaction in CD complexation. For instance, both the induction and dispersion forces 
depend on polarizability, which in turn is related to molecular size and electron 
density, and so to the correlation variables like molar refraction, molecular volume, 
surface area, molecular weight etc. Thus, the correlation between the strength of 
binding and the above parameters is atleast indicative of the importance of van der 
Waals interaction in CD complexation. 
The involvement of van der Waals interaction in CD complexation can also be 
shown by the structure of the complexes. In fact, numerous studies have revealed that 
bulky guest molecules are in close van der Waals contact with the CD cavities. 
Interestingly, sometimes van der Waals interaction might be so strong that the 
hydrophobic but bulky side of the guest molecule can enter the CD cavity. Moreover, 
the fact that CDs can form stable complexes with the guest molecules in pure organic 
solvents such as DMF, DMSO and even heptanes evidently demonstrates that van der 
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Waals interaction is essentially important. ' 
The involvement of van der Waals interaction in CD complexation has also 
been shown by molecular modeling^^° which is usually performed with molecular 
mechanic and molecular dynamic calculations. Most of the modeling studies were 
performed in the gas phase so that the solvent effect plays no role in the results. Many 
authors concluded, from these calculations, that van der Waals interaction makes the 
major contribution to the formation of CD complexes. This conclusion is not 
unexpected because in the calculations the energetic contributions from the 
dehydration and hydration of the host, guest and their complex, and from the 
reorganization of the solvent molecules were not taken into consideration. Whether, 
or not, van der Waals interaction plays a major role in CD complexation in solution is 
not clear. 
It should be mentioned that van der Waals interactions also exist between the 
solvent molecules and the substrates of CD. Thus, in the CD complexation the 
substrate is exchanging one set of van der Waals interaction (with the solvent 
molecules) for another set (with the CD cavity). In fact, this type of exchange is the 
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reason why the ion-dipole interaction is not significant in CD complexation. 
However, as the polarizability of water is much lower than that of the organic 
substrate Hning the CD cavity, it is expected that van der Waals interaction should be 
stronger between CD and the substrates than between water and the substrates. As a 
result, van der Waals interaction has a positive contribution to complex stability. This 
effect can be shown by the complexation of CDs with inorganic ions such as C104' 
and NOs".^ '^ Apparently, hydrophobic interaction cannot make a contribution in these 
systems. As the ion-dipole interaction might be stronger between water and the ions 
than between CD and the ions, the only possible driving force leading to 
complexation is van der Waals interaction. 
Hydrophobic Interaction 
The role of hydrophobic interaction in CD complexation is a controversial problem. 
Traditionally, hydrophobicity was considered to be the result of the enhanced 
structure of the water molecules in the near vicinity of the non-polar solute, which 
would bring about a usually large entropy loss during the hydration. However, 
neither the neutron scattering measurements nor the computer simulations indicated 
any evidence that the structure of the water of hydration close to a non-polar solute 
was more ordered than that of water in the bulk.^ ^^ 
In the experimental studies, however, the association of non-polar molecules 
in water is usually found to be with positive enthalpy and positive entropy change. 
This has long been taken as the experimental signature of hydrophobic interaction. 
The fact that most of the experimental enthalpy and entropy changes of CD 
complexation are negative seems to indicate that the hydrophobic interaction is not an 
important driving force in CD molecular recognition/complexation. It was suspected 
that the above experimental observation was not representative enough, possibly, 
because all the guest molecules that had been studied were not sufficiently 
hydrophobic. Thus, the a-CD complexation with 1-adamantanecarboxylate was 
studied, and the observed positive entropy was believed to settle and issue.^ "^* 
Unfortunately, a reinvestigation of the system showed that the entropy change is still 
negative. 
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The above problem can be settled if we notice that in CD complexation many 
interactions other than the hydrophobic interaction are also involved. For example, 
unlike that in the aggregation of two small non-polar molecules, the van der Waals 
interaction between CD and the guest is quite strong. As the interaction is attractive in 
nature and it tends to restrict the conformational freedom of the complex, it is possible 
that the total enthalpy and entropy of the complexation are both negative in spite of 
the presence of the hydrophobic interaction. Moreover, it is well known that the 
transfer of non-polar gases into water is associated with a large positive heat capacity 
change. Therefore, the fact that CD complexation is often accompanied with a large 
negative heat capacity change also demonstrates that the hydrophobic interaction is 
important in association. 
In addition to using the thermodynamic criteria, there are several other 
methods to show the involvement of hydrophobic interactions. In CD chemistry, the 
most compelling evidence in favour of the presence of hydrophobic interaction is the 
repeated observation that in the CD complexes the most non-polar portions of the 
guest molecules are usually enclosed in CD cavities. 
The involvement of the hydrophobic interaction in CD complexation can also 
be shown by the correlation analyses as, in general, increasing the hydrophobicity of 
the substituents of the guest enhances the complexation.'^ ^^ Parameters of 
hydrophobicity including the partition coefficient log P and the hydrophobic surface 
area are frequently chosen. Sometimes, the correlation between the binding strength 
and the number of the carbon atoms of a homologous series of substrates is also taken 
as evidence of hydrophobic interaction. As an increment of -3.0 KJ/mol in the 
standard free energy of complexation for each methylene group is observed, which is 
close to the value in the transfer of homologous organic compounds from water to 
hydrocarbon solvent, it is repeatedly suggested that the binding mechanism of CD is 
of a hydrophobic nature.^^^ 
Another evidence of the hydrophobic interaction is that the strength of the CD 
complexation is usually weakened upon the addition of organic co-solvents.^^^ 
Addition of inorganic salts, on the other hand, tends to strengthen the binding, simply 
because it makes the bulk solution more polar. The binding constants of CD 
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complexes also increase when D2O is used as the solvent instead of H2O which might 
be caused by the fact that hydrophobic interaction is stronger in D2O than in H2O. 
Hydrogen Bonding 
The role of hydrogen bonding in CD complexation has been well established for the 
complexes in solid state.^ '*' The study of a number of crystal structures of CD 
complexes have clearly shown the well defined hydrogen bonding between the 
substrates and the hydroxyls of CDs. Usually, the host-guest hydrogen bonding is 
restricted to the primary 0(6)-H groups of CDs because they are flexible and can 
rotate, in contrast to the secondary 0(2)-H and 0(3)-H groups which are rigid due to 
the preferred ''Ci form of the glucose units. However, it should be mentioned that 
sometimes there are also C-H 0,^ ^^ C-H N^^ ^ and C-H--/?/^^'' interactions 
between the cavity wall of CDs and the guest molecules. 
On the other hand, the role of hydrogen bonding in CD complexation in 
aqueous solution is still controversial. The primary reason for the problem is that 
water can compete with CDs to form the hydrogen bonds with the substrate 
molecules. For example, molecular dynamic calculations on the complexation of a-
CD with p-chlorophenol and p-hydroxybenzoic acid in water clearly indicated that the 
hydrogen bond is rarely formed between CD and the substrates.^ "*^ Thus, it was 
concluded that hydrogen bonding plays a minor role in complexation. Besides, it has 
been demonstrated that although in the solid complex of a-CD with 4-fluorophenol, 
the OH group of phenol is hidden inside the CD cavity,^''^ in aqueous solution the 
F atom remains inside and OH group outside the CD cavity.^ "*^  
Nevertheless, examples of hydrogen bonding in CD complexation in aqueous 
solution have been shown by some authors. For instance, in the study of the 
complexation of y-CD with pamoic acid, the large observed binding constants were 
thought to indicate the occurrence of hydrogen bonding between the carboxylate of 
the guest and a secondary OH of CD.^ "*^  Sometimes, the occurrence of hydrogen 
bonding in CD complexation can be detected with spectroscopic methods. For 
example, Takahashi et al.^ "*^  used the 'H and ''N NMR techniques to study the 
interaction of aspartame with P-CD in aqueous solution. It was concluded that the 
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amide part of aspartame was hydrogen bonded in CD complexation in aqueous 
solution. Recently, Chen et al.^ ^" studied the pH dependence of the complexation of 
3-hydroxynaphthalene-2-carboxylic acid with p-CD. It was found that with increasing 
pti (pU < \\), the binding constant decreases probably because the deprotonated 
substrate is more hydrophilic. However, at pU > 11 the binding constant increases as 
the pH value rises. The behaviour was thought to be due to the hydrogen bonding 
between the deprotonated secondary OH of CD and the hydroxyl group of the guest at 
the pH range. After P-CD is permethylated, there is a little change in the binding 
constant at pH > 11 with increasing pU value, presumably because permethylated 
(3-CD cannot be deprotonated under the same conditions. Thus it was concluded that 
hydrogen bonding plays an important role in the CD complexation. 
Relief of Conformational Strain 
The conformation of a CD in the solid state is usually less symmetrical than that in 
solution. The crystalline packing and the presence of water molecules in the solid 
state are, probably, responsible for this behaviour. Saenger and coworkers^^' assumed 
that the deviation from the symmetrical conformation of the CDs in the solid state 
constitutes a store of energy whose relief upon complexation is a driving force for the 
complexation. This was identified as an "induced fit" mechanism. However, P- and 
y-CDs exist in nearly symmetrical conformations in solid state, yet their complexes 
tend to be stronger than those of a-CD rendering the doubts about the strain relief 
hypothesis. Actually, the hypothesis is not relevant to the complexation of CDs in 
solution. Though it is possibly true that a CD in the solid state has a higher 
conformational energy than that in solution, the thermodynamics of the CD 
complexation in solution does not involve the energy of a solid state CD. Eftink et 
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al. pointed out that conversion of the a-CD from its distorted to symmetrical 
conformation must cost energy, the process cannot be a source of energy for the 
complexation. Thus there seems no support for the relief of conformational strain as a 
driving force for the CD complexation. 
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Release of Cavity-Bound High-Energy Water 
Two water molecules are present in the a-CD cavity in the solid state. As the CD 
cavity is relatively non-polar, the water molecules included in the CD cavity should 
lack the complement of stabilizing hydrogen bonds that would be available to them in 
the bulk aqueous solution. Thus the water molecules in the CD cavity are energy-rich 
than those in the bulk solution whose release upon complexation was postulated as a 
driving force leading to the complex formation.'^" This hypothesis was largely 
developed around the observations on a-CD. 
Takagi et al.'^ '^* have tried to estimate the thermodynamics of inclusion 
separately from solvation effect which supports this hypothesis but the problem with 
the high energy water hypothesis is that it focuses on the water and neglects the CD or 
more generally it fails to consider the energetics of the entire system. The cavity 
bound water molecules may well be enthalpy rich but they should have more 
conformational freedom than the water molecules in the bulk solution because of the 
lack of hydrogen bonding. Although, the release of the cavity-bound water is 
accompanied with a negative enthalpy change, the free energy change of the process 
is not necessarily negative. The reorganization of the solvent molecules is actually a 
process of enthalpy-entropy compensation without any free energy contribution. As a 
result, the release of cavity-bound high-energy water is not considered a driving force 
for the complexation. 
Charge-Transfer Interaction 
Charge-transfer interaction is usually considered a type of van der Waals 
mteraction. It needs to be discussed separately, however, since in the area of CD 
chemistry the term van der Waals interaction usually refers to the combination of 
induction and dispersion forces. In the CD chemistry, in addition to the charge-
transfer interaction between the substituent groups of CDs and the guest,^ ^^ charge-
transfer interaction between the CD skeleton and the substrate has also been observed 
and it has been recently suggested to be a driving force in CD complexation. The role 
of charge-transfer interaction in the CD complexation can be shown by the fact that 
(1) the binding constant of a-CD complex of the 1, 4-dicyanobenzene radical anion is 
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45 times larger than that of neutral 1, 4-dicyanobenzene-a-CD complex'^" (2) the 
binding constant of the P-CD complex of neutral 10-methylphenothazine is 35 times 
smaller than that of the 10-methylphenothiazine radical cation complex^^^ (3) the 
binding constant of a-CD with the singlet xanthone is much more stable than that with 
the triplet one.'^ ^^ 
Conclusion 
The driving forces leading to the inclusion complexation of CDs should include the 
electrostatic interaction, van der Waals interaction, hydrophobic interaction, hydrogen 
bonding, and the charge transfer interaction. However, enthalpy-entropy 
compensation, release of conformational strain and release of cavity-bound high 
energy water are not energetically contributive to the complex formation. 
Furthermore, van der Waals interaction and hydrophobic interaction constitute the 
major driving forces for CD complexation whereas electrostatic interaction and 
hydrogen bonding can significantly affect the conformation of a particular inclusion 
complex. 
CHAPTER-II 
General Discussion 
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2.1 NMR SPECTROSCOPIC STUDY OF CYCLODEXTRIN 
COMPLEXES 
NMR spectroscopy has become the most important tool for the structural elucidation 
of organic compounds, particularly in solution state. The method is of increasing 
significance for most CD application studies. There are few alternatives to NMR 
spectroscopy in the CD related studies. 
As with many carbohydrates, it is often difficult to obtain single crystals of 
CD derivatives and then to analyze them by X-ray crystallography, or by neutron 
diffraction. Other techniques such as fluorescence, UV/visible spectroscopy, 
calorimetry etc. play a major role in measuring complexation energetics with CDs but 
usually provide very indirect and qualitative information about inclusion modes and 
geometries. 
Structure determination is of particular importance for supramolecular 
host-guest complexes, which are the basis of most CD applications in medicine, 
catalysis, separation and sensor technology and also food chemistry. Pharmaceutical 
uses of CDs for drug protection or targeting now legally require structure 
determination of the administered compounds. NMR spectroscopy is also becoming 
an important tool for in vitro, in future perhaps even for in vivo, studies of CD 
interactions with biological macromolecules such as nucleic acids, proteins, or cell 
membranes. The most obvious incentive to use NMR techniques for the investigation 
of CD complexes is the interest to understand the driving forces and binding modes in 
these non-covalent associations, and then to make optimal use of these factors for new 
applications. It should be remembered that the driving force for CD inclusion often is 
of solvophobic nature and that most CD applications involve action in a liquid matrix, 
which emphasizes again the role of NMR spectroscopy as the most important method 
applicable in solution. 
After the first publication on the use of NMR spectroscopy to study inclusion 
phenomenon by Demarco and Thakkar,^ '^* there has been a virtual explosion of such 
studies. The older work was restricted to the observation of few CD protons, mostly at 
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the anomeric centers, which were sufficiently separateSisfrom'^flfelv^tro^g^ coupled 
signals. The advent of high-field instruments and in parficular 2D methods has 
completely changed the situation, and the possibilities of now available NMR 
techniques are far from being exploited. Nuclear Overhauser Effects (NOEs) have 
already become a major tool in structural studies of complex biomolecules. 
The spectacular advances of NMR techniques, have led to much more detailed 
structural information of CDs and their complexes. These tasks represent a fascinating 
challenge for the NMR spectroscopist in view of the high complexity of the 
underlying cycloamylose ' H NMR spin systems.^ ^ '^^ ^^ These are characterized by 
signals which, apart from the anomeric proton, absorb in a range of only 0.5 ppm and 
are strongly coupled. In addition, the shielding effects of the CD cavity on the 
included guest molecules are limited to a few tenths of a ppm at most, as a 
consequence of a host framework being built up entirely of single, less polar and 
polarizable bonds and thus weak shift tensors. 
The aim of the present discussion is not to discuss or even to mention all the 
work on the study of the CD complexes using NMR spectroscopy. Instead, we will 
illustrate the use of NMR techniques in the structure elucidation of CD inclusion 
complexes with some representative examples, yet without a special focus on this 
method. 
Demarco and Thakkar^^'' first noticed the highfield chemical shift changes in 
the P-CD cavity protons, namely H-3' and H-5', in the presence of a variety of 
aromatic substrate in aqueous solution and envisaged from these observation that the 
aromatic ring is positioned in the p-CD cavity. This observation later become the 
basis for NMR spectroscopic study of the CD inclusion complexes. He used 100 MHz 
instrument for these studies which is actually not suited for this type of work because 
all the CD protons, except H-l', resonate in the 0.5 ppm range and are not easily 
distinguished. He established the assignment for each proton on the basis of analysis 
of individual splitting patterns and coupling constants at 220 MHz, decoupling 
experiments and expected chemical behaviour i.e. H-3' and H-5', being 1, 3 diaxial to 
the Ci axial oxygen should resonate at lower fields than the H-2' and H-4' protons. 
56 
At magnetic fields above 9.4 T, corresponding to 400 MHz for the 'H N M R 
spectra, the dispersion is high enough to locate, in conventional one dimensional 
spectra, most of the CD protons, eased by the high symmetry of the macrocycles. The 
' H NMR spectrum of P-CD in aqueous solution has already been assigned in detail. 
It has been established that, on the NMR time scale, all the seven glucose units have 
identical conformations and the molecule is highly symmetrical. Furthermore, the 
magnitude of the vicinal coupling constants Ji, 2 through to J4,5 are consistent with the 
C| chair form for the glucose units of CDs. 
It is now well accepted that the signals of the cavity protons move highfield 
when the guest molecule or a part of it enters the CD cavity. The chemical shift 
change data obtained from ' H NMR titration experiments can be used to determine 
stoichiometry, binding constant and is thus helpful in the determination of structure of 
the complex. 
The magnitude of the chemical shift changes for the protons positioned in the 
CD-cavity, A5H-3' and A5H-5', increases with an increase in the concentration of the 
guest ^ while that for guest protons increases with an increase in the concentration of 
the CD. The magnitude of the A5H-3' and A5H-5' also depends on the nature of the 
guest. The chemical shift changes are high in the case of aromatic guests while these 
are relatively small if the aliphatic guest enters the CD cavity. Salbutamol (25) forms 
a 1:1 inclusion complex with P-CD whose structure has been confirmed by detailed 
NMR spectroscopic and molecular modeling studies (Fig. 5).'^ °^ It has been 
established that aliphatic part of the guest enters the CD cavity. Fig. 6 shows very 
small shift changes in the p-CD cavity protons in the presence of salbutamol. On the 
other hand these shift changes are quit large when aromatic ring of (IS, 2R)-(+)-
ephedrine (26) enters the p-CD cavity.^^' 
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H3C 
H , C 1 \ /CH3 
,NH 
H . C 
25 
Salbutamol-P-CD complex 
26 
(IS, 2R)-(+)-ephedrine-P-CD complex 
Fig. 5. Structures of inclusion complexes of salbutamol and (IS, 2R)-(+)-ephedrme. 
II-()' H-4' 
H-2' 
H-5' 
,J \J 
(A) 
H-3' •'/ 
H-6' 
H-4' 
H-2' 
H-S' 
lV^f\Kik 
P-CD 
H-3' 
W 
I /H-6* 
,H-5' H-2' H-4' 
3.9 3.8 3.7 3.6 3,5 3.4 
ppm 
Fig. 6. Comparative chemical shift changes in the (3-CD 
cavity protons upon inclusion of an aromatic guest (A) 
and aliphatic guest (B). The [H]/[G] is same in both the 
cases. 
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The CDs generally act as one site ligand and the guest enters the cavity from 
wider rim side. This is always true for a-CD but in case of p- or y-CDs, complexes 
formed by the penetration of the guest from the narrower rim side have also been 
reported.^ ^^ The relative chemical shift change data for the cavity protons (A5H-3' and 
A5H-5) is sometimes taken as an evidence for the mode of penetration of the guest. 
It has been suggested that in the cases where A5H-3>A6H.5S the guest entry from wider 
side'^' and vice versa.'^ ^^ This statement may be true only when the guest is bulky but 
can not be generalized. Kano'^' studied the complexation of pure enantiomers of 
binaphthyl derivatives with various CDs. The chemical shift changes observed for 
H-3' of heptakis(2,3,6-tri-0-methyl)-p-CD (TMe-p-CD) were quite high compared to 
those for H-5' (A5H-3'>A6H.50 in the presence of 1, r-binaphthyl-2, 2'-diyl hydrogen 
phosphate (27). It was established that 27 is shallowly bound to the wider side of the 
TMe-P-CD cavity. The guest being bulky cannot penetrate deep into the cavity. 
Moreover, the mode of penetration of the two enantiomers was found different 
(Fig. 7). 
(R)-27-TMe-p-CD complex (S)-27-TMe-p.CD complex 
Fig. 7. Modes of penetration of two enantiomers of 27 into the P-CD cavity. 
He also studied the complexation of several helical metal complexes with 
modified CDs. A-Ru(phen)3^' ion (28) forms a 1:1 complex with heptakis(6-
carboxymethylthio-6-deoxy)-P-CD (per-C02--P-CD) (Fig. 8). It has been shown that 
the guest approaches the cavity from narrower rim side and for this complex the 
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273 
chemical shift for H-5' was quite high compared to that for H-3' (A5H.5->A6H.3') 
These examples show that the relative values for A5n-3- and A5„.5- can be used in 
support of the mode of penetration of guest into the CD cavity. 
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•ooc 
28 Model of 28-(per-C02>(3-CD complex 
Fig. 8. Mode of inclusion of 28 into the (per-C02')-P-CD cavity. 
Rekharsky,^^' however, made a detailed ' H N M R study of the CD inclusion 
complexes of a variety of guests and showed that while the magnitude of the chemical 
shift changes for H-3' and H-5' protons is a quantitative measure of the stability of 
the complexes, their ratios, A6H-5'/A8H-3-, are related to the depth of penetration of the 
guest into the CD cavity. In all the studied cases, the guest approached the P-CD 
cavity from wider rim side though A6H.5'>A5H-3'- He showed that higher magnitude of 
A5H.3' and A5H-5- values is due to higher stability of the complex. On the other hand, 
their ratios, A8H-5-/A5H-3', which were found as high as 1.2-3.0 for p-CD, indicate a 
deep penetration of the guest into the host cavity. It becomes obvious from these 
examples that the use of relative magnitude of chemical shift changes for cavity 
protons as an evidence in support of the mode of penetration of guest into the CD 
cavity cannot be generalized (Table 9). In fact the mode of penetration can better be 
determined by the NOE experiments. 
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Table 9. Chemical shift changes (A5) of H-3' and H-5' of P-CD protons upon 
complexation with selected ligands in buffered aqueous solutions at pD = 7.0 and 
T = 298.15 K. The mode of penetration of the guest into the p-CD cavity is from 
wider rim side in all the cases. 
Ligand 
Phenethylamine 
L-a-0-BenzylgIycerol 
1 -Benzylimidazole 
4-Benzylpiperidine 
1-Butylimidazole 
(IS, 2S)-(+)-Pseudoephedrine 
(lS,2R)-(+)-Ephedrine 
(lR,2S)-(-)-Ephedrine 
Hydrocinnamate 
Phenyl-p-D-glucopyranoside 
3-Phenyl-l -propylamine 
IG]/IH] 
0.94 
0.59 
0.77 
0.94 
0.95 
0.98 
1.00 
0.97 
0.92 
0.81 
1.03 
H-3' 
0.03 
0.03 
0.09 
0.14 
0.05 
0.07 
0.07 
0.06 
0.04 
0.02 
0.10 
H-5' 
0.06 
0.09 
0.18 
0.22 
0.09 
0.12 
0.12 
0.10 
0.10 
0.05 
0.12 
H-5'/H-3' 
2.0 
3.0 
2.0 
1.6 
1.8 
1.7 
1.7 
1.7 
2.5 
2.5 
1.2 
The formation of the CD inclusion complex also results in the concomitant 
chemical shift changes for the guest protons and generally all the guest protons, and 
not only the part included in the CD cavity, show downfield shift changes, but 
sometimes upfield changes are also observed.^ '** These changes have mostly been 
found to be of qualitative significance though these may also provide important 
information regarding the structure of the complex. 
Due to low water solubility of the guest, sometimes it is not possible to use 
high concentration of the guest in the NMR titrations and in such cases the chemical 
shift changes observed for the CD cavity protons may be very insignificant while 
large chemical shift changes are observed for guest protons. The chemical shift 
change data for guest protons can be used for determining stoichiometry and binding 
constant of the complex but whether guest enters the CD cavity or not can only be 
said on the basis of chemical shift changes in the cavity protons. ROESY experiments 
may be required in such cases to ascertain whether guest has actually entered the CD 
cavity. 
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2.2 NUCLEAR OVERHAUSER EFFECT (NOE) 
Beside the chemical shift changes, observed for hosts and guests, upon complexation 
relative to unbound state, detection of the through-space dipole-dipole interactions 
(NOE and/or ROESY) between the CDs and the guests is another important probe of 
the structure of complexes. NOEs have been used for the study of CD complexes in 
solution since the pioneering work of Bergeron and Rowan.^ ^^ Though the advent of 
high magnetic fields has greatly enhanced the dispersion of signals; at the same time, 
however, the unfavourable correlation times of complexes with molecular weights 
around IQ-* lead to a drop of the observed NOEs, e.g. from 34% at 90 MHz to 9% at 
250 MHz. To obtain sizeable NOEs on a 400 or 500 MHz instrument, application of 
spin-lock techniques such as ROESY are required.^''^ In the ROESY spectra, artifacts 
which possess phase properties different than genuine NOE cross peaks are frequently 
observed between resonances within a common J-coupling network, thus being easily 
distinguishable. Intermolecularly, as in the case of CD complexes, these COSY 
(correlation SpectroscopY)-type peaks are not observed; however, false cross peaks 
with the same phase as genuine interactions may arise from scalar transfer from 
H-3'and/or H-5', the cavity protons being most prone to interact dipolarly with the 
guest. 
The use of NOEs in the structure elucidation of CD complexes is exemplified 
by few representative examples. A typical NOE application is illustrated with a-CD 
complexes with phenol derivatives. Fig. 9 describes different inclusion modes for the 
CDs complexes with phenol derivatives and, obviously, all three modes should lead to 
quite different NOEs and should be distinguishable this way. 
For mode I with no or little immersion of the phenyl ring into the cavity there 
is a sizeable contact only between the guest Hm and H-3' of a-CD and one can expect 
only small ROE at H^ upon irradiation of H-3'. For mode II irradiation at H-3' should 
lead to ROE of both Ho and H i^ signals, at H-5' only of the m-proton. In contrast, no 
effect on the H.^  signal upon irradiation of H-5' can be expected for Mode III. The 2D 
ROESY spectrum of the p-iodophenolate with a-CD (Fig. 10) shows only those cross 
peaks discussed for Mode II.'^ ^^  
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Mode I 
R 
H-3' 
Mode II 
H-5' 
H„ 
OH 
Mode III 
Fig. 9. Various possible modes of penetration of phenol derivatives into the CD 
cavity. 
Hm Ho H I ' H-S'H-i' 
i 
* ^ 
« 
* 
A 
« 
« 
« 
7 
_ _ A . 
• 
» 
• 
1 
• • 
« 
1 
I 
, 
1 
i> 
_JUJL. 
• • 
• 
i % 
•• » 
^ 
» 
Fig. 10. Part of the ROESY spectrum showing 
intermolecular cross peaks between the 
p-iodophenolate and a-CD cavity protons 
supporting the inclusion Mode II. 
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Another interesting example is structure elucidation of a 1:1 complex between 
benzoic acid and p-CD.^ ^^ ID ROESY experiments were performed to confirm the 
structure of the complex. The NOEs on the CD protons were studied on saturation of 
various aromatic protons. The irradiation of Hp did not show any NOE on the CD 
cavity protons. However, intermolecular NOEs were observed on saturation of 
Ho, Hm, H-3' and H-5'. Almost equal NOE values were observed on both the cavity 
protons when Ho was irradiated, while the NOE value for Hm to H-3' was larger than 
for Hm and H-5'. These results clearly suggest an inclusion geometry with the 
aromatic Hp proton located at the CD equatorial plane, Hp on the chiral vertical axis, 
and Ho at similar distances from both the cavity protons. Both the geometries are 
compatible with this NOE data. However, NOEs on both the cavity protons upon 
saturation of Hm can only be explained when a fast equilibrium exists between the two 
inclusion complexes (Fig. 11). 
Fig. 11. Structures of two 1:1 p-CD-benzoic acid inclusion complexes. 
The use of ROESY in the study of chiral recognition mechanism is 
exemplified by the following example. Chiral recognition of an anionic tetrahelicene 
(29) has been studied by native CDs. Fig. 12 shows the ROESY spectra of p-CD-(M)-
29 and p-CD-(P)-29 systems in D2O which show the different connectivities of the 
cavity protons with the protons of two enantiomers. It was interpreted from these 
results that both the CO2" groups of 29 are placed near the rim of the secondary OH 
group side of p-CD and ring A of the 29 penetrate the P-CD cavity. It was shown that 
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there was somewhat deeper penetration of the ring A of (P)-29 compared to that of 
(M)-29 into the CD cavity. 278 
(P)-29 (M)-29 
H' H* H^  CHa 
aU elz »:o 7.6 te v.* zlo I'.a ' P ( " 
Fig. 12. ROESY spectra of (P)-29-P-CD and (M)-29-p-CD complexes. 
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2.3 STOICHIOMETRY AND BINDING/ASSOCIATION 
CONSTANT OF THE INCLUSION COMPLEX 
The most commonly claimed stoichiometric ratio for CD complexes is 1:1 which is 
usually justified. Nevertheless, other ratios are known, most common of these 
probably being 2:1 (H/G) while the ratios 1:2 and 2:2 have also been reported. 268 
Before any structural or association constant determination is performed, it is 
always essential to determine the stoichiometry of the host-guest complex which is 
readily achieved from NMR titration data."^ There are several methods used to 
determine the stoichiometry, namely continuous variation method (Job's plot), molar 
ratio method and several modified Benesi-Hildebrand methods. 
Job's Plot^ *" 
The method of continuous variations involves preparing a series of solutions 
containing both the host and the guest in varying proportions so that a complete range 
of mole ratios is sampled (0> [H]/[H]+[G] <1) and where the total concentration 
[H]+[G] is kept constant for each solution. The experimentally observed parameter is 
a host or guest chemical shift that is sensitive to complex formation. The data are 
plotted in the form [H]/A5obs verses [H]/[H]+[G]. The position of the maximum 
indicates the stoichiometry of the complex (Fig. 13). 
The Mole-Ratio Method^^' 
In this method a series of solutions is prepared in which the formal concentration of 
one of the components is held constant while that of the other is varied. A plot of the 
chemical shift change (A5) verses mole ratio of the components is then prepared. If 
the formation constant is reasonably favourable, two straight lines of different slopes 
are obtained; the intersection occurs at a mole ratio corresponding to the combining 
ratio in the complex (Fig 14). 
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0.0 0.2 0.4 0.6 0.8 
[H]/[H]+[G] 
Fig. 13. A typical Job's plot for 1:1 complex. 
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Fig. 14. A typical molar ratio plot showing 1:1 stoichiometry of the complex. 
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Modifications of Benesi-Hildebrand Method^^^ 
The stoichiometry and association constant of the inclusion complex can also be 
determined by any of the following methods. Assuming that the composition of the 
complex is 1:1, the following expression can be written: 
G + H — ^ GH 
The association constant of the complex (Kg) is given by 
" [H] [G] 
where [H], [G] and [GH] are equilibrium concentration of host, guest and complex, 
respectively. Benesi-Hildebrand studied the complexation of iodine with aromatic 
hydrocarbons by UV-visible spectroscopy^^^ and derived the following linear equation 
(equation 1) for the calculation of Ka'. 
l/£obs = l/(/ir„8max[H]) + l/8„,ax (1 ) 
where, 8obs is the extinction of a layer of solution 1 cm deep containing m moles of I2 
and 8niax is the molar extinction coefficient of the complex at the wavelength of 
maximum absorption. NMR version of the Benesi-Hildebrand equation was 
independently derived by Mathur et al.^" and Hanna and Ashbaugh^^^ (equation 2). 
l/A8obs = l/(^«A8„«x[H]) + 1/A6n,ax (2) 
where, ASobs = (6G-6obs) and A5,„ax = (5G-5GH). 
A plot of l/A5obs against 1/[H] (often referred to as a double reciprocal plot) should be 
linear for a 1:1 complex, with a slope l//:.A5,,ax and intercept 1/A5,„ax allowing the 
determination of association constant (K,). This expression is valid when observing 
one species in presence of a large excess of the other species. 
An alternative solution of Benesi-Hildebrand equation has been proposed by 
Foster and Fyfe (equation 3).^ ^^ 
6 8 
A8obs/[H] = -KA^obs + /ir„A6max (3) 
This is a special form of the more general Scatchard plot.^ ^^ In the Foster-Fyfe 
procedure, a plot of A5obs/[H] against A5obs (referred as an x-reciprocal plot) should be 
linear for a 1:1 complex (Fig. 15). The gradient is equal to -Ka and the intercept gives 
A5n,ax. This modification requires an extrapolation to infinitely dilute solution and the 
Ka is not dependent on the extrapolation. 
50 
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0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 
A5ppm 
Fig. 15. A typical Foster-Fyfe plot showing 1:1 stoichiometry of the complex. 
Another modification of Benesi-Hildebrand equation is Scott's equation 
(equation 4). 287 
[CD],/A6obs= [CD]t/A8c + 1/KaAdc (4) 
In the Scott procedure, a plot of [CD],/A6obs is plotted against [CD], (referred to as a y-
reciprocal plot) which should be linear for a 1:1 complex with the slope 1/A6c and the 
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intercept with the vertical axis to l/Z^^ ASc, allowing the estimation of association 
constant (Ka). A typical Scott's plot is shown in Fig. 16. 
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Fig. 16. A typical Scott's plot showing 1:1 stoichiometry of the complex. 
The stoichiometry and association constant of the 1:1 tetrametlirin and P-CD 
inclusion complex were determined by spectrofluorometry^^^ through double 
7 SO 
reciprocal plot (equation 5). 
l/AFobs=l/(/ir„AF„,ax[H]) + l/AF 
n 
(5) 
where AFobs denotes the change in fluorescence intensity of tetramethrin in the 
presence of P-CD compared to pure tetramethrin and AFmax change in fluorescence 
intensity of tetramethrin, when all of its molecules are complexed with P-CD, 
compared to pure tetramethrin while other symbols have their usual meaning. The 
equation is identical to the Hanna and Ashbaugh (equation 2) except that a different 
property of the complex is studied. 
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Now, assuming the complex to be 1:2, the following expression can be 
written: 
G + 2H ^ GH, 
The association constant of the complex (Ka) is given by 
IGH2] 
Ka = [H]2 [G] 
if [H]»[GH2]»[GH] then the following linear expression (equation 6) is obtained 
for calculating binding constant by fluorospectrometry. 
1/AFobs = l/(/ir„AFn,axIH]') + l/AF,„a, (6) 
where symbols have their usual meaning. A plot of 1/AFobs against 1/[H] gives a 
straight line for a 1:2 complex. Thus, the NMR version of this equation can be written 
as: 
l/A6obs = l/(ii:„A6„,axlH]^) + 1/A8„ax (7) 
-y 
A plot of l/A6obs verses 1/[H] should be a straight line for 1:2 complex with a slope 
l/A^ flA5max and intercept 1/A6max allowing the determination of association constant. 
Throughout the above discussion it is assumed that the guest m.olecule is the observed 
species. It does not matter which species is observed and the most readily observed 
and responsive molecule would normally be chosen. The data treatment for observed 
host is identical, with host and guest symbols switched. 
Throughout discussion the CD protons are numbered as H-l' to H-6'. 
CHAPTER-III 
NMR Spectroscopic Study of Complexation of 
P-Cyclodextrin and Fluvastatin Sodium 
tUBS^^ 
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Fluvastatin sodium (FLU), Lescol, C24H25FN04-Na, FW 433.46, 
chemically known as (±)-(3RS,5SR,6E)-sodium-7-[3-(4-fluorophenyl)-l-(l-
methyIethyl)-lH-indol-2-yl]-3,5-dihydroxy-6-heptenoate, is the first competitive, 
totally synthetic, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitor. FLU is a mevalonolactone derivative of a fluorophenyl-substituted indole 
ring that is distinct from that of fungal products, pravastatin, simvastatin, and 
lovastatin. It helps in preventing heart disease, angina, stroke and heart attacks by 
reducing the cholesterol and certain other fatty substances in the blood.'^ ^ '^ •^ '^ It is a 
competitive inhibitor of HMG-CoA reductase and lowers the overall blood 
cholesterol as well as blood LDL (bad) cholesterol levels, which is responsible for 
coronary artery diseases. It also helps in therapy for hypercholesterolemia.^^^ 
It is a white to pale yellow hygroscopic powder soluble in water, ethanol and 
methanol. FLU is light sensitive and its solubility in water is 1.91 mg/mL. 
ONa 
Fluvastatin sodium 
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3.1 EXPERIMENTAL 
Fluvastatin sodium (FLU) was generously donated by Morepen Laboratories Ltd, 
India, while p-cyclodextrin (p-CD) was obtained from Geertrui Haest, Cerestar 
Application Centre, Food & Pharma Specialities, France, and these were used without 
further purification. All the ' H N M R spectra (Fig. 17-22) were recorded on a Varian 
Mercury Plus-300 MHz instrument while 2D NMR spectra (COSY, DEPTO and 
ROESY) (Fig. 23-26) were recorded on a JEOL a-400 MHz instrument in D2O at 
room temperature. The chemical shift values (5) are reported in ppm. Five samples of 
(3-CD-FLU mixtures were prepared in various molar ratios ranging from 0.2 to 1.1. 
The overall concentration of FLU was kept constant at 1.6x10' M, while that of (3-CD 
was varied. The P-CD/FLU molar ratios were calculated by direct integration of 
appropriate signals. During these studies, no external indicator was used and HDO 
signal at 4.800 ppm was used as internal reference. Distinct peaks for bound and free 
form of the FLU were not observed indicating the rapid exchange of FLU between 
free and bind state on the NMR time scale. Chemical shifts changes (A5) were 
calculated according to the formula: 
A5 = 5(complex) - 5(free) 
73 
-^^ 
'V- =! 
S 8 
M 
I 
5= ^5SS ^ :? 
5l«IS 2i i l l l stssslrttsSg a 
:s *S.AV - 4 < F ( N » V B M « « « « » « W C M t CC3» • o i e v at • • • « « nn •«•« 
£ M M Z « i t«M«t • m 
<• N,<x^ T 5 •» M M 
9 & C e P k M 
a l l ^^-^^ 
-J 
¥ 
o 
C3 
CO 
CO 
> 
3 
H 
3 
a 
N 
X 
o o m 
¥ 
3 
•t-t o u a. 
CO 
z 
I 
^^ 
s s ? 55=1 •sss^sesiilssssla =5 
74 
I - ?3 
" f^ L? 
"- s 
is 
«I<K » i l l ! »t3s':~sl! 
ill5=5l^r;:=-p3- -
i s i ic ^su&ses&tlssssU =£§ 
s 
75 
Q 
I o CO. 
_ o 
M O 
lA C 
M 
s s f i ^&;;i¥ 
sssj'^lsi """ =^ ^ 
m 
c o 
« u V > V< 7 U 
• ^ ^ ^ (. * *-
76 
^1 
PW 5^s|:r:-sir" 
77 
U 
J L-: 1 ) 
^r. 
78 
2? tll i^ i " 
5ozr 
k 
to 
3 
lU 
:3 
u 
o 
l - l 
e 
DO 
C 
1 
E 
O 
}5 I 
3 
c 
« 
O U 
I 
CO. 
<^^ 
O 
D 
^ - » X 
'e 
CO 
o o 
E 3 k. 
O (U 
CL 
(/i 
E6. 
79 
. . » • 
•—r'r— 
• > 
^ . .A ^ J ^ w \ «« JL-JLAJJLJU—. 
A 
J 
«Q0 « 
• 0 
(lillMIMI) 
m I m m u n j»d»M»«i I A j d 
80 
. • — I | i M i | i . i i | i i [ . i i | i | i i i m I I I I 
rm rm rm rta rwi rwi no »tu nn nn 
-»,.. i? ***• •^ •*««« 
81 
o 
IJD 
If) 
Oi 
O . 
•«• 
o 
o 
> - OJ 
in o) 
lu to m 
o x x 
CCX-H 
(J 
N U 
X in 
3 
coorv j 
P) -1:1 
toia 
»-iru 
•V 
m 
u u 
in L) u in 
o> ta 
N M O in loru 
x x n 3 3 a 
U} m 
l o r y r u ' v m o o o o ' v u D i n 
i n r o m r v j o - o o • - < - < 
ru - o o • •<\) 
•-* n o 
IM 
u 
M Nl OJ X X in 
X 3 
CD 
i n c s o o o ( o i r i o o o o 
ID • '10 rv) • - ' o o o 
• m i o i M . . . , 
cntD-v 0000 
CO 
NJ NJ 
M X X 
O O C O 
o t o m 
E 
a. 
a. 
o 
o 0 - < r v o < 
X 
0. X 
< < t -
"-"OOJ 
• CO -< 
>- ru 
< i n 
in w 
X I D 
lU N 
•o o x 
r» •Ho i ru ^ 
^ «-* . »-i CD 
• i n n K 
o ru 
10 
^ligig.iigiiisiis.iliisiiiii ESSiass 
SSSSSSSSSCagEESSSSSSSSgESEESSeSCISSSfeSSSaS 
X « - i X U J _ l 
- l - J O O L . 
C/5 
£ 
o 
o 
II 
u 
e GO 
C 
'E 
I 
PPin 
u J»L JL_jAiAA.,_^ 
- 1 — . — p 
5 
-1 r 1 p 
6 
9 0^- Qo 0 
QO 
e 0 
E 
'•5 
O 
e/3 
si 
> 
-a 
c a 
D 
U 
CO. 
o 
u 
X 
E 
N 
O O 
82 
in 
in tM N M a. X M X M M X X Q. 
en 
o , 
^' 
o 
o 
I 
(A) 
U J I D 
O X 
CC X 
in 03 ocvj 
(O • O —I 
•m - i n 
c n i f i i o 
I en 
a) 01 
in u Lj C3 t-i 
0} OJ N M OJ NNCDtnofu x x c n I X n 3 3 .S 3E_ 3 
( O f * ' CO • ( D < \ > c \ j ^ f o o o o o ^ ( D i n i n c o o o o t D U 3 o o o o o r * * o ) 0 i n n n o j o - o o •^^-.H UJ - j i n rvj i - « o o o o o - o ) 0 
c\j • o o • • <vi 
^ nj r~.o 
•-< m o 
o ^-^ 
0) 
c o m 
: ro 
^ o o o r ~ ' - ' c n c M ' > T 
• CO •«-• ^ ^-* . *H CO 
/ • • r t^H - i n p i r>« 
o o o o o f - i n o «<: i—c\i o ru 
cno-^m X < i n uj 
'-•in-H Q. x i n ^ 
•^ _ j -<x tf) 
I • < • < • -
= 0 0 0 0 1 - ! - P W ( 2 > : 2 i r a : ! - > - h - z o o j - x z to «fvj 
!^.P2li^g^feii^^3§§S2C 
o 
o 
II 
4> 
B 
00 
"x 
O 
00 
L_^ 
_,^k 
ppm 
T—1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 . 1 
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0 
C3 
•i-t 
> 
•a 
c 
Q 
O 
I 
CO. 
o 
• * - » X 
"E 
N 
o 
o 
E 
3 
• 4 - . * 
o 
4) Q. 
1/! 
U 
o 
Q 
<*-
o 
c 
o 
'So 
u 
CO 
E 
o 
c 
_o 
'55 
c 
« 
a , 
bJD 
o 6 
0 
0 
83 
3.2 RESULTS AND DISCUSSION 
' H N M R Chemical Shift Change Data of P-CD 
The assignment of the P-CD protons was made with the help of COSY spectral data 
(Fig. 27). ' H NMR spectra of P-CD in the presence of FLU displayed significant 
upfield shift changes in the signals for cavity proton, namely H-3' and H-5'. The 
protons located outside the cavity of P-CD (H-T, 2', 4', 6') showed insignificant shift 
changes in the presence of FLU. Moreover, the chemical shift changes (A6) for H-3' 
were more pronounced compared to H-5'. Fig. 28 shows the expanded part of ' H 
NMR spectra of P-CD in the presence as well as in the absence of FLU. 
4.1 3.9 3.7 3.5 3.3 
Fig. 27. Part of the COSY spectrum (400 MHz) of a mixture of p-CD 
and FLU showing the interaction of P-CD protons. 
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—H-3',6' 
I 
p-CD/FLU 
H-5' H-2' H-4' 
Fig. 28. Partial 'H N M R (300 MHz) spectra 
showing signals for the protons of P-CD, in the 
absence, as well as in the presence, of FLU. 
The upfield shift of P-CD cavity protons, namely H-3' and H-5', as well as 
concomitant downfiled shift changes of FLU protons in the 'H NMR spectra of 
P-CD-FLU mixture are clear indication of inclusion complexation between the P-CD 
and FLU, in analogy to previous studies.^ ^*'^ '^'^ ^ '^^ ^^ 
' H NMR Spectral Assignment and Chemical Shift Change Data of 
FLU 
The resonance assignment of FLU protons was made with the help of COSY, ROESY 
and DEPTO experiments performed on a mixture of p-CD-FLU. A cursory 
examination of the aromatic region of the FLU spectra, in the presence as well as in 
the absence of the P-CD, points to the presence of two isomeric forms of FLU. The 
signals for the F-substituted aromatic ring of two diastereomers appeared separately in 
all the spectra. 
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The H-1 was observed separately for two isomers as two doublets (7=6.88 Hz) 
in the lowest field in all the spectra. The signal for H-2 for one isomer was found 
merged with H-3, 5 while a triplet (J=6.88 Hz) was observed for H-2 of other isomer. 
The signals for the other aromatic ring were observed as a triplet for H-4, 6 which 
appeared downfield compared to H-3, 5, which was observed as a multiplet because 
H-2 merged with this signal. A doublet (7=16 Hz), which appeared in the aromatic 
region, was ascribed to H-7 while H-8 was found resonating as a doublet of doublet 
around 5.448 ppm. The chemical shift change (A5) data of studied FLU protons in the 
presence of P-CD is given in Table 10. 
Table 10. ' H N M R (300 MHz) chemical shift change (A8) data for studied protons of 
FLU, in the presence of p-CD. 
[p-CDl/[FLUl 
0.2 
0.3 
0.8 
1.0 
1.1 
H-1 
0.3460 
0.3580 
0.3750 
0.3830 
0.4000 
H-1 
0.2420 
0.2590 
0.2760 
0.2890 
0.3060 
H-4, 6 
0.0331 
0.3480 
0.3800 
0.3990 
0.4200 
H-2, 3, 5 
0.4080 
0.4230 
0.4420 
0.4590 
0.4760 
H-2 
0.4170 
0.4470 
0.4640 
0.4650 
0.4690 
H-7 
0.5060 
0.5270 
0.5490 
0.5560 
0.5670 
In the presence of p-CD, all the aromatic protons of FLU significantly shifted 
downfield. The F-substituted aromatic ring protons of FLU shifted more 
pronouncedly than other aromatic protons. These observations clearly indicate that at 
least F-substituted aromatic ring is inserted into the P-CD cavity but whether other 
ring is also involved in complexation is not clear because, generally, all the protons of 
the guest, and not only the part that enters the p-CD cavity, show downfield shift 
changes upon complexation with CDs.^ ^^ Fig. 29 shows the expansions of aromatic 
regions of the spectra of pure FLU and mixtures of p-CD and FLU. 
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FLU 
H-K H-4,6 -H-2 ,3 ,5 ^.7 
1 /H-2 I 
P-CD/FLU=1.1 
7.7 7.5 7 3 
n 1 1 r I, pp»i 
7,1 6.9 6.7 6.5 6.3 
Fig. 29. Partial ' H N M R (300 MHz) spectra showing siiift of 
aromatic protons of FLU in the presence of P-CD. 
COSY and DEPTO Spectrum of p-CD-FLU Mixture 
The signal in the lowest field of the spectrum, which was assigned to H-1 proton, 
showed cross connection peak, in COSY spectrum (Fig. 23), with the multiplet 
assigned to H-2, 3, 5 protons, indicating that the H-2 proton of one isomer is merged 
with H-3, 5 signal which was confirmed by DEPTO experiment (Fig. 30). It became 
possible with help of COSY spectral data that the signal appearing in the lowest field 
(H-1) and the H-2 signal which appeared merged with H-3, 5 signals belonged to the 
same aromatic ring while H-1 and H-2 for other isomer appeared separately. 
Expansions of the part of COSY spectrum of a P-CD-FLU mixture, showing aromatic 
region is given in Fig. 31. 
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?1^ 
H-7 
IL 
H-l/C-l 
H-3.S/C-3..') 
H-l/C-
H-2/C-2 
H-2/C-2 H-7/C-7 
H-4,6/C-4.6 
Fig. 30. Part of the DEPTO spectrum (400 MHz) of a mixture of p-CD 
and FLU showing that H-2 is merged with H-3, 5. 
H-J H-, " l ^ " " ' - ' - ' / " - ^ H.7 
A RA A i l Ik 
O 
H-8 
a ^i^ 
H-3.5/H-4.6 
O) 
» 3 
ti> -O H-I/H-2 
9 * H.I/H-2 
80 1 1 \~i—I—r 70 1—!—I—r 60 
Fig. 31. Part of the COSY spectrum (400 MHz) of a mixture of p-CD and FLU 
showing interaction of aromatic protons. 
aff' j i fr-i. si;:^  
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Stoichiometry and Binding Constant of p-CD-FLU Complex/es 
The stoichiometry and the apparent binding constant (Ka) of the P-CD-FLU inclusion 
complex/es were determined by using Scott's method^*^ which is a modified form of 
Benesi-Hildebrand method.'^ ^^ In Scott's equation, 
[CD],/A5obs= [CD],/A5c+ \/KaA8c 
[CD]t is the molar concentration of the CD, ASobs is the observed chemical shift 
difference for a given [CD]t concentration, A5c is the chemical shift difference 
between a pure sample of complex/es and the free component at the saturation. The 
plots of chemical shift changes (AS) for the FLU protons against [P-CD] in the form 
of [P-CDJ/A6 versus [p-CD] gave almost linear fits (Fig. 32) confirming 1:1 
stoichiometry for the P-CD-FLU complex/es. The slope of the plot thus equals to 
1/A6c and the intercept with the vertical axis to l/ATaASc, allowing the estimation of A^ a^-
The binding constant (Ka) was determined to be 340 M''. 
S 6-
9r 
2 4 
X 
to 1 
I 
CQ. 
H-1 
0 
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 
[p-CD] xl 0-2 M 
Fig. 32. Scott's plot showing 1:1 stoichiometry of the p-CD-FLU complex/es. 
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ROESY Spectrum of p-CD-FLU Mixture 
2D ROESY spectrum was obtained for a mixture of p-CD and FLU under spin lock 
conditions. Expansion of the part of the ROESY spectrum of p-CD-FLU mixture is 
given in Fig 33. A set of cross connection pealcs between H-3' and H-5' cavity 
protons of p-CD and F-substituted aromatic ring (H-1 and H-2) were observed. The 
signals for the other aromatic ring did not show any cross peaks with P-CD cavity 
protons confirming, beyond doubt, the penetration of only F-substituted aromatic ring 
into the P-CD cavity. The intensity of the cross peaks for the two isomers was not 
identical suggesting chiral differentiation by the P-CD between the two isomers.'^^ 
Moreover, the H-1 of the F-substituted aromatic ring also showed cross connection 
peaks with H-2' and H-4' protons of P-CD, which are situated near the wider rim. 
This implies that aromatic ring penetrates deep from the narrower rim side and H-1 
proton of FLU is located near wider rim in the complex/es. 
H-,1 H-K 
H^.6 H-2,3,5, 
.H.2 H.7 
A 
— I — , — . — • — , — • — . — r — I — I — , — 1 — 1 — • — I — . — r — — ' — ' — 1 — ' — ' — ' — r 
7.6 7.4 7,a 7 0 6 8 6.6 
00 
CD 
1 
Fig. 33. Expanded region of ROESY spectrum (400 MHz) 
of P-CD-FLU mixture showing cross peaks of 
F-substituted aromatic ring protons with P-CD cavity 
protons (mixing time=500 ms). 
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Structure of the p-CD-FLU Complex 
The structure for the p-CD and FLU complex (Fig. 34) was proposed taking into 
consideration the stoichiometry, ' H N M R titration results and ROESY spectral data. It 
can be concluded that only F-containing aromatic ring was involved in the 
complexation with P-CD because no interactions were observed between other 
aromatic ring of FLU and P-CD cavity protons. The mode of penetration was 
confirmed on the basis of cross peaks between H-1 and the H-2', 4' which are situated 
at the wider rim. The chemical shift changes (A5) for the F-containing ring protons of 
the two isomers of FLU were not identical which suggest the chiral differentiation by 
the p-CD between the two isomers. 
ONa 
Fluvastatin sodium 
Fig. 34. Proposed structure of 1:1 P-CD-FLU inclusion complex. 
3.3 CONCLUSION 
The ' H NMR spectroscopic studies of the pure FLU, pure p-CD and mixtures of p-CD 
and FLU in D2O confirmed the complexation between P-CD and FLU. The 
stoichiometry and binding constant were determined by the treatment of ' H NMR 
titration data. The mode and depth of penetration and the fact that only one aromatic 
ring was involved in the complexation was established with the help of ROESY 
spectral data. 
CHAPTER-IV 
NMR Spectroscopic Study of Complexation of 
p-Cyclodextrin and Desloratadine 
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Desloratadine (DES), Clarinex, C19H19CIN2, FW 310.8, 8-chloro-ll-(piperidin-4-
ylidene)-6,ll-dihydro-5//-benzo[4,5]cyclohepta[2,l-Z)]pyridine, a new nonsedating 
selective HI-antihistamine, is efficacious and safe in the treatment of perennial 
allergic rhinitis^^^ and chronic idiopathic urticaria.^^ It inhibits important cytokin and 
cellular activity, suggesting an antiallergic and anti-inflammatory profile.''^'' 
It is a white to off-white powder that is slightly soluble in water, but very 
soluble in ethanol and propylene glycol. DES is a chiral, light sensitive drug and its 
solubility in water is 0.01 mg/mL. 
Desloratadine 
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4.1 EXPERIMENTAL 
Desloratadine (DES) was generously donated by Morepen Laboratories Ltd, India, 
while p-cyclodextrin (P-CD) was obtained from Geertrui Haest, Cerestar Application 
Centre, Food & Pharma Specialities, France, and these were used without further 
purification. All the NMR ("H and COSY, ROESY) spectra (Fig. 35-46) were 
recorded on a JEOL a-500 MHz instrument in D2O at room temperature. The 
chemical shift values (8) are reported in ppm. Seven samples of P-CD and DES were 
prepared in various molar ratios ranging from 0.15 to 1.70. The overall concentration 
of DES was kept constant at 1.03x10""'^  M while that of P-CD was varied. The 
p-CD/DES molar ratios were calculated by direct integration of appropriate signals. 
During these studies no external indicator was used and HDO signal at 4.800 ppm 
was used as internal reference. Distinct peaks for bound and free form of the DES 
were not observed indicating the rapid exchange of DES between free and bind state 
on the NMR time scale. Chemical shifts changes (A5) were calculated according to 
the formula: 
A5 = 5(complex) - 5(free) 
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4.2 RESULTS AND DISCUSSION 
' H N M R Chemical Shift Change Data of p-CD 
The assignment of the P-CD protons was made with the help of their characteristic 
shapes, position of signals and COSY spectrum (Fig. 47). A detailed inspection of the 
p-CD proton signals in the 'H NMR spectra of mixture of p-CD and DES displayed 
upfield shift changes in the H-3' and H-5' proton resonances of P-CD, located inside 
the cavity, compared to pure P-CD. Other p-CD protons (H-T, 2', 4', 6') also 
displayed shift changes but these were not significant. Expansions of part of the 
spectra showing P-CD protons, in the presence as well as in the absence of DES, are 
shown in Fig. 48. 
4:0 3^ 9 3.8 3.7 3.6 3^ 5 3.4 
Fig. 47. Part of the COSY spectrum (500 MHz) of a mixture of 
P-CD and DES showing the interaction of p-CD protons. 
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H-6' 
H-2 
p-CD/DES 
Jil l/^  
3.9 3.8 3.7 3.6 3.5 ppm 
H-2' H-4' 
3.9 3.8 3.7 3.6 3.5 ppm 
Fig. 48. Part of 500 MHz 'H N M R spectra showing P-CD 
protons in the presence, as well as in the absence, of DES. 
The upfield shift of p-CD cavity protons, namely H-3' and H-5', and 
concomitant downfiled shift changes of DES protons in the 'H NMR spectra of 
P-CD-DES mixtures, can be attributed in terms of ring current effect of aromatic ring 
penetrating the p-CD cavity, confirming the complexation between p-CD and DES, 
in analogy to previous studies.^ ^*' ^ °^ 
H NMR Spectral Assignment and Chemical Shift Change Data of 
DES 
To establish which of the two rings was involved in the complexation, an 
unambiguous resonance assignment of guest protons (DES) in the free as well as 
complexed state was required which was made with the help of 2D COSY spectral 
data performed on a mixture of P-CD and DES. The COSY spectrum showing cross 
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connection peaks between the aromatic regions of DES in p-CD-DES mixture is given 
in Fig. 49. 
H-5 H-6 H-9 
H-7 H-10 H-8 
Jl A A U l 
o 
• ' 
o 
00* • 
H-5/H-6 
H-6/H-7 
T! 1 11 1 I 
8.0 
^ 
i? 
— ? 
7.0 
Fig. 49. Part of the COSY spectrum (500 MHz) of a 
mixture of P-CD and DES showing the interaction 
of aromatic protons. 
As expected, the signals for the pyridine ring protons appeared downfield 
compared to chlorophenyl ring. The most downfield doublet appearing at 8.5334 
(J=5.75 Hz) was assigned to H-5 and it showed the cross connection peak with the 
doublet of doublet at 7.8009 (y/=5.72 Hz, J2=8.05 Hz) ascribed to H-6. The doublet at 
8.2704 (y=8.0 Hz) was assigned to H-7 as it showed the cross peak with H-6. The 
signal at 7.3786 (d, J=1.7 Hz) was assigned to H-10 protons of DES. The doublet of 
doublet signal at 7.3250 (J/=2.5 Hz, 7^=8.8 Hz) was easily attributed to H-9 because it 
showed interaction with two other signal (H-8 and H-10). The doublet signal at 
7.1821 (J=8.6 Hz) was assigned to H-8 and it shows the coupling with H-9. The 
chemical shift change (A6) data for the aromatic protons of DES protons in the 
presence of p-CD is given in Table 11. 
Dit> 
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Table 11. 'H N M R (500 MHz) chemical shift change (A6) data of aromatic protons of 
DES, in the presence of P-CD. 
P-CD/DES H-5 H-7 H-6 H-10 H-9 H-8 
0.15 
0.31 
0.44 
0.65 
1.06 
1.40 
1.70 
0.0100 
0.0108 
0.0155 
0.0236 
0.0332 
0.0366 
0.0377 
-0.0094 
-0.0164 
-0.0235 
-0.0240 
-0.0407 
-0.0568 
-0.0580 
-0.0260 
-0.0337 
-0.0377 
-0.0394 
-0.0499 
-0.0540 
-0.0588 
0.0367 
0.0538 
0.0653 
0.0867 
0.1047 
0.1138 
0.1203 
0.0271 
0.0293 
0.0341 
0.0354 
0.0467 
0.0532 
0.0540 
0.0101 
0.0246 
0.0376 
0.0404 
0.0467 
0.0524 
0.0546 
Negative values indicate upfield shift changes 
In the presence of p-CD, all the aromatic signal of DES exhibited induced shift 
changes as well as splitting indicating the chiral differentiation of DES by P-CD.'^ ^ 
These spectral investigations further confirm the involvement of aromatic ring/s in 
complexation but whether one or both the aromatic ring/s are penetrating into P-CD 
cavity cannot be confirmed by this data, because generally, all the protons of the 
guest, and not only the part that enters the P-CD cavity, show downfield shift changes 
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upon complexation with CDs. Fig. 50 shows the expansions of aromatic regions of 
the spectra of pure DES and DES in the presence of varying amount of P-CD. 
Stoichiometry and Binding Constant of p-CD-DES Complex/es 
The stoichiometry and the apparent binding constant (Ka) of the p-CD-DES 
complex/es were determined by using Scott's method^ *^  which is a modification of 
Benesi-Hildebrand method.^ ^^  In Scott's equation, 
[CD],/A5obs = [CD],/A5c + l/Ka^b, 
[CDl is the molar concentration of the CD, A6obs is the observed chemical shift 
difference for a given [CD], concentration, A8, is the chemical shift difference 
between a pure sample of complex/es and the free component at the saturation. The 
plots of chemical shift changes (A5) for the DES protons against [p-CD] in the form 
of [p-CD]/A5 versus [p-CD] gave excellent linear fits (Fig. 51) confirming 1:1 
stoichiometry for the P-CD-DES complex/es. The slope of the plot thus equals to 
1/A8e and the intercept with the vertical axis to \/KaA5„ allowing the estimation of ^ ^ 
to be 124 M''. 
R, Ji DES M l 
I m P-^ P^ PE^ -Q-^ ^ PI 
i A p-CD/DES=0.31 
CD/DES=0.44 A. 
1^ _1._ 
p.CD/DES=Q.65 ^ _ __ J L A J L 
. B-CD/DES=1.06 . , 
._. A_.A. L, 
At'^''/^^^:\-^lM A__A_. 
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'H-9 ./H-8 l .H-5 H.7 H-6 H-lUs^, / | | / 
A llM P-CD/DES=1.70 t ) ^ )IL__JH II 
I I I I I i i I I I I I 1 1 I I ppm 
8.6 8.5 8 4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 
Fig. 50. A part of H NMR spectra (500 MHz) showing aromatic protons of DES in 
the absence, as well as in the presence, of varying amount of P-CD. 
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Fig. 51. Scott's plot showing l.i stoichiometry of the p-CD-DES complex/es. 
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ROESY Spectrum of p-CD-DES Mixture 
To ascertain whether chlorophenyl or pyridine ring was involved in complexation, 
ROESY spectrum was performed on p-CD-DES mixture under spin lock conditions. 
The ROESY spectrum of P-CD-DES mixture exhibited intermolecular cross peaks 
between chlorophenyl ring (H-8, H-9 and H-10) and p-CD cavity proton, and no cross 
peaks between pyridine ring protons and P-CD cavity protons were present, thus 
confirming that only one ring was involved in the complexation. Taking into account 
the 1:1 stoichiometry of the P-CD-DES complex/es and ROESY data, it becomes 
obvious that only one 1:1 inclusion complex is formed. Expansions of the part of the 
ROESY spectrum of P-CD-DES mixture showing aromatic region is given in Fig. 52. 
H-5 H-7 H-6 H-10 H-9 H-8 
. 1^' I I I I I I M I 
8.4 7.87.6 7.47.2 7.0 
Fig. 52. Expanded region of ROESY spectrum 
(500 MHz) of p-CD-DES mixture showing cross 
peaks of aromatic ring protons with p-CD cavity 
protons (mixing time=500 ms). 
Structure of the p-CD-DES Complex 
On the basis of stoichiometry, ' H N M R titration results and ROESY spectroscopic 
data, there are two probable structures of complex that can be considered as shown in 
Fig. 53. The entry of the guest from narrower rim side was ruled out because no 
I l l 
interaction between DES protons and protons located on the narrower rim was 
observed. Mode II was ruled out because it cannot explain the interaction of H-8 with 
P-CD cavity protons, especially H-5'. The structure shown in mode I was therefore, 
assigned to the complex formed between p-CD and DES under the experimental 
conditions studied. 
4 3 
Desloratadine 
+ 
P-Cyclodextrin 
Fig. 53. Proposed model for p-CD-DES inclusion complexes. 
4.3 CONCLUSION 
The 'H N M R spectroscopic studies of pure DES, pure P-CD and mixtures of P-CD 
and DES in D2O confirmed the complexation between P-CD and DES. The 
stoichiometry and binding constant were determined by the treatment of ' H NMR 
titration data. The ROESY spectroscopic data confirmed that the chlorophenyl ring 
acts as the guest and it penetrates into the p-CD cavity from the wider rim side. The 
splitting of most of the signals of DES in the presence of p-CD suggests chiral 
differentiation of the guest by P-CD. 
CHAPTER-V 
NMR Spectroscopic Study of Complexation of 
P-Cyclodextrin and Cetirizine Dihydrochloride 
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Cetirizine dihydrochloride (CTZ), Zyrtec, C2iH25ClN203-2HCl, 
FW 461.82, (±)-[2-[4-[(4-chlorophenyl)phenylmethyl]-l -piperazinyl]ethoxy]acetic 
acid, dihydrochloride, is a potent, second-generation, HI-receptor antagonist, 
antihistamine drug with the amine piperazine in its molecule.'^^' It is used to treat the 
symptoms of allergies, chronic urticaria, hay fever, angioedema, hives, and as a 
treatment adjunct in asthma.^°^ CTZ is also effective in the treatment of Kimura's 
disease, pruritus and as an anti-inflammatory agent 303 
It is a hygroscopic, white to off-white crystalline powder, freely soluble in 
water, practically insoluble in acetone and dichloromethane. CTZ is a light sensitive 
drug and its racemic mixture is used for pharmaceutical purposes. 
Ph-H 
V^ 
/ 
N 
\ 
\ 
1 
/ 
Cetirizine dihydrochloride 
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5.1 EXPERIMENTAL 
Cetirizine dihydrochloride (CTZ) was generously gifted by Dr. Reddy's Laboratory, 
India, while P-cyclodextrin (p-CD) was obtained from Geertrui Haest, Cerestar 
Application Centre, Food & Pharma Specialities, France, and these were used without 
further purification. All the 'H N M R and 2D NMR (COSY, ROESY) spectra 
(Fig. 54-63) were recorded on a JEOL a-500 MHz instrument in D2O at room 
temperature. The chemical shift values (5) are reported in ppm. No external indicator 
was used and HDO signal at 4.800 ppm was used as internal reference throughout this 
work. ' H NMR spectra of five samples of mixtures of-p-CD and CTZ with CTZ/p-CD 
molar ratios ranging from 0.2 to 1.2 were recorded. The CTZ/p-CD molar ratios were 
calculated by direct integration of appropriate signals. The overall concentration of 
P-CD was kept constant at 10 mM while that of CTZ was varied from 2.0 to 12.0 mM. 
Distinct peaks for bound and free form of CTZ were not observed indicating a rapid 
exchange of guest between free and bind state on the NMR time scale. Chemical 
shifts changes (A6) were calculated according to the formula: 
A5 - 5(complex) - 5(free) 
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5.2 RESULTS AND DISCUSSION 
' H N M R Chemical Shift Change Data of P-CD 
The assignment of p-CD signals, in the spectra of P-CD-CTZ mixture, was made with 
the help of their characteristic shapes, position of signals and 2D COSY spectrum 
(Fig. 64). A cursory examination of the spectra of p-CD-CTZ mixtures indicate 
highfield shift changes in the p-CD cavity protons, H-3' and H-5', while other p-CD 
protons showed relatively negligible shift changes. Moreover, the chemical shift 
changes (A5) for H-3' were more pronounced compared to H-5'. 
H-6 
_ - ^ 
o 
4.0 3.9 3.8 3.7 3.6 3.5 
Fig. 64. Part of the COSY spectrum (500 MHz) of a mixture of 
P-CD and CTZ showdng the interaction of P-CD protons. 
The inclusion of an aromatic guest molecule into the P-CD cavity generally 
produces highfield shifts for cavity protons (H-3' and H-5') of p-CD due to 
anisotropic shielding by aromatic ring on the p-CD protons located above or below 
the 7i-electron cloud. Thus, highfield shift changes observed in the H-3' and H-5' of 
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p-CD, located in the cavity, in the presence of CTZ, confirm the formation of 
inclusion complex/es between p-CD and CTZ under the studied conditions as reported 
earlier?^ '^ ^^^' ^'''' ^ ^ Expansions of the part of the spectra of pure P-CD and mixtures 
of p-CD and CTZ are shown in Fig. 65 while their chemical shift change (A6) data is 
given in Table 12. 
H-3' r ^ 
CTZ/p-CD=1.2 
H-5' 
4.0 3.9 3.8 3.7 3.6 3.5 TpTT 
Fig. 65. Expansions of part of 'H NMR spectra (500 MHz) showing P-CD 
protons in the presence, as well as in the absence, of varying amount of CTZ. 
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Table 12. 'H N M R (500 MHz) chemical shift change (A5) data for the p-CD protons 
in presence of CTZ. 
rCTZl/[p-CD] 
0.2 
0.4 
0.6 
0.8 
1.2 
H-r 
-0.071 
-0.073 
-0.079 
-0.086 
-0.098 
H-2' 
0.004 
0.022 
0.031 
0.030 
0.031 
H-3' 
-0.091 
-0.164 
-0.222 
-0.273 
-0.353 
H-4' 
-0.008 
-0.005 
-0.012 
-0.018 
-0.025 
H-5' 
-0.078 
-0.139 
-0.188 
-0.224 
-0.282 
H-6' 
-0.005 
-0.003 
-0.002 
-0.008 
-0.018 
Negative values indicate upfield shift changes 
' H NMR Spectral Assignment and Chemical Shift Change Data of 
CTZ 
To establish the structure of the complex/es, an unambiguous resonance assignment of 
CTZ protons was required. The assignment of resonances of guest protons was made 
with the help of COSY and ROESY spectral data, in the presence of P-CD, because 
some of the signals which appeared completely merged in the spectrum of pure CTZ 
separated in the presence of P-CD helping in assignment. There are two aromatic 
rings in CTZ and their signals appeared separately. The chlorophenyl ring protons 
were found resonating at a lower field compared to phenyl ring protons. The 
chlorophenyl ring protons were observed as a pair of partially overlapped doublets. 
The doublet at 7.6198 (J=6.85 Hz) was assigned to H-2, 3 proton while the doublet at 
7.6044 (J=6.80 Hz) was assigned to 1, 4-protons because it exhibited through space 
interaction with benzylic proton. The phenyl ring protons appeared as complex 
multiplet, totally integrating for five protons. In the presence of p-CD, the signals for 
both the aromatic ring protons exhibited splitting.'^' 
In the presence of P-CD all the aromatic protons of CTZ significantly shifted 
downfield. The expansions of aromatic region of spectra of CTZ in the presence as 
well as in the absence of P-CD are shovra in Fig. 66. 
127 
Ph-H 
Fig. 66. Expansion of part of 'H N M R spectra (500 MHz) of 
CTZ protons in the presence, as well as in the absence, of 
P-CD. 
Stoichiometry and Association Constant of p-CD-CTZ Complex/es 
The stoichiometry and the association constant (Ka) of the p-CD-CTZ complex/es was 
determined on the basis of Scott's modification^^^ of Benesi-Hildebrand equation.'^ ^^  
In Scott's equation, 
[CTZ]t/A8obs = [CTZ],/A8c + \/KaAbo 
[CTZ]t is the molar concentration of the guest, A5obs the observed chemical shift 
change for a given [CTZ]t concentration, A5c is the chemical shift change between a 
pure sample of complex/es and the free component at the saturation. The plot of 
chemical shift changes (A5) for the P-CD cavity protons (H-3' and H-5') against 
[CTZ] in the form of [CTZ]/A5obs versus [CTZ] gave excellent linear fits (Fig. 67) 
confirming 1:1 stoichiometry for the P-CD-CTZ complex/es. The slope of the plot is 
thus equal to 1/A5c and the intercept with the vertical axis to l/A:aA5c, allowing the 
estimation of Ka to be 70 M'' which is the average of two Ks calculated from two 
plots. 
128 
45 
40 
a, 
CO 
35 
30 -
25 
20 
0 
H-5' (P-CD) 
H-3' (P-CD) 
6 8 
[CTZ] mM 
10 12 14 
Fig. 67. Scott's plot showing 1:1 stoichiometry for the P-CD-CTZ complex/es. 
These results were submitted to Spectrcoscopy for publications. The reviewers 
desired that the Foster-Fyfe method be used for the determination of stoichiometry 
and association constants. The Foster-Fyfe method was therefore, also used to further 
confirm the stoichiometry and association constant. 
In the Foster-Fyfe^^^ equation, 
A8obs/[G]t = -ATflASobs + ATflASmax 
A5obs is the observed chemical shift change for a given [G], [G]t is the molar 
concentration of the guest, ASmax the chemical shift change between a pure sample of 
the complex/es and the free component at the saturation. A plot of A5obs/[G]t against 
ASobs (referred as an x-reciprocal plot) should be linear for 1:1 complex/es, whose 
negative gradient equals Ka. This modification requires an extrapolation to infinitely 
dilute solution and the Ka is not dependent on the extrapolation. The overall 
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association constant (Ka) was determined to be 70 M"' which is the average of two Ks 
calculated from two plots (Fig. 68). 
50 
45 
I 40 
OH 
N 35 ^ 
H 
U 
S^  30 
< 
25 
20 
H-3' (P-CD) 
H-5' (P-CD) 
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 
A5ppm 
Fig. 68. Foster-Fyfe plot showing 1:1 stoichiometry for p-CD-CTZ complex/es. 
ROESY Spectrum of p-CD-CTZ Mixture 
To clearly establish the structure of P-CD-CTZ complex/es, ROESY spectral data 
were required. The 2D ROESY spectrum was obtained for a mixture of P-CD and 
CTZ under spin lock conditions. The spectrum exhibited strong cross correlation 
peaks between cavity protons (namely H-3' and H-5') of p-CD and protons of both 
the aromatic rings of CTZ, confirming the penetration of both the phenyl as well as 
chlorophenyl rings into the P-CD cavity. Moreover, strong cross peaks between H-2' 
and H-4' of P-CD with the protons of both the aromatic rings were also observed. 
This is a clear indication that both of the aromatic rings penetrate into the P-CD cavity 
from wider rim side. Fig. 69 shows the expansions of parts of the 2D ROESY 
spectrum, showing cross peaks between protons of aromatic rings of CTZ and P-CD 
cavity protons. 
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H-6' H-2' H-4 
3.9 3.8 3.7 3.6 3.5 
Ph-H 
rn" 
en" 
7.7 7.6 7.5 7.4 7.3 
Fig. 69. Expansion of Part of 2D ROESY (500 MHz) spectrum of p-CD-CTZ 
mixture showing cross peaks of aromatic ring protons with P-CD cavity 
protons (mixing time=500 ms). 
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Structure of the p-CD-CTZ Complexes 
Taking into account the 1:1 stoichiometry of the (3-CD-CTZ complexation and 2D 
ROESY data, it can be concluded that two 1:1 inclusion complexes were present in 
solution formed by the penetration of aromatic rings from wider rim side of P-CD 
cavity (Fig. 70). The penetration of the guest from narrower rim side was ruled out on 
the basis of 2D ROESY spectral data. 
Ph-H 
Fig. 70. Proposed structures of two 1:1 P-CD-CTZ inclusion complexes. 
5.3 CONCLUSION 
'H NMR titration studies of CTZ with p-CD in DjO confirmed the formation of two 
1:1 inclusion complexes by the penetration of aromatic ring into the P-CD cavity. The 
structures of the two complexes have been deduced with the help of 2D ROESY 
spectral data. The overall association constant was determined by reported methods. 
CHAPTER-VI 
NMR Spectroscopic Study of Complexation of 
p-Cyclodextrin and Flunarizine 
Dihydrochloride 
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Flunarizine dihydrochloride (FLN), Flurium, C26H26F2N2-2HC1, FW 477.42, 
1 -[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine, dihydrochloride, is 
the difluorinated derivative of Cirmarizine with similar chemical structure and 
pharmacological profile.''''^ It is a selective calcium entry blocker with calmodulin 
binding properties and histamine HI blocking activity. It prevents cellular calcium 
overload by reducing excessive transmembrane influxes of calcium and does not 
interface with normal cellular calcium hemostasis. FLN is also effective in the 
prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and 
peripheral origin, and as an adjuvant in the therapy of epilepsy. It also has 
antihistaminic and sedative properties. 
It is a white crystalline powder, sparingly soluble in methanol, ethanol and 
chloroform, poorly soluble in water, insoluble in acetone, ether and iso-propyl 
alchohol. 
2HC1 
1 1 % ^ 9 
10 
Flunarizine dihydrochloride 
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6.1 EXPERIMENTAL 
Flunarizine dihydrochloride (FLN) was kindly donated by Geno Pharmaceutical Ltd. 
India, while the P-cyclodextrin (P-CD) was obtained from Geertrui Haest, Cerestar 
Application Centre, Food & Pharma Specialities, France, and these were used as 
obtained. All the ' H N M R and 2D NMR (COSY, ROESY) spectra (Fig. 71-81) were 
recorded on a JEOL a-500 MHz instrument in D2O at room temperature. The 
chemical shift values (5) are reported in ppm. No external indicator was used and 
HDO peak at 4.800 ppm was kept as an internal reference throughout this work. 
' H NMR spectra of six samples of mixture of FLN and P-CD with FLN/p-CD molar 
ratios ranging from 0.2 to 1.8 were recorded. The FLN/p-CD molar ratios were 
calculated by direct NMR integration of their appropriate signals. The overall 
concentration of p-CD was kept constant at 10 mM while that of FLN was varied 
from 2.0 to 18.0 mM. The smooth variation in chemical shifts and the absence of new 
peaks that could be assigned to the complex/es suggested that, on the NMR timescale, 
the inclusion complexation of P-CD with FLN is a fast exchange process. Chemical 
shifts changes (A5) were calculated according to the formula: 
A8 = 6(complex) - 5(free) 
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6.2 RESULTS AND DISCUSSION 
' H N M R Chemical Shift Change Data of p-CD 
The assignment of the p-CD signals, in the spectra of mixture of (3-CD and FLN, was 
made with the help of their specific shapes, position of their signals and 2D COSY 
spectral data (Fig. 82). On investigation of 'H NMR spectra of mixtures of p-CD and 
FLN, an upfield shift in H-3' and H-5' (located inside the cavity) signals of P-CD was 
observed. Other P-CD signals (H-T, 2', 4', 6') also exhibited upfield shift changes 
but these were negligible. In the presence of FLN, the chemical shift changes (A5) for 
H-5' were more pronounced than those of H-3' signal of P-CD. 
H-6' H-2' 
H-4',5' 
3.9 3.8 3.7 3.6 3.5 
Fig. 82. Part of the COSY spectrum (500 MHz) of a mixture of P-CD and 
FLN showing the interaction of P-CD protons. 
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The clear upfield shift of protons located inside the cavity, namely H-3' and 
H-5', have been attributed to magnetic anisotropy effect in the p-CD cavity, due to the 
inclusion of groups rich in n-electrons. The continuous upfield shift changes 
observed in the H-3' and H-5' of P-CD in the 'H N M R spectra of mixtures of 
P-CD-FLN, thus confirm the formation of inclusion complex/es between P-CD and 
FLN in analogy to previous studies.^^' ^^ *' ^ ''' ^°'' Expansions of part of 'H NMR 
spectra of pure P-CD and mixture of P-CD and FLN in varying amounts of FLN are 
given in Fig. 83 while there chemical shift change (A8) data is listed in Table 13. 
H-2\y -H-4',5' 
FLN/p-CD=1.8 
H-3' A /H-6' _^  H-2' H-4 
jyOlAA_!!ft^ 
FLN/p-CD=1.3 
FLN/p-CD=1.0 
FLN/p-CD=0.7 
FLN/p-CD=0.4 
=0.2 
JAJJW. P-CD 
4,0 .19 3,8 3.7 3.6 3.5 ppm 
Fig. 83. A part of 'H NMR spectra (500 MHz) showing protons of p-CD in 
the absence, as well as in the presence, of varying amount of FLN. 
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Table 13. 'H N M R (500 MHz) chemical shift change (A6) data for the p-CD protons 
in the presence of FLN. 
[FLNl/rP-CDl 
0.2 
0.4 
7.0 
1.0 
1.3 
1.8 
H-r 
-0.0559 
-0.0672 
-0.0775 
-0.0842 
-0.0859 
-0.0882 
H-2' 
-0.0003 
-0.0005 
-0.0010 
-0.0013 
-0.0049 
-0.0073 
H-3' 
-0.1053 
-0.1574 
-0.2029 
-0.2275 
-0.2436 
-0.2586 
H-4' 
-0.0220 
-0.0333 
-0.0428 
-0.0585 
-0.0602 
-0.0620 
H-5' 
-0.1171 
-0.1837 
-0.2399 
-0.2745 
-0.2943 
-0.3193 
H-6' 
-0.0090 
-0.0199 
-0.0450 
-0.0516 
-0.0525 
-0.0572 
Negative values indicate upfield shift changes 
' H NMR Spectral Assignment and Chemical Shift Change Data of 
FLN 
To clearly establish the geometry of the P-CD-FLN complex/es, and to established 
which of the three rings are involved in complexation, an unambiguous resonance 
assignment of guest protons (FLN) in the free as well as complexed state was 
required, which was made with the help of 'H NMR as well as 2D COSY spectral 
data. Part of the 2D COSY spectrum of the mixture of p-CD and FLN, showing cross 
connection peaks between aromatic protons of FLN is shown in Fig. 84. 
The aromatic protons were observed as three signals, a triplet at 7.2046 
integrating for four protons, a multiplet at 7.4559 for three protons and a multiplet at 
7.5873 for six protons. The triplet at 7.2046 (/=8.6 Hz) was assigned to H-2 protons 
and it showed interaction with the multiplet at 7.5873 which was ascribed to H-1 and 
H-10 protons. The multiplet at 7.4559 was due to H-9, 11 protons. The signal for H-2 
was expected to be a doublet but it was observed as triplet. It seems that two doublets 
for H-2 of two rings have merged to give a triplet. Similarly, in some cases, the signal 
for H-1 and H-10 separated and the nature of H-1 was also like a triplet. A doublet at 
6.9712 (/=16.0 Hz), which appeared in the aromatic region was ascribed to H-8, 
while the H-7 was found resonating as a merged doublet of triplet at 6.3195. 
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H-1,H> 
H-941 
\ 
H-8 H-7 
H-2 
/ 
AJLJI__JUI 
7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 
Fig. 84. Part of the COSY spectrum (500 MHz) of a mixture of 
J3-CD and FLN, showing the interaction of aromatic protons. 
In the presence of P-CD, all the aromatic protons of FLN significantly shifted 
downfleld and exhibited splitting, indicating some chiral differentiation of FLN by 
P-CD.'^ ^ The signal for H-1, 10 which appeared merged in the spectrum of pure FLN, 
separated in the spectra of some mixtures. These observations clearly indicates the 
involvement of aromatic ring/s in complexation but which of these aromatic ring/s are 
penetrating into P-CD cavity cannot be confirmed by this data, because mostly, all the 
protons of the guest, and not only the part that enters the P-CD cavity, show 
downfield shift changes upon complexation with CDs.^ '^' The expansions of aromatic 
regions of spectra of FLN in the presence as well as in the absence of P-CD are shown 
in Fig. 85. 
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Fig. 85. Expansion of parts of ' H N M R spectra 
(500 MHz) of FLN protons in the presence, as 
well as in the absence, of P-CD. 
Stoichiometry and Association Constant of p-CD-FLN Complex/es 
The stoichiometry and the association constant {Kg) of the P-CD-FLN complex/es was 
established with the help of the Scott's modification^^^ of Benesi-Hildebrand 
282 
equation. In Scott's equation. 
[FLN]t/A5obs = [FLN],/A5c + l/Ka^h 
[FLN]t is the molar concentration of the guest, A6obs the observed chemical shift 
change for a given [FLN]t concentration, A5c the chemical shift change between a 
pure sample of complex/es and the free component at the saturation. The plot of 
chemical shift changes (A5) for the P-CD cavity protons (H-3' and H-5') against 
[FLN] in the form of [FLN]/A5obs versus [FLN] gave excellent linear fits (Fig. 86) 
confirming 1:1 stoichiometry for the P-CD-FLN complex/es. The slope of the plot is 
thus equal to 1/A5c and the intercept with the vertical axis to l/Ka^bc, allowing the 
estimation of Ka to be 157 M'' which is the average of two Ks. 
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Fig. 86. Scott's plot showing 1:1 stoichiometry for the P-CD-FLN complex/es. 
ROESY Spectrum of p-CD-FLN Mixture 
To clearly establish which of the aromatic rings were involved in complexation 
between p-CD and FLN, a 2D ROESY spectrum of mixture of (3-CD and FLN was 
obtained under spin lock condition. The spectrum exhibited strong cross correlation 
peak between the cavity protons of P-CD and protons of the F-substituted aromatic 
ring of FLN, confirming the penetration of F-substituted aromatic rings into the P-CD 
cavity. The cross peaks between phenyl ring protons and P-CD cavity protons were 
also observed but these were relatively very weak. It was obvious for the ROESY 
spectrum that H-2 exhibited cross peak with only H-5' while H-1 displayed cross 
peaks with both the H-3' and H-5' protons, through the quality of ROESY spectrum is 
not as good as it should have been. Expansions of the parts of the 2D ROESY 
spectrum, showing cross peaks between protons of aromatic rings of FLN and P-CD 
cavity protons, are shown in Fig. 87. 
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H-1 H-2 H-7 
H-8 H-10 H-9,11 
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Fig. 87. Partial ROESY (500 MHz) spectra of mixture of p-CD 
and FLN showing interactions between FLN and p-CD 
protons (mixing time=500 ms). cavity 
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Structure of the p-CD-FLN Complexes 
On the basis of 1:1 stoichiometry of the P-CD-FLN complexation and 2D ROESY 
spectral data, it can be argued that F-containing aromatic ring preferentially enters the 
P-CD cavity to form the inclusion complexes. Also, the non-observance of cross peak 
between H-3' and H-2 suggested that penetration takes place from narrower rim side. 
The penetration from wider rim side would have brought H-2 closer to H-3' also. It 
seems that complexation also takes place between phenyl ring and P-CD but the 
concentration was very small compared to complexes formed involving F-containing 
aromatic ring. The plausible structure of the P-CD-FLN inclusion complexes are 
shown in Fig. 88. 
Fig. 88. Plausible structures of two 1:1 P-CD-FLN complexes. 
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6.3 CONCLUSION 
The ' H N M R spectral data of pure FLN, pure P-CD and mixtures of p-CD and FLN in 
D2O confirmed the complexation between the P-CD and FLN. The stoichiometry and 
the association constant were determined with the help of the ' H NMR titration 
studies. The 2D ROESY spectral data confirmed that F-substituted aromatic ring acts 
as a guest and it penetrates into the P-CD cavity from the narrower rim side. The 
splitting of the most of the signals of the FLN, in the presence of P-CD, suggests the 
chiral differentiation of guest FLN by P-CD. 
CHAPTER-VII 
NMR Spectroscopic Study of Complexation of 
P-Cyclodextrin and Midazolam Hydrochloride 
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Midazolam hydrochloride (MDL), CsHnClFNa-HCl, FW 362.23, 
chemically known as 8-Chloro-6-(2-fluorophenyl)-l-methyl-4H-imidazo[l,5a][l,4]-
benzodiazepine hydrochloride, is a pre-operative anaesthetic which belongs to the 
class of imidazobenzodiazepine compounds which are useful as antivonvulsants, 
anxiolytic, amnestic, hypnotic, skeletal muscle relaxant and sedatives. It is 
commonly used as probe substrate to evaluate cytochrome P450 function in 
humans.^°^ MDL is a short-acting benzodiazepine central nervous system depressant. 
The intrathecal administration of MDL has been reported to have antinociceptive 
action and to be an effective analgesic agent in animals and humans.^ "^  
MDL is a white to light yellow crystalline compound, insoluble in water. At 
25 °C and at apU of 3.4, 10.3 mg of MDL is soluble in 1 mL of water. 
.HCl 
Midazolam hydrochloride 
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7.1 EXPERIMENTAL 
Midazolam hydrochloride (MDL) was kindly gifted by Morepen Laboratories Ltd, 
India, while p-cyclodextrin (P-CD) was obtained from Geertrui Haest, Cerestar 
Application Centre, Food & Pharma Specialities, France, and these were used without 
further purification. All the ' H N M R and 2D COSY spectra (Fig. 89-98) were 
recorded on a Bruker-500 MHz instrument while 2D ROESY spectrum (Fig. 99) was 
recorded on Inova-500 MHz instrument in D2O at room temperature. Chemical shift 
values, reported in 6 (ppm), were calculated with reference to HDO signal at 4.700 
ppm. ' H NMR spectra of seven samples of mixture of P-CD and MDL with 
P-CD/MDL molar ratios ranging from 0.1-1.6 were recorded. The concentration of 
MDL was kept constant at 1.1x10 M while the concentration of P-CD was varied. 
Distinct peaks for complexed and uncomplexed form of MDL were not observed 
indicating that MDL is undergoing rapid exchange between free and bind state on the 
NMR time scale. Chemical shifts changes (A5) were calculated according to the 
formula: 
Ao = 6(comple\) - 5(frce) 
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7.2 RESULTS A N D DISCUSSION 
' H N M R Chemical Shift Change Data of p-CD 
The resonance assignment of P-CD proton was made with the help of COSY spectral 
data. All the ' H NMR spectra of mixtures of P-CD and MDL displayed significant 
upfield shifts in the signals of H-3' and H-5' located inside the p-CD cavity, while 
other p-CD protons, located outside the cavity (H-l', 2', 4', 6') showed insignificant 
shift changes in the presence of MDL. Moreover, the chemical shift changes (A8) for 
H-5' were more pronounced compared to H-3'. Expansion of part of the COSY 
spectrum showing p-CD region is shown in Fig. 100 while Fig. 101 displays the 
expansions of the part of the ' H NMR spectra showing p-CD protons signals, in the 
presence as well as in the absence of MDL. 
H-3',6' 
H-5' 
5.0 4.5 4.0 3.5 3.0 
Fig. 100. Part of the COSY spectrum (500 MHz) 
of a mixture of P-CD and MDL showing the 
interaction of P-CD protons. 
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H-?',6' 
ri H-2' H-4' 
H-5' 
n 
h 
PVA] P-CD/MDL 
3.9 3 8 3. 3,6 3.5 3 4 
Fig. 101. Partial 'H NMR (500 MHz) spectra showing signals 
for the protons of P-CD, in the absence as well as in the 
presence of MDL. 
The upfield shift of p-CD cavity protons and concomitant shift changes in the 
signals for MDL protons in the mixtures of P-CD and MDL can only be attributed to 
the ring current effect of aromatic ring penetrating the P-CD cavity, thus, confirming 
the formation of P-CD-MDL inclusion complex/es in analogy to previous 
studies.2^ «-^ °^ 
' H NMR Spectral Assignment and Chemical Shift Change Data of 
MDL 
To establish the structure of the complex/es, an unambiguous resonance assignment of 
MDL protons was required. The assignment of resonances of guest protons was made 
with the help of 2D COSY spectral data, performed on a mixture of p-CD and MDL, 
because some of the signals which appeared completely merged in the spectrum of 
pure MDL (H-5, 7) separated in the presence of P-CD helping in assignment. The 
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aromatic region of the 2D COSY spectrum of p-CD-MDL mixture showing cross 
connection peaks is given in Fig. 102. 
H-10 H-2. 
Fig. 102. Part of the COSY spectrum (500 MHz) of a mixture of P-CD and 
MDL showing the interaction of aromatic protons. 
MDL has a methyl group (H-1) that corresponds to a singlet at 2.704 
(§ Fig. 89). Two methylenic protons (H-3) of the benzodiazepine ring were observed 
as two interacting doublets at 4.1595 and 5.0305 showing large geminal couplings 
(y=13.5 Hz). The most downfield doublet at 7.7703 {J=9.25 Hz) was assigned to the 
H-9 proton and it exhibited cross connection peak with the doublet at 
7.668 (y=9.0 Hz), ascribed to H-10 proton. The signal at 7.3425 was, therefore, easily 
assigned to H-8 because it also showed interaction with H-9. The protons of the 
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fluorine containing ring appeared separately and were characterized by their 
interactions. Two triplets observed at 7.0187 and 7.2235 could arise due to H-4 and 
H-6 protons. The remaining two protons were observed merged at 7.5365 and could 
be ascribed to H-5, 7 protons only. The singlet at 7.4257 (J=7.5 Hz) was assigned to 
H-2 as it does not show cross correlation peak with any other signals. The chemical 
shift change (A5) data for the aromatic protons of MDL in the presence of P-CD is 
given in Table 14. 
Table 14. 'H N M R (500 MHz) chemical shift change (A5) data of aromatic protons of 
MDL, in the presence of p-CD. 
P-CD/MDL 
0.1 
0.2 
0.4 
0.7 
0.8 
1.3 
1.6 
H-9 
0.0105 
0.0182 
0.0284 
0.0378 
0.0401 
0.0474 
0.0503 
H-10 
0.0127 
0.0211 
0.0316 
0.0400 
0.0420 
0.0485 
0.0510 
H-7 
0.0248 
0.0259 
0.0828 
0.0858 
0.0893 
0.1463 
0.1472 
H-5 
0.0248 
0.0259 
0.0028 
0.0128 
0.0218 
0.0318 
0.0340 
H-2 
0.0100 
0.0163 
0.0251 
0.0301 
0.0316 
0.0352 
0.0382 
H-8 
-0.0537 
-0.0577 
-0.0997 
-0.1022 
-0.1032 
-0.1516 
-0.1717 
H-6 
0.0063 
0.0105 
0.0161 
0.0207 
0.0218 
0.0249 
0.0261 
H-4 
-0.0148 
-0.0262 
-0.0431 
-0.0592 
-0.0629 
-0.0767 
-0.0827 
Negative values indicate upfield shift changes 
In the presence of P-CD, the signals for H-9 and H-10 of the chlorine 
containing aromatic ring did not show any significant shifts while H-8 exhibited 
significant highfield shift. The fluorine containing aromatic ring protons, H-5, 7, 
exhibited downfield shifts in the presence of P-CD and the H-4 showed highfield shift 
while H-6 did not exhibit any significant change. Moreover, signals for H-2, H-6, H-
8 showed splitting also, in the presence of p-CD, indicating chiral differentiation of 
MDL by p-CD.'^'^ The chemical shift change for H-7 was most prominent among all 
the aromatic proton signals. It is difficult to draw any conclusion about the 
involvement of aromatic ring/s in the complexation because all the protons of the 
guest, and not only the part included in the p-CD cavity, are affected by the 
complex/es formation. It was established with the help of ROESY spectral data that 
only fluorine containing ring was penetrating the p-CD cavity. Fig. 103 shows the 
expansions of aromatic regions of the spectra of pure MDL and MDL in the presence 
of varying amount of P-CD. 
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H-8 H-2 
H-6 H-4 
H-5,7 H-2 j^_g 
MDL 
p-CD/MDL=0.1 
H-5,7 H-2 H-8 
A ^AA^ 
P-CD/MDL=0.2 
p-CD/MDL=0.4 
7.9 7.7 7.5 7.3 7.1 6.9 
ppm 
Fig. 103. A part of ' H N M R spectra (500 MHz) showing aromatic region of 
MDL in the absence, as well as in the presence, of varying amounts of P-CD. 
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Stoichiometry and Association Constant of p-CD-MDL Complex/es 
The stoichiometry and the association constant (Ka) of the P-CD-MDL complex/es 
287 
were also determined by using Scott's method. In the Scott's equation 
[CD],/A6obs = [CD],/A5c + \/KaA5o 
[CD]t is the molar concentration of the CD, A6obs is the observed chemical shift 
difference for a given [CD]( concentration, A5c is the chemical shift difference 
between a pure sample of complex/es and the free component at the saturation. The 
plot of chemical shift change (A5) for H-4 of the MDL against [p-CD] in the form of 
[P-CD]/A8 versus [P-CD] gave excellent linear fit (Fig. 104) confirming 1:1 
stoichiometry for the P-CD-MDL complex/es. The slope of the plot thus equals to 
1/A5c and the intercept with the vertical axis to l/Ka^^c, allowing the estimation of Ka 
to be 108 M"'. 
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Fig. 104. Scott's plot showing 1:1 stoichiometry of the p-CD-MDL complex/es. 
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ROESY Spectrum of P-CD-MDL Mixture 
2D ROESY spectrum was recorded on a P-CD-MDL mixture under spin lock 
conditions to clearly establish the structure of the inclusion complex/es. The spectrum 
exhibited strong cross correlation peaks between cavity protons (namely H-3' and 
H-5') of P-CD with protons of F-substituted aromatic ring (H-4, H-6 and H-5, 7) of 
MDL. The signals for the chlorine containing aromatic ring did not show any cross 
peaks with P-CD cavity protons confirming, beyond doubt, the penetration of only 
F-substituted aromatic ring into the p-CD cavity. Expansions of the part of the 
ROESY spectrum of P-CD-MDL mixture showing aromatic region is given in 
Fig. 105. 
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Fig. 105. Expanded region of 2D ROESY spectrum 
(500 MHz) of P-CD-MDL mixture showing cross 
peaks of aromatic ring protons with P-CD cavity 
protons (mixing time=500 ms). 
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Structure of the p-CD-MDL Complex 
Taking into account the 1:1 stoichiometry of the P-CD-MDL complexation and 2D 
ROESY spectral data, it can be concluded that only fluorine containing ring is 
penetrating the p-CD cavity resulting in the formation of the complex. It can be 
argued that protons H-4 and H-6 have identical orientations in the cavity because of 
their identical nature of the cross connection peaks with the P-CD cavity protons. Two 
probable structures can be considered, one formed by the penetration of the aromatic 
ring from wider rim side while the other from the narrower rim side. The penetration 
of the ring from the wider rim side was ruled out because the cross peaks with H-5' 
were stronger compared to those with H-3' indicating close proximities of H-4 and 
H-6 with H-5' compared to H-3'. The structure of the P-CD-MDL inclusion 
complexes was therefore, characterized as shown in mode I (Fig. 106). 
HCl 
HCl 
Midazolam hydrochloride 
Mode II 
Fig. 106. Plausible modes of 1:1 p-CD-MDL inclusion complexes. 
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7.3 CONCLUSION 
The ' H N M R spectroscopic studies of pure MDL, pure P-CD and mixtures of (3-CD 
and MDL in D2O confirmed the formation of a 1:1 P-CD-MDL inclusion complexes 
by the penetration of fluorine containing aromatic ring into the P-CD cavity from the 
narrower rim side. The stoichiometry and association constant were determined using 
Scott's method by the treatment of ' H NMR titration data. The splitting of most of the 
signal of MDL in the presence of P-CD suggests some chiral differentiation of MDL 
by P-CD. 
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Abstracts 
'H NMR spectroscopic study of fluvastatin sodium (FLU), ^-Cyclodextrin (/?-CD) and their mixtures confirmed the 
formation of FLU//3-CD inclusion complex in solution. The stoichiometry of the complex was determined to be 1:1 
and the overall binding constant (Z^ ,) was calculated to be 340 M"'. Two dimensional COSY, ROESY and DEPTO 
experiments were performed for the unambiguous assignment of aromatic proton resonances and it was found that 
two isomeric forms of FLU are present in solution. It was confirmed with the help of ROESY spectral data that 
only F-substituted aromatic ring penetrates the /S-CD cavity and there is chiral differentiation by the ^-CD as one of 
the isomer binds more strongly, which is indicated by the intensity of correlation peaks. The mode of penetration of 
the guest into the /?-CD cavity was also established and structure of the complex has been proposed. 
Introduction 
Fluvastatin sodium (FLU) helps in preventing heart 
disease, angina, stroke and heart attacks by reducing the 
cholesterol and certain other fatty substances in the 
blood [1,2]. It is a competitive inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase and 
lowers the overall blood cholesterol as well as blood 
LDL (bad) cholesterol levels, which is responsible for 
coronary artery diseases. FLU is light sensitive and its 
solubility in water is 1,91 mg/ml. 
Complexation of pharmaceutical compounds with 
cyclodextrins (CDs) leads to altered physicochemical 
properties of the guest. Inclusion complexes of phar-
maceutical compounds with CDs, therefore, have been 
extensively studied and utilized to improve the solubility 
[3], dissolution rate [4] and bioavailability of poorly 
water-soluble drugs [5] and other desirable properties [6]. 
CDs are cyclic oligomers of a-D-glucose linked 
through glycosidic a-l,4-bonds resulting in the forma-
tion of doughnut shaped molecules having one rim 
(narrow) lined with n primary hydroxyl groups while 
the other rim (wider) lined with In secondary hydr-
oxyl groups. The H-3', H-5' and glycosidic oxygen are 
located inside the cavity which is relatively hydrophobic. 
The CDs, therefore, act as hosts for a variety of non-
polar molecules [7-9]. 
* Author for correspondence. E-mail: smashhoodali(aJyahoo.com 
NMR spectroscopy is an important tool to study CD 
inclusion complexes [10]. ' H NMR spectra of mixtures 
of CD and guest molecule are recorded and changes in 
the chemical shifts (A )^ of both the host as well as guest 
are studied. The formation of the inclusion complex is 
indicated by highfield shift changes in the CD protons 
situated inside the cavity, namely H-3' and H-5' and 
downfield shift changes in the guest protons. The 
chemical shift change data can be used for the deter-
mination of stoichiometry, binding constant and mode 
of penetration of the guest into the CD cavity. ROESY 
[11] spectroscopy is particularly useful in the study of 
inclusion complexes. NOE correlation peaks observed 
between the protons of the included part of the guest 
and )5I-CD cavity protons give direct evidence for the 
formation of inclusion complex and provide very useful 
information regarding the structure of the complex. 
We are interested in the study of the inclusion com-
plexes of pharmaceutical compounds with J?-CD in 
solution [12, 13] and report herein our results on the 
detailed NMR spectroscopic study of y9-CD-fluvastatin 
sodium complexation. 
Results and discussion 
All the ' H NMR spectra were recorded on a Varian 
Mercury Plus-300 instrument while COSY, DEPTO 
and ROESY experiments were performed on a JEOL 
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a-400 MHz instrument in DiO at room temperature and 
the chemical shift values (3) are reported in ppm. No 
external indicator was used and HDO signal at 4.800 
was used as internal reference throughout this work. H 
NMR spectra for five samples of FLU and j8-CD with 
;3-CD/FLU molar ratios ranging from 0.2 to 1.1 were 
recorded. The concentration of the FLU was kept con-
stant at 1.6 X 10"^  M while that of jS-CD was varied. 
Distinct peaks for bound and free form of the FLU were 
not observed indicating the rapid exchange of FLU 
between free and bind state on the NMR time scale. 
. ' H NMR spectra of mixtures of FLU and /?-CD 
displayed highfield shift changes in the H-3' and H-5' of 
the ^-CD, located inside the cavity, while insignificant 
shift changes were observed for other ^-CD protons. 
Expansions of part of the spectra showing /?-CD pro-
tons, in the presence as well as in the absence of FLU, 
are shown in Figure 1. These high field shift changes in 
the /3-CD cavity protons can only be explained in term 
of ring current effect of aromatic ring penetrating 
the ^-CD cavity and thus confirm the formation of 
FLU/^-CD complex, in analogy to previous studies [10, 
14]. This is also supported by concomitant downfield 
shift changes in the aromatic protons of the FLU in the 
FLU/^-CD mixtures compared to pure FLU [14]. 
To clearly establish whether both or either of the two 
rings is involved in complexation, an unambiguous 
resonance assignment of FLU protons was required. A 
cursory examination of the aromatic region of the FLU 
spectra, in the presence as well as in the absence of 
CE)/F1,U=0.2 i j p-CD/ L 
p p m 
P-CD, points to the presence of two isomeric forms of 
FLU. The COSY, ROESY and DEPTO experiments 
were performed on a mixture of FLU/)5-CD, which 
proved very helpful in resonance assignment of the two 
isomers. Only the signals for the F-substituted aromatic 
ring appeared separately for the two isomers. The dou-
blet at 7.5634 (7 = 6.88 Hz) was assigned to the H-1 of 
one of the isomers. This signal showed cross peak, in the 
COSY spectrum, with the multiplet at 7.1048 suggesting 
that H-2 of one isomer is merged with H-3, 5 signal. 
It was confirmed by the DEPTO experiments that 
signals for the protons of the two aromatic rings are 
merged in the multiplet at 7.1048. The doublet at 7.3876 
(7=6.88 Hz) and triplet at 6.9742 (7=6.88 Hz) were 
assignable to H-1 and H-2, respectively, of the other 
isomer. The cross peaks between signals at 6.9742 and 
7.1048, observed in COSY spectrum, may arise due to 
the interaction between H-2 and H-3. Expansions of the 
COSY (Figure 2) and DEPTO (Figure 3) spectra of a 
FLU//S-CD mixture, showing aromatic regions, support 
H-1 
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Figure 2. Part of the COSY spectrum (400 MHz) of a mixture of FLU 
and ^-CD showing interaction of aromatic protons. 
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Figure 4 Partial 'H N M R (300 MHz) spectra showing downfield shift 
of aromatic protons in the presence of ^-CD. 
the assignment of FLU aromatic proton resonances 
beyond doubt. 
In the presence of /S-CD, all the aromatic protons 
significantly shifted downfield but the shift for the sig-
nals of the F-substituted aromatic ring was more pro-
nounced (Figure 4). These observations clearly indicate 
that atleast F-substituted aromatic ring is inserted into 
the ^-CD cavity but whether other ring is also involved 
in complexation is not clear because, generally, all the 
protons of the guest, and not only the part that enters 
H-4.e lH-2.3.5 
H-1 H-1 . II ,H-2 H-7 
IJ %4 >> ».« *'« *•* 
O 
Figure 6. Expanded region of ROESY spectrum of ^-CD/FLU mix-
ture showing cross peaks of F-substituted aromatic nng protons with 
j?-CD cavity protons 
the ^-CD cavity, show downfield shift changes upon 
complexation with CDs [15]. 
The stoichiometry of the complex was determined 
using Scott's modification [16] of Benesi-Hildebrand 
equation. In Scott's equation 
[CD],/A,5obs = [CD],/AS, + \/K,AS, 
[CD], is the molar concentration of the CDs, A o^bs is the 
observed chemical shift difference for a given [CD], 
concentration, A c^ is the chemical shift difference be-
tween a pure sample of complex and the free component 
at the saturation. The plot of chemical shift changes (A )^ 
for the FLU protons against [jS-CD] in the form of 
[P-CD]IAd versus [jS-CD] gave excellent linear fit 
(Figure 5) confirmimg 1:1 stoichiometry for the com-
plex. The slope of the plot of [CD] is thus equal to l/AS, 
and the intercept with the vertical axis to l/K^AS,, 
allowing the estimation ofK^. The binding constant (K^) 
was determined to be 340 M' ' . 
In order to clearly establish the structure of the 
complex, ROESY experiment was performed on a 
ONa 
[P -CD]X10 ' 'M 
Figure 5 Scott's plot showing 1 1 stoichiometry of the ^-CD/FLU 
complex Figure 7 Plausible structure of the 1 1 /?-CD/Fluvastatin sodium complex 
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FLU/^-CD mixture under spin lock conditions The 
result is displayed in Figure 6, a set of cross peaks 
connects H-3' and H-5' resonances of ^-CD to the 
signals for the F-substituted aromatic ring The signals 
for the other aromatic ring did not show any cross peaks 
with P-CD cavity protons confirming beyond doubt the 
penetration of only F-substituted aromatic ring into the 
/?-CD cavity The intensity of the cross peaks for the two 
isomers was not identical suggesting chiral differentia-
tion by the ^-CD cavity [17] Moreover, the H-l of the 
F-substituted aromatic ring also showed cross connec-
tion peaks with H-2' and 4' protons, which are situated 
near the wider rim This implies that aromatic ring 
penetrates deep from the narrower rim side [18] and H-l 
IS located near wider rim in the complex The plausi-
ble structure for the FLU//?-CD complex is shown in 
Figure 7 
In conclusion, the detailed NMR spectroscopic study 
of FLU in solution in the presence of /3-CD confirmed 
the formation of 1 1 inclusion complex resulting by the 
penetration of the F-substituted aromatic ring into the 
P-CD cavity from narrower rim side FLU is a mixture 
of two isomers and /?-CD seems to play a role in their 
chiral difierentiation by favourably binding to one of the 
isomers The structure for the )?-CD-fluvastatin sodium 
complex has been proposed 
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Abstract Desloratadine (DES) is an antihistamine used 
in the treatment of allergies and chronic urticaria. 'H NMR 
spectroscopic study of varying ratios of DES and 
/J-Cyclodextrin (/?-CD) in D2O suggests the formation of a 
1:1 inclusion complex formed by the penetration of 
Cl-substituted aromatic ring into the /?-CD cavity. The 
stoichiometry and binding constant of the complex were 
determined by Scott's method. 
Keywords Desloratadine • /?-Cyclodextrin • Inclusion 
complex • NMR spectroscopy • ROESY • COSY 
Introduction 
Desloratadine (DES), 8-chIoro-ll-(piperidin-4-ylidene)-6, 
n-dihydro-5//-benzo[4,5]cyclohepta[2,l-fc]pyridine, a new 
nonsedating HI-antihistamine, is efficacious and safe in the 
treatment of perennial allergic rhinitis [1] and chronic 
idiopathic urticaria [2]. It inhibits important cytokin and 
cellular activity, suggesting an antiallergic and anti-
inflammatory profile [3]. DES is a chiral, light sensitive 
drug whose solubility in water is 0.01 mg/mL. 
We are interested in the study of complexation of 
pharmaceutical compounds with j3-cyclodextrin (^-CD) 
because inclusion of the guest or part of it into the CD 
cavity leads to altered physicochemical properties of the 
guest. The host-guest complexes of pharmaceutical com-
pounds with CDs have, therefore, been extensively studied 
and utilized to improve their solubility [4], dissolution rate 
S. M. Ali (El) • S. K. Upadhyay • A. Maheshwari 
Department of Chemistry, Aligarh Muslim University, Aligarh 
202002 UP, India 
e-mail: smashhoodali@yahoo.com 
[5] and bioavailability of poorly water-soluble drugs [6]. 
Other applications of CD complexes with pharmaceuticals 
[7] include elimination of undesirable drug properties, such 
as irritation and unpleasant odor or taste and improved 
stability of light and oxygen sensitive drugs. 
CDs are doughnut-shaped cyclic oligosaccharides com-
posed of six (a), seven (fi), and eight (7) glucopyranose 
units linked by a-(l,4) linkages. The exterior of the CDs is 
highly hydrophilic due to the presence of numerous hy-
droxyl groups while the interior of the CDs cavity is 
hydrophobic and, thus, interacts with a variety of hydro-
phobic compounds to form inclusion complexes [8,9]. The 
size and shape of the torus shaped hydrophobic cavity in 
combination with the size, polarity and polarizability of the 
guest are major determinants for the formation of inclusion 
complexes. 
Various techniques are used to study the CD inclusion 
complexes but NMR spectroscopy has been found to be an 
important tool in this type of studies [10]. ' H NMR spectra 
of mixture of CD and guest molecules are recorded and 
chemical shift changes (Ad) for both host as well as guest 
protons are studied. Inclusion of a molecule inside the CD 
cavity is characterized by the shift variation of the CD 
protons located inside the cavity (H-3' and H-5'), while 
other CD protons (H-2', H-4' and H-6') are less affected. 
The highfield shift changes in the CD cavity protons are 
attributed to the anisotropic ring current effect of the aro-
matic guest. Beside the determination of stoichiometry and 
binding constant of the complex, inferences like mode of 
penetration of the guest, stability of the complexes and 
depth of penetration may be drawn from simple 'H NMR 
complexation induced shift data. 
ROESY spectroscopy has been found very useful for the 
investigation of the interactions between CDs and guest 
molecule [10, 11] since cross peaks are observed in 
^ Springer 
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ROESY spectrum between the protons that are closer than 
0.4 nm in space. The relative intensities of cross peaks 
depend on the spaces between the corresponding protons. 
NOE cross correlation peaks between the guest and ^-CD 
cavity protons (H-3' and H-5') are observed when the guest 
molecule is included into the ^-CD cavity. The data proves 
very helpful in determining the mode and depth of pene-
tration of the guest, and thus establishing the structure of 
the complex. 
We are interested in the study of complexation of 
pharmaceutical compounds with CDs and report herein our 
results on the detailed 'H NMR spectroscopic study of the 
complexation between desloratadine (DES) and ^-cyclo-
dextrin (/3-CD) in aqueous solution. 
4 3 
Desloratadine 
DES/p-CD inclusion complex in analogy to previous 
studies [10, 12]. Other /?-CD protons also displayed shift 
changes but these were not significant. Expansions of part 
of the spectra showing signals for ^-CD protons, in the 
presence as well as absence of DES, are shown in Fig. 1. 
To establish which of the two rings was involved in the 
complexation, an unambiguous resonance assignment of 
guest protons (DES) in the free as well as complexed state 
was required which was made with the help of 2D COSY 
spectral data (Fig. 2). As expected, the signals for pyridine 
ring protons appeared downfield compared to chlorophenyl 
H-6' H-3',4' 
39 
I I I 1 ppm~ 
38 37 36 35 
Fig. 1 Pan of 500 MHz 'H NMR spectra showing ^-CD protons in 
presence as well as in absence of DES 
Results and discussion 
All the 'H NMR spectra were acquired on a JEOL 
a-500 MHz instruments at room temperature in D2O. The 
chemical shift values are reported in S (ppm) relative to the 
HDO peak at 4.800 ppm. 'H NMR spectra for seven 
samples of mixtures of DES and ^-CD with /J-CD/DES 
molar ratios ranging from 0.15 M-1.70 M were recorded. 
The concentration of the DES was kept constant at 
1.03 X 10~- M while that of /?-CD was varied. All the re-
corded spectra contained one set of resonances suggesting 
a fast reversible exchange between free and the complexed 
drug, on the NMR time scale. 
A detailed inspection of the /?-CD proton signals in the 
'H NMR spectra of mixture of DES and ^-CD displayed 
upfield shift changes in the H-3' and H-5' proton 
resonances of /S-CD compared to pure /?-CD. The upfield 
shift of ^-CD cavity proton signals can be explained in 
terms of ring current effect of aromatic ring penetrating the 
P-CD cavity, and therefore, confirming the formation of 
H-^  H--
I I 
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s' 0 - 0 
Fig. 2 Part of the COSY spectnim (500 MHz) of a mixture of DES 
and ^-CD showing the interaction of aromatic protons 
^ Springe 
J Incl Phenom Macrocycl Chem (2007) 59:351-355 353 
Table 1 'H N M R chemical 
shift change {AS) data of 
aromatic protons of DES, in the 
presence of ^-CD 
Negative values indicate upfield 
shift changes 
/(-CD/DES 
0.15 
0.31 
0.44 
0.65 
1.06 
1.40 
1.70 
H-5 
0.0100 
0.0108 
0.0155 
0.0236 
0.0332 
0.0366 
0.0377 
H-7 
-0.0094 
-0.0164 
-0.0235 
-0.0240 
-0.0407 
-0.0568 
-0.0580 
H-6 
-0.0260 
-0.0337 
-0.0377 
-0.0394 
-0.0499 
-0.0540 
-0.0588 
H-10 
0.0367 
0.0538 
0.0653 
0.0867 
0.1047 
0.1138 
0.1203 
H-9 
0.0271 
0.0293 
0.0341 
0.0354 
0.0467 
0.0532 
0.0540 
H-8 
OOlOl 
0.0246 
0,0376 
0.0404 
0.0467 
0.0524 
0.0546 
Fig. 3 A pan of 'H NMR 
spectrum (500 MHz) showing 
aromatic protons of 
desloratadine (DES) in the 
absence as well as in the 
presence of varying amount of 
/i-CD 
J H. DES A i fl -_IL. 
I m _^r""'!_.Ji )l_ JlL_JL 
H |l^y_ f>-CIWES-0.44 jjVy 
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«V, K'« .'4 »', «': n'l K'O 7', 7:» 7'7 7.'* 7'.. T'J 7.3 T'J ^'l""^ 
ring. The signal in the lowest field appearing at 8.5334 was 
assigned to H-5 and it showed interaction with H-6 
(7.8009) signal in the COSY spectrum. The doublet at 
8.2704 was assigned to H-7 as it displayed cross peak with 
H-6. The signal at 7.3250 was easily attributed to H-9 
because it showed interaction with two other signals (H-8 
and H-10). The signal at 7.1821 was assigned to H-8 
because it exhibited coupling with H-9. 
4U 
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Fig. 4 Scott's plot showing 1:1 stoichiometry of the /^-CD/DES 
complex 
In the presence of /?-CD, all the aromatic signals of DES 
exhibited induced shift changes and splitting. The chemical 
shift change (A^) data for the aromatic protons of DES in 
presence of ^-CD is given in Table 1, while Fig. 3 shows 
aromatic region of spectra of DES, pure and in the presence 
H-5 H-" H-6 H-10 H-9 H-S 
I \ \ \ \ / 
I I I I ''' I I I I I 1 I I 1 
S 6 S -1 " 8 " 6 " 4 " : " 0 
Fig. 5 Expanded region of ROESY spectrum of /i-CD/DES mixture 
showing cross peaks of aromatic ring protons with )?-CD cavity 
protons 
^ S p : rmger 
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Fig. 6 Proposed model for 
DES/i3-CD inclusion complex 
of varying amount of ^-CD. It was established with the 
help of ROESY data that only chlorophenyl ring was in-
volved in complexation. 
The stoichiometry of DES/)S-CD complex was deter-
mined by using Scott's modification [13] of Benesi-Hil-
debrand equation. In Scott's equation, 
(CD],/A^obs = [CD],/A.5c + l/KaA^c 
[CD], is the molar concentration of the CD, A5obs is 
the observed chemical shift difference for a given [CD], 
concentration, A^^  is the chemical shift difference be-
tween a pure sample of complex and the free component 
at the saturation. The plot of chemical shift changes (A6) 
for the DBS protons against [p-CD] in the form of 
[)S-CD]/A5 versus [/?-CD] gave excellent linear fit con-
firming 1:1 stoichiometry for the DES/P-CD complex 
(Fig. 4). 
The slop of the plot is thus equal to l/A5^ and the 
intercept with the vertical axis to l/Ka^S^ allowing the 
estimation of binding constant (K^) to be 124 M"' 
ROESY spectrum of a DES//?-CD mixture under spin 
lock conditions exhibited cross peaks between chlorophe-
nyl ring and y?-CD cavity protons, confirming that only one 
aromatic ring was involved in the complexation and taking 
into account the stoichiometry, it becomes obvious that 
only one 1:1 inclusion complex was formed. Expansion of 
the part of the ROESY spectrum of DES//?-CD mixture 
showing aromatic region is given in Fig. 5. 
There are two probable structures that can be considered 
(Fig. 6) which involve the entry of the guest ring from 
wider rim side. The deep penetration of chlorophenyl from 
narrower rim side can be ruled out on steric grounds. Mode 
II was ruled out because it can not explain the interaction 
of H-8 with /?-CD cavity protons, especially H-5'. The 
mode I was therefore assigned to the complex formed 
between DES and ^-CD under the experimental conditions 
studied. 
Conclusion 
' H N M R spectroscopic studies of desloratadine (DES) in 
the presence of P-CD in D2O at room temperature con-
firmed the formation of a 1:1 DES//?-CD inclusion complex 
in which chlorophenyl ring acts as the guest. The binding 
constant (^„) for the DES//?-CD complex was determined 
to be 124 M-' 
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NMR spectroscopic study of inclusion 
complexes of cetirizine dihydrochloride 
and /3-cyclodextrin in solution 
Syed Mashhood Ali % Santosh Kumar Upadhyay and Arti Maheshwari 
Department of Chemistry, Aligarh Muslim University, Aligarh-202 002 (UP), India 
Abstract Cetirizine dihydrochloride (CTZ), an antihistamine, forms two I: I inclusion complexes with /3-cyclodextrin (P-Ct>) 
in aqueous solution as confirmed by detailed' H NMR, COSY and ROESY spectroscopic studies. The stoichiometry and overall 
binding constant of the complexes were determined by the treatment of' H NMR chemical shift change (A5) data. Most of the 
CTZ protons exhibited splitting in the presence of ^ -CD. 
Keywords: Cetirizine dihydrochloride, /3-cyclodextrin, inclusion complex, NMR spectroscopy, ROESY, COSY 
1. Introduction 
Cetiiizine dihydrochloride, (CTZ) is a second-generation, HI-receptor antagonist, antihistamine drug 
with the amine piperazine in its molecule [1]. It is used to treat the symptoms of allergies, chronic ur-
ticaria, hay fever, angioedema, hives and as a treatment adjunct in asthma [2]. Chemically it is described 
as (±)-[2-[4-[(4-chlorophenyl)phenyImethyl]-l-piperazinyl]ethoxy]acetic acid, dihydrochloride. It is a 
light sensitive drug and is used as a racemic mixture. 
The study of inclusion complexes with cyclodextrins (CDs), especially /9-CD, is a subject of great 
interest [3-5], because inclusion of the guest molecule, or part of it, included into /9-CD cavity leads to 
altered physiochemical properties of the guest. The inclusion complexes of pharmaceutical compounds 
with CDs, therefore, have been extensively studied and utilized to improve the solubility [6], dissolution 
rate [7] and bioavailability of pooriy water-soluble pharmaceuticals [8] and the stability of oxygen and 
light sensitive drugs [9]. 
CDs are toroidal or cone shaped molecules composed of six (a), seven (/?) and eight (7) 
D-glucopyranose units linked by a-(l, 4) linkages [3,10]. The H-3', H-5' and glucosidic oxygen are 
located inside the cavity which is relatively hydrophobic. The exterior of the CDs is fairiy hydrophilic 
due to presence of large number of hydroxyl group. CDs, therefore, can accommodate a variety of non-
polar molecules, or part of these, inside the cavity through non-covalent interactions, to form inclusion 
complexes [3,4,10]. 
There has been extensive work in the area of NMR analysis of CDs inclusion complexes and it is one of 
the most acceptable techniques for the study of inclusion complexes [11-13]. Evidence for the inclusion 
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of the guest into the host CD cavity is obtained by simple 'H NMR titration data. 'H NMR spectra of 
mixtures of CD and guest molecule are recorded and changes in the chemical shift (A )^ for protons of 
both the host as well as guest are studied. When a guest is accommodated within the CD cavity, there 
is an upfield NMR shift in /3-CD cavity protons while guest protons generally show downfield shift 
changes. These shift changes are attributed to the ring current effect of the aromatic guest. Information 
regarding the stoichiometry and association/dissociation constant of the complex can also be obtained 
by the treatment of simple 'H NMR titration data. 
2D ROESY [11-13] spectroscopy is a very useful technique for establishing the structures of CD 
inclusion complexes. NOEs cross correlation peaks between the guest and /3-CD cavity protons (H-3', 
H-5') are observed in the ROESY spectrum, when the guest molecule is included into the 0-CD cavity. 
According to the relative intensities of these cross peaks, it becomes possible to estimate the orientation 
of the guest molecule into the /3-CD cavity. This information proves very helpful in determining the 
mode as well as depth of penetration of the guest and thus establishing the structure of the complex. 
We are interested in the preparation and characterization of inclusion complexes of pharmaceutical 
compounds with /3-CD in solution [14]. In continuation of our work, we report herein our results on 
the detailed study of the complexation between cetirizine dihydrochloride (CTZ) and /3-CD in aqueous 
solution by NMR spectroscopic methods. 
2. Results and discussion 
All the 'H NMR spectra were recorded on a JEOL a-500 MHz in D2O at room temperature and their 
chemical shift values (<J) are reported in ppm. No external indicator was used and HDO signal at 4.800 
ppm was used as internal reference throughout this work. 'H NMR spectra of five samples of mixtures 
of CTZ and i3-CD with CTZ/jS-CD molar ratios ranging from 0.2 to 1.2 were recorded. The overall 
concentration of /3-CD was kept constant at 10 mM while that of CTZ was varied from 2.0 to 12.0 mM. 
Distinct peaks for bound and free form of the CTZ were not observed indicating that CTZ is undergoing 
rapid exchange between free and bind state on the NMR time scale. 
The signals for /3-CD protons, in spectra of mixtures, were identified with the help of 2D COSY 
spectrum. A cursory examination of the spectra of CTZ//3-CD mixtures indicated highfield shift changes 
in the /3-CD cavity protons while other /3-CD protons showed relatively negligible shift changes. 
The highfield shift of /3-CD cavity protons, in the presence of CTZ, can be explained in terms of 
ring current effect of aromatic ring penetrating the /3-CD cavity, thus confirming the formation of CTZ/ 
;3-CD inclusion complex, in analogy to previous studies [15,16]. Expansions of the part of the spectra 
containing /3-CD proton resonances, in the absence as well as in the presence of CTZ, are shown in 
Fig. 1 while their chemical shift change (A5) data is given in Table I. 
The stoichiometry and the association constant (Ka) [17] of the CTZ//3-CD complex/es were deter-
mined by Foster and Fyfe [18] method, an alternative solution of Benesi-Hildebrand equation [19]. In 
the Foster-Fyfe equation 
A(Jobs/[G], = -KaAddtys + KaAS,„,„ 
A<Jobs is the observed chemical shift change for a given [G], [G], is the molar concentration of the guest 
A(J,„ax the chemical shift change between a pure sample of the complex and the free component at the 
saturation. A plot of A5obs/[G], against AS^, (referred as an x-reciprocal plot) should be linear for 1:1 
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H-V H-V 
P-CD/CTZ 
4.0 3.9 3.8 3.7 3.6 3.5 
Fig. 1. Expansion of part of ' H NMR spectra (500 MHz) showing /?-CD protons in the presence as well as in the absence of 
CTZ. 
Table 1 
' H NMR chemical shift change (A<J, ppm) data for the /?-CD protons in presence of CTZ 
[CTZ]/l^-CD] 
0.2 
0.4 
0.6 
0.8 
1.2 
H-l' 
-0.071 
-0.073 
-0.079 
-0.086 
-0.098 
H-2' 
0.004 
0.022 
0.031 
0.030 
0.031 
H-3' 
-0.091 
-0.164 
-0.222 
-0.273 
-0.353 
H-4' 
-0.008 
-0.005 
-0.012 
-0.018 
-0.025 
H-5' 
-0.078 
-0.139 
-0.188 
-0.224 
-0.282 
H-6' 
-0.005 
0.003 
-0.002 
-0.008 
-0.018 
Negative values indicate upfield shift. 
complex. The negative gradient is equal to Ka. This modification requires an extrapolation to infinitely 
dilute solution and the Ka is not dependent on the extrapolation. The overall association constant {Ka) 
was determined to be 70 M"' which is the average of two Ks calculated from two plots (Fig. 2). 
An unambiguous resonance assignment of CTZ protons was required to ascertain whether both or one 
aromatic rings are involved in complexation. The assignment of resonances of guest protons was made 
with the help of COSY and ROESY spectral data of CTZ, in the presence of j3-CD because some of the 
signals which appeared completely merged in the spectrum of pure CTZ separated in the presence of 
/3-CD helping in assignment. 
The protons of the two aromatic rings appeared separately. The chlorophenyl ring protons were found 
resonating at a lower field compared to phenyl ring protons. The chlorophenyl ring protons were ob-
served as a pair of partly overlapped doublets. The highfield ortho-coupled doublet at 7.604 was assigned 
to 1,4-protons because they exhibited through space interaction with benzylic proton. The phenyl ring 
protons appeared as complex multiplet. totally integrating for five pix)tons. In the presence of/?-CD, the 
signals for both the aromatic ring protons exhibited splitting due to chiral recognition by /3-CD. The 
expansions of aromatic region of spectra of CTZ in the presence as well as absence of fl-CD are shown 
in Fig. 3. 
2D ROESY spectrum was obtained for a mixture of /3-CD and CTZ under spin lock conditions with 
a mixmg time of 0.5 s. The spectrum (Fig. 4) exhibited strong cross correlation peaks between H-3' 
and H-5 of /3-CD protons, located in the cavity, with the protons of both the aromatic rings of CTZ 
confirming the penetration of both the phenyl as well as chlorophenyl rings into the /3-CD cavity More-
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Fig. 2. Foster-Fyfe plot showing I; 1 stoicliiometry for the 0-CD/CTZ complexes. 
Ph-H 
H-2,3 
w-i,^ 11 
P-CD/CTZ 
H-2.3-pL, r--H-l,4 Ph-H 
7.7 7.6 7.5 7.4 
Fig. 3. Expansions of part of ' H NMR spectra (500 MHz) of CTZ protons in the presence as well as in the absence of jS-CD. 
over, strong cross peaks between H-4' of I3~CD with the protons of both the aromatic rings were also 
observed. This is a clear indication that both the aromatic rings entered the 0-CD cavity from wider rim 
side. Fig. 4 shows the part of the expansion of the 2D ROESY spectrum showing cross peaks between 
protons of aromatic rings and /?-CD. The proposed structures for the two inclusion complexes formed 
between P-CD and CTZ are shown in Fig. 5. 
In conclusion, 'H NMR titration studies of mixture of cetirizine dihydrochioride (CTZ) and 
/3-cyclodextrin (/3-CD) in DiO confirmed the presence of two 1:1 inclusion complexes formed by the 
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H-6' H-2' H-4' 
1—7.8 
-7.7 
1—7.6 
-7.5 
—7.4 
—7.3 
•7,2 
Fig. 4. Expansion of Part of 2D ROESY (500 MHz) spectrum (mixing time = 0.5 s) of mixture of /3-CD and cetirizine 
dihydrochloride. 
Fig. 5. Proposed structures of two 1:1 0-CD/CTZ inclusion complexes. 
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penetration of aromatic ring into the /3-CD cavity. The stoichiometry and the overall binding constant 
(Ka) have been determined. The structures of the complexes have been proposed which are well sup-
ported by the ROESY spectral data. 
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High Resolution NMR Spectroscopic Study of Complexation of 
Hydroxyzine Hydrochloride with p-Cyclodextrin in Aqueous Solution 
Syed Mashhood Ah,'* Arti Maheshwari,' Santosh Kumar Upadhyay' and Kye Chun Nam'' 
'Department of Chemistry Aligarh Muslim University Aligarh-202002 (UP) India 
^Department of Chemistry, Chonnam National University Gwangju 500-757 Korea 
Hydroxyzme hydrochloride forms two 1 1 inclusion complexes with p-cyclodextrin in aqueous solu-
tion as confirmed by the 'H NMR titration and ROESY studies One complex is formed by the deep pene-
tration of the chlorophenyl ring from the wider rim side, while the mode of entry of the phenyl ring into the 
P-CD cavity is not clear The stoichiometry and overall association constant of the complexes have been 
determined by the treatment of 'H NMR shift data Some chiral discrimination by the host between the two 
enantiomers of hydroxyzine hydrochloride is also indicated 
Keywords: Hydroxyzine hydrochloride, P-Cyclodextnn, 
plexes 
'H NMR, ROESY, Inclusion com-
INTRODUCTION 
Hydroxyzine hydrochloride, [2-(2-{4-[(RS)-(4-chlo-
rophenyl)phenylmethyl]piperazine-l-yl}ethoxy]ethanol 
dihydrochloride, a piperazine derivative, belongs to the an-
tihistamine family ' In addition to its antihistaminic effects, 
hydroxyzine possesses antichlolinergic, sedative, antispas-
modic, tranquiiizing, bronchodilative and antiemetic activ-
ities ^ 
The study of inclusion complexes of pharmaceuticals 
with cyclodextnns (CDs), especially P-CD, have attracted 
great interest because of their utility to improve the solubil-
ity, dissolution rate and bioavailability of poorly water sol-
uble drugs ' •* Other applications of CDs include elimina-
tion of undesired drug properties, such as irritation, un-
pleasant odour or taste and adverse drug ingredient interac-
tions ' ' They are also used as chiral selectors for enanti-
omeric separation by chromatographic techniques '* 
CDs are a family of cyclic oligosaccharides, the three 
most common a, P and y-CDs, consisting of 6, 7 and 8 D-
glucopyranosyl units, respectively, linked through a(l-4) 
glycosidic bonds They have toroidal shapes with all the 
secondary hydroxyl groups, 0(2')-H and 0(3')-H, located 
on the wider rim and all the primary hydroxyl groups, 
0(6')-H, on the narrow rim The glucose units are in the "Ci 
chair conformation" ' ' ° The hydrogen atoms (H-3' and 
H-5') and glycosidic oxygen atoms are located inside the 
cavity, which is relatively hydrophobic, while the exterior 
of the CDs IS fairly hydrophilic due to the presence of 
hydroxyl groups By virtue of their shape and the hydro-
phobic nature of their cavity, CDs accommodate a variety 
of molecules, or part of it, inside the cavity through non-
covalent interactions, to form inclusion complexes 
Various techniques are used to study inclusion com-
plexes of CDs but NMR spectroscopy has proved to be the 
most useful tool since it provides direct evidence for the 
formation of a complex Simple 'H NMR titration experi-
ments provide very useful information about the mode of 
complexation, stoichiometry and association or dissocia-
tion constants of the complex '^  The study of CD-complexes 
by 'H NMR was initiated by Demarco and Thakkar '•* They 
noticed the highfield shift changes m the P-CD cavity pro-
tons upon addition of a variety of compounds and inferred 
that inclusion of a guest into the P-CD cavity had taken 
place The use of H NMR spectroscopy has since then be-
come the most preferred technique to study CD complexes 
The mode and depth of penetration of the guest can only be 
determined with certainty by ROESY spectral data though 
the chemical shift changes in the cavity protons have also 
been used to predict the mode and depth of penetration of 
the guest into the cavity " NOE cross peaks between the 
protons of host and guest, which are closer than 0 4 nm in 
space, are observed in the ROESY spectrum which give 
valuable information about the geometry of the complex 
* Corresponding author E-mail smashhoodali@yahoo com 
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Table 1 ' H NMR chemical shift change (A8, ppm) for the p-cyclodextnn protons upon complexation 
A5(H-5'yA5 (H-3') Sample [H]/[G] H-l' H-2' H-3' H-4' H-5' H-6' 
A 
B 
C 
D 
E 
2 88 
2 50 
2 18 
156 
1 00 
00164 
0 0164 
00134 
0 0064 
0 0032 
0 0408 
0 0433 
0 0403 
0 0438 
0 0473 
-0 0945 
-0 1055 
-0 1065 
-0 1645 
-0 2135 
0 0211 
0 0161 
00131 
0 0071 
0 0021 
-0 0905 
-0 1012 
-0 1130 
-0 1467 
-0 1977 
-00J2I 
-0 0136 
-0 0196 
-0 0226 
-0 0266 
0 957 
0 959 
1 061 
0 892 
0 926 
Negative values indicate upfield shift 
We are interested in the study of inclusion complexes 
of pharmaceutical compounds with P - C D ' * '^  and report 
herein our results on the ' H NMR spectroscopic study of 
hydroxyzine hydrochloride in the presence as well as in the 
absence of p-CD m D2O at room temperature 
RESULTS AND DISCUSSION 
All the experiments were performed on a Vanan 300 
MHz Unity instrument at room temperature for pure hy-
droxyzine hydrochloride (guest), pure P-CD (host) and for 
their mixtures with host/guest ratios ranging from 1 00 to 
2 88 The concentration of the host was kept constant at 10 
mM while the concentration of the guest was varied The 
ROESY and COSY spectra of a mixture ([H]/[G] = 0 58) 
were recorded on a Bruker DRX 600 instrument All the 
spectra consist of only one set of concentration dependent 
resonances, for each proton or group of equivalent protons, 
indicating that the reversible exchange between free and 
complexed drug is rapid on the NMR time scale The water 
signal at 4 800 ppm was used as internal reference through-
out this work 
H NMR spectra of mixtures of hydroxyzine hydro-
chloride and P-CD in D2O exhibited large highfield shift 
changes for H-3' and H-5', located inside the cavity, smaller 
shift changes for H-6' and insignificant shift changes for 
H-2' and H-4' of P-CD (Table 1) The magnitude of A6H 3 
and ASH-S increased with increasing the amount of hy-
droxyzine hydrochloride The progressive upfield shift of 
H-3', H-5' and H-6' resonances of P-CD with increasing 
amounts of hydroxyzine hydrochloride is shown in Fig 1 
which shows the region of the spectra containing p-CD 
proton signals The assignment for P-CD signals was made 
with the help of COSY These results can be explained in 
terms of the ring current effect of the aromatic ring/s in-
cluded in the P-CD cavity'* thus confirming the formation 
of hydroxyzine-p-CD inclusion complex/es 
The stoichiometry and the dissociation constant (Kj) 
of the complex were determined on the basis of Scotts mod-
ification" of the Benesi-Hildebrand equation ^^  In Scotts 
equation, 
[G],/A6obs = [G],/A5c + KjA5c 
[G], is the molar concentration of the guest, ASobs is the ob-
served chemical shift change for a given [G], concentra-
tion, A6c is the chemical shift change between a pure sam-
ple of complex and the free component at the saturation 
The plot of A5H 5 against [G] in the form of [G])/A6obs vs 
[G] gave an excellent linear fit (Fig 2) confirming I 1 
hydroxyzine hydrochlonde-P-CD complexation The slope 
of the plot is thus equal to 1/A5c and the intercept with the 
vertical axis to l/A'ASj, allowing the estimation of AT^/ The 
dissociation constant (Kj) was determined to be 1 72 x 10 ^ 
M 
Fig 1 A part of 'H NMR spectrum (300 MHz) show-
mg signals for p-CD protons m the presence of 
varying amounts of hydroxyzine hydrochloride 
in D2O [H]/[G] ratios (A) 2 88 (B) 2 50 (C) 
218(D) 1 56(E)1 00 
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There are two aromatic rings present in the guest mol-
ecule so two 1 1 complexes can be expected to be formed 
To ascertain whether two equilibria really exist, the chemi-
cal shift changes for hydroxyzine were studied In the pres-
ence of P-CD, the observation of hydroxyzine hydrochlo-
nde signals proved to be of little help due to reduced solu-
bility of drug and much weaker signals (compared to P-
CD) owing to their low weight percentage The resonances 
for non-aromatic protons of hydroxyzine appeared m the 
P-CD region and therefore could not be studied In the ab-
sence of P-CD, the phenyl ring protons appeared in the re-
gion 7 29-7 40 while chlorophenyl ring protons were ob-
served as a pair of partially merged doublets (7 = 72 Hz) at 
7 47 and 7 45, each for two protons, which could easily be 
assigned to H-2,3 and H-1,4, respectively In the presence 
of p-CD, two of the p-chlorophenyl ring protons (H-2,3) 
displayed upfield shift and merged with phenyl ring pro-
tons while phenyl and two of the chlorophenyl ring (H-1,4) 
proton resonances showed downfield shifts The highfield 
shift of two chlorophenyl ring protons can only be ex-
plained m terms of hydrogen bonding between the CI and 
rim hydroxyl group which will make the ortho to CI posi-
tion less deactivated resulting m the highfield shift of H-
2,3 '^ These assignments are supported by ROESY data 
Moreover, the signal for H-1,4 exhibited splitting which 
suggests some chiral differentiation by the P-CD The pat-
tern of the aromatic region, in the case of mixtures, re-
mained almost unchanged and shift changes were not sig-
nificant except for H-2,3 Aromatic region of the spectra of 
mixtures and pure hydroxyzine hydrochlonde is shown m 
Fig 3 
' H N M R , C O S Y and ROESY spectra were, therefore, 
recorded for a mixture ([H]/[G] = 0 58) on a Bruker DRX 
600 instrument which confirmed the involvement of both 
the aromatic rings in complexation The ROESY^^ spec-
trum (Fig 4) exhibited strong cross correlation peaks be-
tween H-3' and H-5' of P-CD and protons of both the aro-
matic rings of hydroxyzine hydrochloride confirming the 
penetration of both the chlorophenyl and phenyl rings into 
the p-CD cavity Moreover, strong cross peaks between 
H-6' of P-CD and phenyl ring protons were also observed 
Thus, taking into consideration the ROESY spectral 
data and 1 1 stoichiometry, in conjunction with the chemi-
cal shift changes observed m the ' H NMR spectra, it can be 
said that hydroxyzine hydrochloride forms two 1 1 inclu-
sion complexes with p-CD m aqueous solution Since CI is 
hydrogen bonded to nm OH, it must be positioned near the 
narrower nm suggesting the penetration of the chlorophen-
yl ring from the wider nm but nothing can be said with cer-
tainty about the mode of penetration of the phenyl ring but 
It IS more likely also from the wider side The structures for 
the two 1 1 p-CD-hydroxyzine hydrochlonde complexes 
are proposed as shown in the Scheme I 
7 25 
Fig 2 A modified Benesi-Hildebrand plot showing 
1 1 stoichiometry of the complex 
Fig 3 A part of 'H NMR spectrum (300 MHz) show-
ing aromatic protons of hydroxyzine hydro-
chloride (G) m the absence as well as in the 
presence of varying amounts of P-CD in DjO 
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Scheme I Proposed model of the inclusion equilib-
ria for the hydroxyzine hydrochloride-|J-
cyclodextrin complexes 
Hydroxyzine hydrochloride 
i 
K , 
p-Cyclodextnn 
1 
H-T-p. 1 . - ^ ^ 
HT ' "~J 
Pl»-H 
\OS 
<g« 
r'M 7JS 
« ^ H - M 
^ ^ l^ a 
1 ( C ^ 
7Ji9 r i 
• M 
-u 
- M 
- 3 J 
>5 
Fig 4 Part of the 2D ROESY (600 MHz) spectrum 
(spin lock time 225 ms and 2K x 512 increment) 
of mixture of 3-CD and hydroxyzine hydro-
chloride ([H]/[G] = 0 58) showing cross peaks 
between protons of the two aromatic rings of 
the hydroxyzine hydrochloride and H-3', H-5' 
and H-6' protons of P-CD The phenyl ring pro-
tons show strong interaction with H-6' while 
cross peaks between chlorophenyl ring protons 
and H-6' are weak 
CONCLUSION 
In conclusion, a detailed ' H N M R spectroscopic 
study of complexation of hydroxyzine hydrochloride with 
P-cyclodextnn is described. Hydroxyzine hydrochloride 
forms two 1:1 inclusion complexes with P-CD m D^G The 
stoichiometry and dissociation constant (KJ) have been de-
termined. The structures for the two complexes which have 
been proposed well supported by NMR spectral data 
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